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ABSTRACT
In this thesis a study of peroxisome proliferator- 
induced rat liver tumours was performed, and the 
antigenic characteristics of the tumour cells examined. 
Peroxisome proliferators are non-genotoxic, non- 
mutagenic carcinogens which produce tumours in rodents, 
notably hepatocellular carcinomas. These tumours are 
similar in histology to hepatocellular carcinomas of 
other etiology.
1. The ciprofibrate-induced rat liver tumour cells 
exhibited a significantly longer survival time in vitro 
as compared to their normal counterparts. They also 
exhibited a potential for cell proliferation in vitro. 
The tumour cells were clearly transformed showing 
characteristically higher agglutinibility with plant 
lectins (wheat germ agglutinin and concanavalin-A) and 
a potential for growth and colony formation in 
semisolid media such as soft agar and methylcellulose.
2. Monoclonal antibodies (MoAbs) were raised against 
the tumour cells using two different schedules of 
immunization. The schedule of prolonged and multiple 
immunization was found to be more efficient for the 
production of tumour-specific MoAbs. A number of clones 
were obtained showing reactivity with either tumour 
cells, normal cells or both. A total of 23 MoAbs were 
obtained showing preferential or selective reactivity 
with the tumour cells. On further characterization, 
five of these (M-19, M-23, M-28, M-54 and M-56) did not 
react with any other normal or fetal rat tissues.
3. Some of the MoAbs also reacted with pre-neoplastic 
and peri-neoplastic tissues from the ciprofibrate- 
treated rat livers, and most of the MoAbs were 
reactive with liver tumours induced by ciprofibrate in 
other rats.
4. The antigens identified by these MoAbs were mainly 
cytoplasmic, as observed by immunocytochemical methods. 
The MoAbs were also tested in a cross-species system, 
but showed no reactivity with normal human tissues and 
little reactivity with non-hepatic human tumours. Two 
of the MoAbs (M-23 and M-28) reacted strongly with 
human hepatocellular carcinoma.
5. Immunoblotting was used to study further the 
antigens identified by the MoAbs. The antigens 
demonstrated a size range between 45 kd and 159 kd. 
While some of these molecular weights may correspond to 
cellular enzymes induced by peroxisome proliferators 
(e.g. cytochrome P-450), several of them appear to be 
new antigens not previously described. The elucidation 
of their structure and function, and their examination 
as specific tumour markers may help in the diagnosis or 
treatment of human hepatocellular carcinoma.
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SECTION-1
INTRODUCTION
1.1 INTRODUCTION:
Cancer is one of the most ancient diseases known 
and has existed for most of the evolutionary period of 
life on earth affecting animals as well as plants. 
Cancerous lesions have been found in the bones of 
dinosaurs and in Egyptian mummies. Stomach and uterine 
cancers were described as early as fourth century B.C. 
Hippocrates coined the term "Carcinoma", which referred 
to tumours that spread and destroy (LaFond,1988).
Galen suggested the similarity between a crab and 
cancer (Vincent,1985) and described tumours in the 
following ways:
1) "Tumours according to nature" - like breast 
enlargement with normal female maturation.
2) "Tumours exceeding nature" - like bone 
proliferation in fracture reunion.
3) "Tumours contrary to nature" - which we call 
neoplastic or tumour growth today.
This definition, proposed some 1800 years ago, is still 
reasonably correct.
Cancer, at present, is not the commonest cause of death 
but epidemiological studies show that every year
930,000 persons develop cancer in U.S.A and for 470,000 
it is fatal (Cascito and Lowitz, 1988 ). In the U.K one 
in every five persons is likely to develop some form of 
cancer in his lifetime. This incidence rate has changed 
very little over the past years. There are a number of
factors influencing the development of cancer like age, 
sex, diet and environment. Generally speaking, the 
common sites of tumours in males are liver, lungs, 
gastrointestinal tract, urinary tract, prostate ; while 
in females they are breast, liver, gastrointestinal 
tract, uterus, skin, bronchus and ovaries.
The liver , however, remains the most common and 
predominant site especially secondary metastatic 
growths because of its dual and enormous circulation, 
from both portal and systemic circulation. Liver, in 
addition, is the site of most metabolic and biochemical 
processes of the living body and is exposed to all 
intermediate and metabolic end products.
A tumour or neoplasm is defined as an abnormal mass of 
tissue the growth of which exceeds, and is 
uncoordinated with, that of normal tissues persisting 
in the same excessive manner even after cessation of 
the evoking stimuli (Vincent,1985). Tumourogenesis, 
irrespective of cause, usually involves specific 
genetic alterations in an individual cell which then 
proliferates to form the tumour mass. The final 
expression of transformed "pre-cancerous cell" can be 
modulated by immunological, hormcnal, vascular and 
nutritional factors. These , together with cell 
proliferation kinetics, influence the final outcome. 
There are a number of other growths like fetus, 
haematoma, thyroid goitre, haemorrhoids and female 
breast but they stop their growth as soon as growth
stimuli are over.
Most tumours, irrespective of their tissue of origin, 
tall in one of the following two categories:
1) Benign or innocent tumour.
2) Malignant tumour.
PsT'fsct innocence and absolute malignancy are in fact 
endpoints of a spectrum of behaviour and often there 
is debate about the degree of malignancy. Two 
behavioral criteria determine malignancy, local 
invasion and distant metastasis or spread. There are 
other differences also between benign and malignant 
tumours. Some of these important differences are shown 
in table 1.1 .
Cancer is the term used to describe a malignant tumour 
and suggest the capacity of a tumour to reach out to 
form separate colonies in distant parts of the body 
which are known as metastasis or secondaries.
All tumourous cancer cells present characteristic 
features which clearly and distinctly distinguish them 
from their normal counterparts, independent of the 
etiological agent.
1.2 THE TUMOUR CELL:
In a normal living organism cells grow under strict 
growth control mechanisms , differentiate to perform 
specialised function and finally die to be replaced by 
new ones. Cancer is a disorder of cells with
TABLE 1.1
DIFFERENCES BETWEEN BENIGN AND MALIGNANT TUMOURS
FEATURE BENIGN TUMOUR MALIGNANT TUMOUR
Resemblance to 
tissue of origin. yes no
Chromosomes normal abnormal
Differentiation obvious poor
Mitosis rare frequent
Encapsulation present absent
Growth rate slow rapid
Local invasion no frequent
Distant metastasis no common
Normal cell patten1 present lost
Cell size & shape normal variable
Size of nucleus normal increased
Density of nuclear 
staining normal increased
defective differentiation or defective growth. The 
visible tumour mass is the end result of a whole series 
of changes which may have taken many years to develop. 
Johannes Mueller, a German microscopist, showed 140 
years ago that cancer or tumour was made up of cells 
(Vincent,1985). This started search for the specific 
differences between normal and cancerous cells and to 
exploit them for screening, diagnostic, therapeutic and 
prognostic purposes.
Cancer development is a multistage and multistep 
process (Farber,1984 ; Langman,1980). This involves a 
number of initiating agents like carcinogenic 
chemicals, viruses, unknown factors, radiation and 
replication errors and promoting agents such as 
hormones, normal growth promoters, inflammation, 
specific promoters. Some initiating agents can also 
work as promoting agents. The mere exposure of cells to 
a carcinogenic agent does not necessarily mean that 
cell will transform. Transforming efficiency of 
etiological agents is variable and depends upon nature 
of etiological agent, dose, exposure time and tissues 
exposed.
The mechanism of cell growth control is an important 
but less understood area. If a tissue is damaged by 
injury, surviving cells (irrespective of the nature and 
type of injury) begin to grow either in size 
(hypertrophy) or in number (hyperplasia) to replace the
damaged cells. When original tissue mass or number of 
cells is accomplished, this process of repair stops. 
These normal growth controlling mechanisms, which are a 
balance between growth promoting and growth inhibiting 
factors (Mead and Fausto,1989), persist throughout 
life.
Most normal adult cells, under normal 
circumstances do not grow beyond their normal 
physiological confines. Tumour cells differ from normal 
cells in that they are no longer responsive to normal 
growth controlling mechanisms and cell loss rate is 
lower than cell birth rate in tumours. Loss of growth 
control is gradual and normal controls are only 
slightly relaxed at first. Some tumour cells, 
especially soon after their transformation, may not be 
growing at all (Franks, 1988).
A cell can be converted to a cancerous cell through the 
process of cell transformation. Whenever a potential 
agent, capable of inducing cancer or tumour, acts on 
some tissue the cells can undergo a number of changes. 
It is not necessary that all tissues pass through the 
same stages. Moreover, the process can become arrested 
at any stage. Tumour mass may be a heterogeneous 
population of cells including normal and neoplastic 
ones. Even neoplastic cnes may not be at the same stage 
of transformation. Epithelial tumours may also contain 
some transformed connective tissue elements (Knowles 
and Franks,1978). The identifiable changes, in a normal
tissue when it changes to malignant one, in a 
chronological order are:
1. Hypertrophy or increase in cell size.
2. Hyperplasia or increase in number of cells.
3. Metaplasia or change in type of cells, for example 
changes in the respiratory epithelium due to smoking.
4. Dysplasia or abnormal appearance and arrangement of 
cells as observed in carcinoma In situ.
5. Neoplasia or appearance of a tumourous growth.
6 . Anaplasia or invasive nature of growth locally and 
at distant sites (metastasis).
1.2.1 CHARACTERISTICS OF THE TUMOUR CELL:
The process by which a normal cell changes to acquire 
properties of a malignant, cancer or neoplastic cell is 
called transformation. Spontaneous cell transformation 
in culture is also a universal and known phenomenon 
(Colburn et al,1978 : Sanford et al,1970). Its onset is 
unpredictable and depends on culture method and 
condition but it is being detected as early as eighth 
passage or 8-12 weeks (Sanford et al,1970). Cells 
derived from normal mammalian tissues can be assumed 
normal upto 4-6 weeks. The term, transformed cell, is 
relative as it refers especially to in vitro cell 
culture. The errors of in vitro and in vivo correlation 
are unstable phenotype in vitro with partial or total 
reversion (Jamasbi and Nettesheim,1979), cell selection
by different culture methods, heterogeneity of tumour 
cells and in vitro spontaneous transformation. A 
transformed cancer cell has lost control of growth and 
position and is not under the same restraints as a 
normal cell (Cameron and Pool,1981). Transformed cell, 
however, retain some characteristic features of their 
tissue of origin enabling identification and 
classification of tumour cells.
Cancer transformation causes a number of biochemical, 
morphological, behavioral and immunological 
changes in cells. Not all transformed cells exhibit all 
the changes identified so far. That is why transformed 
cell is a relative term and often there is talk about 
degree and type of transformation (Rubin and Xu,1989). 
The unique distinguishing features of transformed 
cancer cells are described and discussed by many 
authors (Borenfreund et al,1989 : Freshney,1988a : 
Spier,1988). None of the criterion described so far has 
an absolute significance or validity in a broad 
spectrum of different cell types as a definate 
demonstrable indicator of cellular transformation. 
Cells in culture are unstable both genetically and 
karyotypically. Normal cells can transform and 
transformed cells can revert. The status of cells in 
vitro can not be assumed to be constant. The search for 
a single absolute criterion of malignancy or its in 
vitro correlate is still on but at the moment a number 
of criteria are looked for as a sign of malignant
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change or transformation. Some of these important 
features are :
(1) IMMORTALIZATION AND INCREASED SURVIVAL: Tumour 
cells are mostly de-differentiated cells and show 
either immortality or increased survival in vivo and in 
vitro (Bischoff et al,1981 : Willson et al,1987). Some 
cells remain differentiated with a finite life span but 
increased survival time as compared to normal 
counterparts (Bugaisky and Zak,1989 : McCormick and 
Maher,1989). Even pre-neoplastic cells show slow growth 
and limited proliferation potential (Guyotat et al,1990 
: Kerler and Rabes,1988). On the other hand, growth of 
cells in an established culture can cease even after 
years (Tateyama et al,1988).
(2) CHANGES IN CELL MORPHOLOGY: Transformation leads to 
a number of changes in the cell like changes in cell 
size and shape, nuclear number and morphology, nuclear 
and cytoplasmic ratio and cytoplasmic and nuclear 
staining (Barker and Sanford,1970).
(3) ANCHORAGE INDEPENDENT GROWTH AND DECREASED 
requirement for SUBSTRATUM: Normal mammalian cells 
®2ihibit better growth and survival when attached to a 
solid phase rather than in a suspension (Stoker et
,19 6 8 ). Transformed cells do not always require a 
solid support and are thus generally not anchorage 
dependent (Freedman and Shin,1977 : Weinstein et 
al, 1975 ) .
(4) EXCRETION OF PROTEOLYTIC ENZYMES; Transformed cells 
can produce proteolytic enzymes. Plasminogen 
activators, for example, are responsible for increased 
fibrinolytic activity of a number of tumour transformed 
cells (Hince and Roscoe,1978).
(5) AGGLUTINATION WITH PLANT LECTINS: Lectins are plant 
derived macromolecules with high affinity for the 
carbohydrate moiety of glycoproteins (Ozanne and 
Sambrook,1971). They cause inhibition of cell mobility 
and phagocytosis, redistribution of cell surface 
receptors, stimulation of cell mitosis, inhibition of 
monolayer dissociation by various proteases (Brown, 
1973) and inhibition of enzyme release of cell surface 
glycoproteins by trypsin (Brown, 1973). They also 
agglutinate a wide variety of transformed cells which 
phenomenon is used as a marker of malignancy (Moscona, 
1971 : San et al, 1979).
(6 ) FASTER RATE OF GROWTH AND DIVISION: Normal 
mammalian cells have a variable but limited potential 
for growth and division but tumour cells have an 
enormous capability of growth and division both In vivo 
and in vitro (Smerts et al,1976 : Willson et al,1987). 
There are numerous mitotic figures with hyperchromatic 
nuclei. These are encountered both in vivo and in 
vitro. A transformed cell in vitro does not encounter 
as many restraints as a tumour cell in vivo especially 
immune system of the host (Smerts, 1980).
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(7) DECREASE IN CONTACT INHIBITION OF GROWTH: 
Increasing cell density inhibits growth in normal 
mammalian cell culture (Vintermyr andDoskeland,1989 ). 
Transformed cells are able to attain a higher 
saturation density in comparison to normal cells under 
identical culture conditions (Holley,1972). Transformed 
cells lack growth control at higher densities (Glick et 
al, 1974 : Smerts et al, 1976) and they do not stop 
growth under conditions where normal cells stop it 
effectively.
(8 ) INCREASED GLUCOSE CONSUMPTION: Transformed cell 
utilise and require more glucose than normal cells, 
probably due to a higher metabolic rate and higher 
mitotic index.
(9) INCREASED CLONING EFFICIENCY: Transformed cells 
show a higher colony forming efficiency as compared to 
normal cells. Low colony forming efficiency is not 
necessarily a definite indicator of normalcy but a 
moderate to high colony forming efficiency is a 
reasonably good indicator of transformation (San et 
al,1979 : Skehan and Friedman,1981).
(10) DECREASED REQUIREMENT FOR GROWTH PROMOTORS: Normal 
mammalian cells require growth factors in medium like 
serum and other factors acting synergistically 
(Francavilla et al,1989). There are a number of growth 
promoting and growth inhibitory factors (Nakamura,1989 
: Prehn,1989) and net result is a balance between
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growth promoting and growth inhibiting factors in both 
in vivo and in vitro system (Mead and Fausto,1989 ) . 
Transformed cells are known to secrete their own growth 
factors and transforming factors (Coffey et al,1986 : 
Klein et al, 1987 : Liu et al, 1988 ) which may be 
responsible for tumour growth as in carcinoma breast 
(Kommoss et al,1990). Some normal cells, on the other 
hand, seem to produce growth inhibitory factors which 
may suppress growth of transformed cells (Farber,1982).
(11) CHANGES IN KARYOLOGY; Transformed cancerous cells 
show changes in chromosome number and structure. These 
are identified in a variety of tumours. Examples are 
malignant mesothelioma (Popesce et al,1988), paediatric 
brain tumours (Griffin et al,1988), primary breast 
tumours (Devilee et al,1988), leukemia (Rowley,1990), 
lymphoma (Konishi et al,1990) and Wilm’s tumour (Wang- 
wuu et al,1990).
(12) TUMOURIGENICITY IN NUDE MICE: One of the criterion 
for determining the transformation character of a cell 
in vitro is to demonstrate its ability of 
transplantation in syngenic host or nude mice. Anterior 
eye chamber, brain, peritoneal cavity, cheek pouch and 
foot pad are used for this purpose (Hara et al, 1988 : 
Reddy and Lalwani,1983).
(13) ALTERATION IN CELL SURFACE ANTIGENS: One important 
feature of tumour transformed cells is immunological 
changes at tumour cell surfaces, involving mainly cell 
surface glycoproteins, glycolipids, gangliosides and
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proteoglycans (Bhavandan and Davidson,1982 : Bischoff
et al,1981 : Durrant et al,1986 : Edelman,1983 : 
Farber,1984 : Hynes,1976 : San et al,1979 ; Spitalnik 
et al,1986). Antigenicity of tumour cells can be so 
strong to block and evade hosts’ immune system. These 
cell surface changes are important in terms of cell to 
cell interactions, cellular growth, immunological 
reactions and responses (Clayberger et al,1987).
(14) DECREASED PRODUCTION OF FIBRONECTIN, LAMININ, 
FILAMIN AND L.E.T.S. (Large external transformation 
sensitive protein): Transformation of cells leads to a 
decrease in the production of these molecules by cells, 
possibly because the requirement for them is decreased 
(Bannikov et al,1980 : Vaheri and Maher,1978).
(15) CHARACTERISTICS OF IN VITRO GROWTH: These are
multiple foci, multilayered growth and piled up criss 
cross pattern of growth. These are not found in normal 
cells. Transformed cells have, in addition, poor 
ability to flatten on the substrate.
(16) METASTASIS : Transformed tumour cells have the 
ability of anaplasia or spreading out, invading and 
destroying surrounding structures. They can detach 
from their site of origin, enter and survive in the 
circulation and settle in a new location to colonize 
and start growth there. This is called metastasis and 
is a hallmark of all cancerous growths (LaFond,1988).
(17) GROWTH IN SOFT AGAR: Cells from solid tumours
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grow in soft agar semisolid medium. In vivo tumour 
cells are probably more anchorage dependent than in 
vitro transformed cells. This colony forming potential 
of cells from a single cell in semisolid medium is an 
important criterion indicating metastatic potential 
(Ahmann et al,1986 : Freedman and Shin,1977 : Glick et 
al,1974 : Ottestad et al,1988 : Pretlow et al,1986).
Tumour transformed cells also exhibit a number of other 
features like delocalization of microfibres and 
microfibrils, phosphorylated vinculin, loss of various 
cell markers, etc. Hopefully other differentiating 
features of transformed tumour cells will be found in 
future which will be significant and important.
A fully transformed cell should presumably demonstrate 
differences from normal cells in most, if not all, of 
these characters. These characteristics of transformed 
cells can be acquired by cells, independent of each 
other, during transformation.
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1.3 CARCINOGENESIS:
Normally a growing cell passes through the different 
stages of cell cycle in its life time namely G^, S, G2 , 
M and G q . In the G^ phase there is increase in cell 
size without DNA synthesis. S phase involves active DNA 
synthesis. The Gap phase between S and M is called G2 . 
M is the mitotic phase where two mirror image DNA 
, copies are formed, migrate and separate as spindles. G q 
is the resting phase (fig 1.1). Growth factors in G q  
act as switches determining whether or not a cell will 
enter the growth cycle. Cancer cell may be defective in 
this mechanism.
Cell differentiation is a process which means that a 
primitive cell has been committed to one specific cell 
lineage or type and expresses unique proteins and 
functions. Ultimately it departs permanently from the 
cell growth cycle to serve a specialised function. The 
terminal differentiation is usually irreversible 
e.g,loss of nucleus in RBCs, fusion of muscle fibres 
etc. Some cells e.g, hepatocytes and fibroblasts do not 
apparently go into terminal differentiation but perform 
their functions in a type of reversible G q  phase. 
Carcinogenesis or development of cancer is a multistage 
process irrespective of site of tumour or organ 
involved (fig 1.2). The whole process of carcinogenesis 
can now be divided into three relatively well defined 
stages as:
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(a) Initiation.
(b) Promotion.
(c) Progression.
The application of a tumour-inducing agent does not 
lead to tumour production immediately. There are 
usually a series of changes after the initiation step. 
Subsequent changes can be produced by the same 
carcinogen or by other substances called promoting 
agents. Initiation, however, is the essential but 
reversible primary step and initiated cells are fixed 
or committed cells that can persist in a dormant state 
until acted upon by promoting agents. Promotion is an 
irreversible step further ahead in the series of events 
marked by cellular proliferation. Tumours induced by 
initiation - promotion may differ from those induced by 
a carcinogen alone as in papilloma (Reddy and 
Fialkow,1983). The final stage , progression , is 
characterized by an increase in growth rate, increased 
invasiveness, biochemical and structural changes, 
instability of karyotype, metastasis and increased 
expression of proto-oncogenes. Many agents can induce 
cell mitosis but only carcinogens and promoting agents 
can induce cancer indicating the involvement of other 
possible factors in carcinogenesis. The final outcome 
is a balance between the cell growth control factors 
and the extent and degree of changes in the initiated 
cells. This explains the failure of growth,
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differentiation and the spontaneous regression of some 
pre-neoplastic cells, cancer cells and fully 
transformed tumours (Carlsen ,1990 : Gaffey Michael et 
al, 1990 : Ono et al, 1986). Tumours can be identified 
as foreign by the immune system of the host and 
rejected (Berendt et al,1978) and that is probably how 
tumours are more common in immune compromised hosts. 
Tumours can differentiate to normal tissues when 
transplanted in embryos and differentiation of tumour 
cells can be observed in vitro when grown in chemically 
defined medium or with normal cells (Bugaisky and Zak,
1989).
1.3.1. ETIOLOGY OF TUMOURS:
There have been many theories put forward to explain 
development of cancer and its causative agents and 
mechanisms like infectious, irritational, embryonic, 
genetic and non-genetic mechanism. Predominantly 
evidence points to the genetic mechanism suggesting a 
change in genetic information of the transformed cell. 
Many factors were found to be associated and were 
implicated with different tumours e.g, age (fig 1.3). 
The etiological agents believed to be responsible may 
be categorised in four groups namely physical agents, 
chemical agents or carcinogens, biological agents and 
spontaneous tumours. The agents of different groups can 
interact synergistically and as agonists (Gensler,1988)
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and may use similar mechanisms to induce cell 
proliferation (Guy and Gordon,1989).
1.3.1.1. PHYSICAL AGENTS:
The role of radiation in cancer development was known 
since early 19th century (Ulrich,1988). Cancer is the 
only long term cause of death that is increased by 
radiation (Kohn and Fry, 1984). A variable latent 
period elapses between radiation exposure and tumour 
development. The damage and depletion of the ozone 
layer by CFCs, carbon monoxide and other gases has 
increased the amount of radiation reaching the globe 
and thus increasing the risk of cancer development but 
ozone itself may be carcinogenic (Borek et al,1986a). 
Physical agents like radiation can cause cancer in 
almost any tissue but highly sensitive ones are bone 
marrow (leukemia being the commonest), thyroid, testis 
and ovary while least sensitive ones are bone, pancreas 
and stomach. The tumours developed are identical to 
tumours caused by any other etiological agent. The 
atomic bomb survivors show an increased incidence of 
leukemia, multiple myeloma, cancer of the lung, breast, 
stomach, colon and urinary tract (Kohn and Fry, 1984). 
Radiation can transform cells in culture (Hall et 
3.1 f 1986), The process of radiation-induced tumours is 
well known in experimental animal systems and humans 
(Emmet,1973 : Gross et al,1988). Occupational and 
other risks are accidental exposure by nuclear
20
explosion (Kato and Schull,1982), radiotherapy (Smith 
and Doll,1982), watch dial painters (Rowland et 
al,1983), Uranium miners (Waxweiler et al, 1981),
thorotrast patients (Van kaick et al,1983) and 
childhood cancer because of radiation in utero (Totter 
and MacPherson,1981).
Ionizing radiation is a potent carcinogen (Ulrich, 
1982). High energy ionizing radiation can be 
particulate (like beta particles, neutrons and alpha 
particles) or electromagnetic photons (X-rays and gamma 
rays). Electrons and ions are formed which lead to 
highly reactive free radical formation. Non-ionizing 
radiations, on the other hand, cause molecular 
excitation like vibrations and electron movements only. 
The mammalian tissue is 70% water. Absorbed radiation 
energy cause radiolysis (ionization and splitting) of 
water molecules releasing chemical species and free 
radicals which may be the main damaging factors. There 
can be chromosomal breaks, translocations and mutations 
involving single or both strands of the DNA helix. 
Cells can partly recover to repair the damage (Wolf and 
Carrano, 1986).
1.3.1.2 CHEMICAL AGENTS OR CARCINOGENS:
Chemical carcinogens are important etiological agents 
responsible for cancer development and many human 
cancers are believed to be caused by chemicals 
(Heidelberger, 1970 : Heidelberger,1977). The list of
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supposed cancer causing chemicals is ever increasing. 
However there are only about some 20-30 chemicals which 
are known to be carcinogenic to humans and there is 
great controversy as to the significance of high dose 
animal experiments to carcinogenicity in humans. The 
exposure to human beings of chemicals is usually for a 
longer duration due to a greater life expectancy of 
humans. All chemicals should be treated with respect 
particularly new ones.
Carcinogenic chemicals can be naturally occurring as 
well as synthetic. Some carcinogens are direct acting 
while others require activation. Chemical carcinogens 
can cause tumours in almost any tissue of the body and 
trans—piacental transfer of some of the carcinogenic 
chemicals is also reported (Denning et al,1990). There 
are numerous examples of tumour development in humans 
as well as experimental animal systems (DeLeo and 
Srivastava,1985 : Lalwani et al,1981a : Sato et al,1987 
: Wang et al,1990 : Wirth et al,1986). Cells can be 
transformed with chemicals in vitro (Borenfreund et 
al,1989 : Lee et al,1989 : McCormick and Maher,1989 : 
Montesano et al,1973). Cells derived from chemically- 
induced tumours can be cultured in vitro (Bentel et 
3lfl989 : Smith et al,1988). The potential risk to 
humans is measured on basis of the results of these 
experimental model systems in animals (Merletti et 
31,1934:), Table 1.2 shows chemical / industrial
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TABLE 1.2
INDUSTRIAL/CHEMICAL PROCESS SITE OF TUMOUR
Auramine manufacture Urinary bladder
Shoe repair or manufacture Nasal cavity 
Urinary bladder
Furniture manufacture Nasal cavity
Isopropyl alcohol manufacture Paranasal sinuses
Nickel refining Nasal cavity 
Lung
Rubber industry Urinary bladder
Haematite mining Lung
Plastic industry Liver
Genitourinary
Gasoline manufacture Kidney
Scrotum
Cadmium using industry Prostate
Lung
Chromate processing Lung
Nasal cavity
Nickel refining Lung
Nasal cavity
(Tomatis et al,1978)
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processes believed to be involved in various cancers 
and table 1.3 gives a list of chemical compounds known 
to be carcinogenic with their target organs. This list 
is , of course, not complete. Some of these important 
chemicals are described below in detail (Tomatis et 
al,1978).
(1) Polycyclic aromatic hydrocarbons are usually found 
in smoke and cause cancer of lung, skin and intestinal 
tract (Phillips,1983).
(2) More than 100 chemical compounds have been 
identified in the nitrosamine group. They are converted 
to active carcinogenic metabolite, methyl nitrosamines, 
partly in saliva (Mirvish,1977). They cause tumours of 
lung, kidney, oesophagus and nasal cavity. They also 
cause liver tumours in rodents (Magee and Barnes,1956).
(3) Dialkyl triazenes are direct acting carcinogens 
causing tumours of peripheral and central nervous 
system, kidney, uterus, ovary and heart.
(4) Aromatic amines, amides and nitro compounds require 
metabolic activation and cause tumours of urinary 
tract.
(5) 2—Acetylaminofluorene can cause tumours of urinary 
bladder, kidney, liver, intestines, ear, skin, 
subcutaneous tissue and mammary gland.
(6) Nitrofurans can cause tumours of gall bladder, 
breast and different leukemias.
( "7 ) Alkylating agents are direct acting carcinogens and 
alkylate DNA via the formation of a carbonium ion. They
24
TABLE 1.3
CHEMICAL EXPOSURE ROUTE TARGET ORGAN
Actinomycin-D Medicinal Ingestion
Injection
Mesothe1ioma
Aflatoxin Environmental
Occupational
Ingestion
Inhalation
Liver
4-amino
biphenyl
Occupational Ingestion
Inhalation
Skin
Urinary
Bladder
Arsenic
compounds
Occupational
Environmental
Medicinal
Ingestion
Inhalation
Skin, Lung, 
Liver
Asbestos Occupational Ingestion
Inhalation
Lung, Pleura, 
GIT
Azothioprine Medicinal Ingestion Skin
Blood cells
Benzene Occupational Inhalation
Skin
Blood cells
Benzidine Occupational Ingestion
Inhalation
Skin
Urinary
bladder
Betel quid Environmental Ingestion Oral mucosa
Bis(chloro- 
methyl)ether
Occupational Inhalation Lung
Cyclophospha­
mide
Medicinal Ingestion
Injection
Urinary
bladder
Chloramphen­
icol
Medicinal Ingestion
Injection
Blood cells
Chlorambucil Medicinal Ingestion
Injection
Blood cells
Cigarette Environmental Smoke
Inhalation
Lung
Pancreas 
stomach 
Esophagus 
U. bladder
Cycasin Medicinal Ingestion
Injection
Liver
GIT
Daunomycin Medicinal Ingestion Kidney
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Injection
Diethyl
stilboestrol
Medicinal Ingestion
Placental
Uterus
Vagina
Grisofulvin Medicinal Ingestion
Injection
Liver
GIT
Hydrazine Medicinal Ingestion
Injection
Liver
GIT
Inorganic 
salt of 
heavy metals
Environmental Ingestion
Inhalation
Skin
Blood cells
Isopropyl
oils
Occupational Inhalation Nasal cavity 
Larynx
Melphalan Medicinal Ingestion
Injection
Blood cells
Mustard gas Occupational Inhalation Lung
Larynx
Myelaran Medicinal Ingestion 
Inj ection
Blood cells
2-Naphthyl
amine
Occupational Inhalation
Ingestion
Skin
Urinary
bladder
Oxymetholone Medicinal Ingestion Liver
Phenecitin Medicinal Ingestion Kidney
Phenytoin Medicinal Ingestion Lymphoreti- 
cular system
Safrole Medicinal Ingestion
Injection
Liver
Soot, tar 
and oils
Occupational
Environmental
Inhalation
Skin
Lung
Scrotum
Sterigmato-
mycin
Medicinal Ingestion
Injection
Liver
Treosulphan Medicinal Ingestion
Injection
Blood cells
Vinyl
chloride
Occupational Inhalation
Skin
Liver, lung. 
Brain
(Tomatis et al,1978)
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can cause tumours of skin, lung and lymph node.
(8) Natural carcinogens are found in nature, usually 
products of bacteria or fungi. Examples are aflatoxin B 
- a very potent hepatocarcinogen (Peers et al,1976), 
sterigmatocystin (Aspergillus versicolor or Pénicillium 
luteum), Griseofulvin (antifungal drug), daunomycin 
(renal carcinogen), actinomycin-D (causing 
mesothelioma) and streptozotocin.
(9) Carcinogens of plant origin are safrole causing 
liver tumours (Miller et al,1983), cycasin (causing 
liver, intestinal and kidney tumours) and pyrrolizidine 
alkaloids (retrorsine).
(10) Inorganic chemical carcinogens are arsenic, 
beryllium, chromium, cadmium, lead, asbestos, nickel, 
cisplatin and its salts causing lung tumours.
1.3.1.3 BIOLOGICAL AGENTS:
important group of cancer causing biological agents 
are viruses (Wykes and Weiss,1984). The evidence for 
bacteria, fungi and parasites as potential carcinogenic 
agents is not well established (Hill et al, 1973). 
There are ,however, examples like bilharzisis 
(Schistosomiasis) in cancer of the urinary bladder, 
etc.
Shope first recognised viral involvement in cancer 
(Shope,1933). Some viruses cause cancer in 
experimental animals and may be closely associated with
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human cancers while others are frankly carcinogenic. 
Viruses can transform cells in vitro (Faisst et ai,1989 
: McCormick and Maher,1989 : Phillips and Ruch,1986). 
Some viruses are only tumourigenic in immunodeficiency 
states. There can be a long latent period and virus can 
persist in body in a dormant state for a whole life 
time, like herpes viruses. Both RNA (retroviruses) and 
DNA viruses are thought to be capable of inducing 
cancer. All oncogenic viruses enter the cell nucleus 
and introduce new DNA, a part of which binds covalently 
or integerates into chromosomal DNA. A small part of 
the viral genome is used in cell transformation (Varmus 
and Levine,1983).
RNA viruses interact and thus incorporate 
proto-oncogenes of host cells into their own nucleic 
acid later to be activated into oncogenes. These 
viruses thus have ability to spread oncogenes from one 
cell to the other and from one host to the other , the 
so called infectious cancer. Some RNA viruses are 
weakly oncogenic while others can induce tumours in 
days. DNA viruses , on the other hand, encode in their 
chromosomes the genetic information to trigger 
oncogenic process. Necrogenic effect of DNA viruses is 
usually more potent one.
A list of RNA and DNA oncogenic viruses (table 1.4) is 
Given. Some important tumour viruses are described as 
under :
(1) Hepatitis B virus is a DNA virus strongly
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TABLE 1.4
NAME OF THE VIRUS TUMOUR CAUSED
RNA Oncogenic Viruses:
Avian sarcoma virus (ASV)
Avian myeloblastosis virus (AMV) 
Avian erythroblastosis virus (AEV) 
Avian lymphoid leukosis 
virus (ALV)
Avian reticuloendotheliosis 
virus (REV)
Mouse mammary tumour virus (MMTV) 
Murine sarcoma virus and 
osteosarcoma virus (MuSV)
Murine leukemia virus (MuLV) 
leukemia virus (FeLV) 
sarcoma virus (FeSV) 
leukemia virus (BLV) 
sarcoma virus (SiSV) 
ape leukemia virus (GaLV) 
leukemia virus
Feline 
Feline 
Bovine 
Simiam 
Gibbon 
Human T-cell 
(HTLV/ATLV)
DNA Oncogenic Viruses:
HEPADNAVIRUS:
Hepatitis B virus 
Animal Hepatitis virus
PAPOVAVIRUS:
Polyoma virus 
SV40 virus 
JC virus 
BK virus 
Papilloma virus
ADENOVIRUS :
ADV 1-31
HERPES VIRUS:
Epstein Barr virus (EBV)
Herpes simplex virus 1 & 2 (HSV) 
Cytomegalo virus (CMV)
Marek's disease virus (MDV) 
Saimiari virus (SV)
Sarcoma
Haemopoietic tumours 
Haemopoietic tumours 
Haemopoietic tumours
Haemopoietic tumours
Reticular tumours
Mammary tumours
Osteosarcoma
Sarcoma
Leukemia
Leukemia
Sarcoma
Leukemia
Sarcoma
Leukemia
Leukemia
Hepatocellular
carcinoma
Tumours of skin. 
Cervix and gastro­
intestinal tract
Different human and 
animal tumours
Burkitt's lymphoma 
Nasopharyngeal 
carcinoma 
Cervical cancer 
Kaposi's sarcoma 
Neurolymphomatosis 
Lymphoma R leukemia
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associated with human hepatocellular carcinoma (Dejean 
et al,1986).
(2) Papilloma virus is a DNA virus associated with skin 
cancer, cervical cancer and gastrointestinal cancers 
(Nielsen,1990).
(3) Eps te in-Barr virus is a DNA herpes virus and is 
strongly associated with Burkitt's lymphoma, nasal T 
lymphoma and nasopharyngeal carcinoma (Guy and 
Gordon,1989 : Harabuchi et al,1990 : Old,1981 : Zur 
Hausenet aI^1970 ).
(4) Herpes simplex virus type 1 and 2 are DNA viruses 
associated with cervical carcinoma.
( 5) Cytomegalo-virus is a DNA herpes virus associated 
with Kaposi sarcoma (Boldogh et al,1981).
( 6 ) Bovine leukemia virus is a RNA virus and can cause 
lymphosarcoma (Aida et al,1985).
(7) Avian sarcoma virus is a RNA virus causing avian 
sarcomas (Phillips and Ruch,1986).
(8) Murine leukemia virus, a RNA virus, can cause 
lymphomas, leukemias and sarcomas in rodents (Bakouche 
and Gerlier,1986).
(9) Mouse mammary tumour virus can cause mammary 
adenocarcinomas.
(10) Small pox virus can cause different benign 
tumours.
(11) Feline T-cell and bovine B-cell leukemia viruses 
can cause leukemias and lymphosarcomas.
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1.3.1.4 ONCOGENES:
An oncogene is a genetic sequence coding for specific 
information required for cell growth or 
differentiation. The major players in cell control are 
growth factors, growth factor receptors, signal 
transducers and dominant or suppressor/recessive 
oncogenes (Arbeit, 1990). Proto-oncogenes of cell can 
be activated to oncogenes, by intrinsic or extrinsic 
factors (any cancer causing agent), and may produce 
neoplastic change (Boyd and Barrett, 1990 : Rhim et al,
1990). Chemicals, radiation and diet can also activate 
oncogenes (Burns et al, 1989 : Hsieh et al, 1989 : 
Lokotionov et al, 1990 : Ueda, 1989). A number of 
tumour suppressor or recessive oncogenes are also 
described being the negative regulators of cell growth 
(Della Porta et al, 1989 : Levine, 1990). The ras
oncogenes are described in carcinomas of cervix, 
breast, lung, liver, skin, colon, etc (Guillem et al, 
1990 : Lee et al, 1990a : Lokotionov et al, 1990 : 
Sagae et al, 1990 : Telang et al, 1990). The ras and 
myc oncogenes are also found in a number of tumours 
(Field and Spandidos, 1990 : Goh et al, 1990 : Lee et 
al, 1990b). The raf, ret and fos oncogenes are also 
found active in a number of tumours (Greenhalgh et al, 
1990 : Ishizaka et al, 1990 : Nagao et al, 1990 : Smith 
al, 1990 : Norland et al, 1990). Oncogenes can also 
transform cells In vitro (Rhim, 1989 : Rhim et al,
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1990).
1.3.1.5 SPONTANEOUS TUMOURS :
Many tumours in animals and humans arise 
spontaneously and in spite of intensive efforts a 
definite cause has not been established. There are a 
number of examples of tumours in this group like T-cell 
leukemia (Badger et al,1986) and lung carcinoma (Bentel 
et al, 1989 : Smith et al, 1988 ). There are also 
examples of in vitro spontaneous cell transformation 
(Lee et al,1989 : McCormick and Maher,1989 : Rubin and 
Xu,1989 : Tsao et al,1990). The causative agents in 
these cases, in fact, may well be hereditary, physical, 
chemical or biological. The incidence rate varies with 
species, environment and geographic conditions.
1.3.2 CHEMICAL CARCINOGENESIS:
The concept of chemicals in cancer development is not 
new (Heidelberger,1970). In 1761 John Hill described 
nasal polyposis in snuff takers. Percival Pott, in 
1775, observed higher incidence of scrotal cancer in 
^^Olish chimney sweeps. In 1795, Von Soemmering 
described association between clay pipe smokers and 
carcinoma of the lip. Tumours were first induced 
experimentally with chemicals in 1915 (Yamagiwa and 
Ichikawa, 1918).
Chemicals can induce tumours at site of application
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(skin), at site of absorption (bowel), at site of 
metabolism (liver) and finally at site of excretion 
(urinary bladder).
Human exposure to chemicals of potential or proven 
carcinogenicity can be from many sources. Mostly this 
exposure is by occupation, industry and medicines but 
can be through water, food and environment 
(Miller,1970). Chemically-induced cancers can be 
controlled and prevented by identification of potential 
chemical carcinogens, their elimination or limitation 
from exposure or modifying their interactions with 
living cells.
Cell injury leads to increased levels of growth factors 
and hormones and a decreased cell density. This is a 
stimulus for cell proliferation till the correct size 
is attained at the cost of differentiation functions. 
The switch between G q  and is controlled by levels of 
growth factors or other molecules sensed by cells. 
There can be a defect at this level in cancer. Various 
chemicals can trigger this on/off switch of the 
differentiation-dedifferentiation system. In leukemias 
for example there is loss of sensitivity of cells to 
terminal differentiation, loss of balance of growth 
control and escape from replicative senescence system.
A chemical carcinogen can be a direct acting 
compound or a stable pre-carcinogen activated to 
ultimate carcinogen by enzymes in liver or lungs
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(Shimada and Okuda,1988). They are electrophiles 
seeking electrons and react readily with nucleotides, 
proteins, nucleic acids (guanine is usual target) or 
even water^rookes and Lawley, 1964). Some show minimal 
or no interaction with DNA like chloroform, carbon 
^®trachloride and peroxisome proliferators (lype et 
al,1985). DNA damage is repaired by deletion of the 
damaged part and addition of a new patch but continued 
exposure severely impairs repair capabilities.
Whenever a carcinogen starts acting on any tissue (as 
described in a rodent model system), a small number of 
cells get activated. These activated cells start 
leading to appearance of abnormally altered 
and discrete focal areas. Actual growth rate in some 
tumours is very low even less than their normal 
counterparts like chronic leukemia and carcinoma of 
small intestine with tumour cells surviving whole life 
time without going in actual cell division. Growth 
signals can be sent or generated by macromolecular 
proteins, calcium/magnesium/sodium ions (Koch and 
Leffert,1979), cyclic AMP or inositol phosphate. Growth 
promotion, on the other hand, can be due to increased 
EGF receptors, production of TGF alpha or internal 
short circuiting of growth signals. These altered 
focal (pre-neoplastic or pre-cancerous) areas are more 
likely to develop cancer. Finally there is usually one 
big single tumour from these multiple areas. This is 
because of the difference in growth rate of one of the
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pre-neoplastic focal areas, enabling it to dominate and 
present as a single large tumour. This is the basis of 
monoclonal origin theory of tumours (Fialkow,1976 : 
Williams et al,1983).
Carcinogenesis is a multistep process (Farber and 
Cameron,1980 : Wirth et al,1986) and steps of
initiation and promotion are identifiable in chemical 
carcinogenesis. If a single chemical substance itself 
induces a tumour, the substance is called a complete 
carcinogen (acting as initiator as well as promotor). 
Chemical carcinogens, with a few exceptions 
(Weisburger,1988), are mutagenic and genotoxic acting 
on DNA, RNA or proteins (Ames et al,1973). Cytochrome 
P-450 is a specialized inducible cytochrome residing in 
endoplasmic reticuli and cause hydroxylation of a wide 
variety of hydrocarbons, steroids and drugs in the 
presence of molecular Oxygen and a reductant usually 
NADPH. It is classified as a mixed function oxidase or 
a hydroxylase. It has an important role in detoxifying 
drugs by hydroxylation in liver. The overall metabolism 
of chemical carcinogens is complex and involves both 
activation and detoxification pathways by cytochromal 
enzymes of the mono-oxygénase family like 
acetyltransferases, sulfotransferases, epoxide 
hydrolase and glutathione transferase. It is a two step 
process. In the first step hydroxyl/epoxide groups are 
iritroduced to nitrogen/carbon. In the second step
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conjugation with glucoronic acid occurs to form water 
soluble metabolites. Some of these steps generate 
reactive intermediates, which are substrates for the 
next metabolic phase. These inactive substrates, 
instead of being harmlessly and efficiently 
metabolised, may persists longer to interact covalently 
with genetic material to initiate carcinogenesis as a 
consequence of imperfect metabolism.
There a few known factors (co-carcinogens) which are 
agonist or enhancer to chemical carcinogenesis but 
alone can not cause cancer. These are partial 
hepatectomy in rodents , phorbol esters, catechols, 
phenobarbitone, choline or a methionine deficient diet, 
bacterial products and green marine algae.
There are some identified antagonistic influences on 
chemical carcinogenesis as well by antioxidants, 
retinoic acid, vitamin E, Selenium and indoles.
1.3.3 PEROXISOME PROLIFERATORS:
The term peroxisome proliferator (Reddy et al,1975) is 
used to designate a drug or xenobiotic which induces 
proliferation of peroxisomes in the cells. 
Physiological conditions can also cause peroxisome 
proliferation like diabetes mellitus or starvation 
(Thomas et al,1989), high fat diet (Itoga et al,1990), 
some species factors as in rodents and dietary 
deficiency of vitamin E (Reddy and Lalwani,1983).
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Peroxisome proliferator chemicals are mainly 
concentrated in the liver (Waddell et al,1989). They 
cause proliferation of endoplasmic reticulum and P-450. 
Cytochrome P-450 induced by Clofibrate have been 
isolated and designated as P-452. It is a protein, also 
inducible by other peroxisome proliferators. The 
peroxisome proliferators have common effects in an 
animal strain (Dwivedi et al,1989). There are , however 
, some sex related (Kawashima et al,1989), species 
related (Elcombe,1985 : Styles et al,1988) and genetic 
differences (Butler et al,1988a) in their potential 
effects.
Peroxisomes are membrane bound cytoplasmic organelles 
(0.5 uM in size) found in both animal and plant cells 
(Beevers,1979). They contain inducible beta oxidation 
(hydrogen peroxide generating) enzymes such as 
oxidases, catalase and uricase, which degrades the 
hydrogen peroxide (catalase is supposed to reduce 
hydrogen peroxide to water). Peroxisomes are involved 
in respiration, gluconeogenesis, lipid metabolism, 
thermogenesis, purine metabolism and various other 
metabolic functions (Reddy and Lalwani,1983).
Peroxisome proliferators are a group of structurally 
unrelated chemical compounds (table 1.5) which, inspite 
of their structural diversity, produce certain common 
effects in rodents and humans (Nemali et al,1989 : Rao 
al, 1986a ; Rao et al, 1988a ; Reddy and
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TABLE 1.5 
PEROXISOME PROLIFERATORS
COMMON NAME CHEMICAL NAME
Clofibrate and structural analogues:
Clofibrate
Nafenopin
Methyl clofenapate
SaH-42.348
S-8527
AT-308
Gemfibrozil
Bezafibrate
Fenofibrate
LS-2265 
Ciprofibrate
Simfibrate
Ethyl-a-p-chlorophenoxyisobutyrate
2-Methyl-2-[p-(1,2,3,4,-tetrahydro 
-1-naphthyl)phenoxy]propionic acid 
Methyl-2-[4-(p-chlorophenyl)phenoxy 
-2-methyl]propionate
1-Methyl-4-iperidyl-bis(p-chloro- 
phenoxy)acetate
1,1-bis[4'-(1"-Carboxy-1"-methyl- 
propoxy)phenyl]cyclohexane
3-[4-(1-Ethoxycarbonyl-l-methyleth- 
oxy)phenyl]5-(3-pyridyl)1,2,4-oxa- 
diazole
5-2[2,5-Dimethylphenoxy]2-2-dimeth- 
yipropionic acid
2-[4-(2-{4-chlorobenzamide)ethyl) 
phenoxy]2-methyl propionate 
Isopropyl-[4-(p-chlorobenzoyl)-2- 
phenoxy-2-methyl]propionate 
Taurine derivative of fenofibrate 
2-[4-{2,2-Dichlorocyclopropyl}phen­
oxy] -2-methyl propionic acid
1,3-Propanediol-bis(2-p-chlorophen- 
oxy)-isobutyrate
Compounds structurally unrelated to Clofibrate:
Tibric acid
Wy-14,643
BR-931
Tiadenol
RMI-14,514
DG-5685
DH-6463
LK-903
Chlorocyclizine
Aspirin
2-Chloro—5-(3,5-dimethylpiperidino- 
sulphonyl)benzoic acid 
[4-chloro-6-(2,3-xylidino)2-pyrimi- 
dinylthio]acetic acid
4-chloro-6-(2,3-xylidino)2-pyrimid- 
inylthio(N-B-hydroxyethyl)acetamide 
Bis[hydroxyethylthio]7,10-decane
(5-Tetracycloxy)2-furancarboxylic 
acid
5-{4-Phenoxybenzyl}trans-2-(3-pyri- 
dyl)1,3-dioxane
5-[4-Phenoxybenzyl}trans-2-(3-pyri- 
midinyl)1,3-dioxane 
alpha-Methyl-p-myristyroxycinnamic 
acid-1-monoglyceride 
N-(benzyloxy)-N-(3-phenylpropyl)ac­
etamide- 1-benzylimidazol e 
Acetyl salicylic acid
Plastcizers and related compounds :
DEHP
DEHA
DEHS
Di(2-ethylhexyl)phthalate
Di(2-ethylhexyl)adipate j
Di(2-ethyl hexyl)sebacate
2-Ethylhexanol
2-Ethylaldehyde
2-Ethylhexanoic acid
2-(4-Dibenzofuranyloxy)-2-methyl-
propionic acid
Dietry manipulations :
High fat diet 
Vitamin E deficiency
(Reddy and Lalwani,1983)
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Lalwani,1983):
(a) Hypolipidemia (also seen in humans).
(h) Peroxisome proliferation.
(c) Hepatomegaly.
(d) Carcinogenicity especially hepatic and thyroid.
Chemicals can cause peroxisome proliferation by two 
mechanisms (Lock et al, 1989). There can be specific 
gene activation by the chemical or its metabolite 
directly or mediated by a receptor. Alternatively it 
can be caused by the substrate overload.
These chemicals play an important role in our society 
and are potential risk factor for development of cancer 
in humans (Elcombe,1985). The hypolipidemic drugs such 
as clofibrate (Atromed), ciprofibrate (Atromed-S) and 
fenofibrate are used in control of hyperlipidemia, a 
major risk factor for coronary ischemic heart 
disease. They are also peroxisome proliferators and 
cause tumours in animal systems (Moody and Reddy,1978 : 
Rao et al, 1988a : Reddy and Lalwani, 1983 ) . New
peroxisome proliferators are also identified which are 
not hypotriglyceremic (Borges et al,1990). The 
phtha1 ate esters are used extensively in the 
formulation, processing and manufacture of highly 
versatile flexible vinyl plastics (Paton, 1972 ). A 
number of these plasticizers are identified as 
peroxisome proliferators and carcinogens (Warren et 
al,1982). Several new hypolipidemic drugs, which are in
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development and evaluation, are recognized as 
peroxisome proliferators. Chemicals are increasingly 
being identified as new peroxisome proliferators (Berge 
et al,1989 : Butler et al,1988b). Several new
peroxisome proliferators will be identified in future 
due to the current emphasis on development of 
non-mutagenic chemicals in industry, pharmacy, 
herbicides and pesticides etc (Goel et al,1986).
1.3.3.1. PEROXISOME PROLIFERATORS AS CARCINOGENS:
The morphological and biochemical alterations induced 
by different peroxisome proliferators in rodents are 
Qualitatively similar but can be different 
quantitatively, as already mentioned. A growing 
concern, in recent years, has centred on the 
tumourigenic potential of potent peroxisome 
proliferators in rodents (Reddy and Qureshi,1979 :
Reddy et al,1979 : Reddy et al,1980). These studies 
were carried out to investigate peroxisome 
proliferator-induced carcinogenesis because of the long 
term administration of hypolipidaemic drugs in primary 
prevention of ischaemic heart disease. The WHO trial of 
clofibrate has highlighted some adverse effects in man, 
possibly including cancer (Oliver et al,1978 : Oliver 
et al,1980). Human exposure to industrial plasticizers 
can be from gloves, vascular grafting material, 
iutrauterine devices, catheters, dialyzing units,
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transfusion sets, disposable syringes, plastic bags, 
insulations of wires and cables, floor tiles, weather 
stripping, swimming pool lines, footwear and clothing, 
food wrapers and containers (Thomas and Thomas,1984). 
Humans are exposed to a number of chemicals, from 
different sources in the environment, which are capable 
of causing peroxisome proliferation and other 
associated toxic effects (Conway et al,1989). 
Peroxisome proliferators are a novel class of 
carcinogens since they can act as an initiating agent, 
a promoting agent or as a complete carcinogen (Reddy et 
al,1980). Most chemicals of this group are retained in 
liver (Waddell et al,1989), gut and kidney (Weil et
3.1, 1938 ), Cells in vitro also show peroxisome 
proliferator-induced changes like in vivo systems but 
to a lesser degree and magnitude (Reddy and 
Lalwani,1983). These chemicals are not good initiating 
agents (Garvey et al,1987) but their promotional 
activity is much more important (Glauret and 
Clark, 1989). They are good promotors of initiated pre- 
neoplastc foci (Reddy and Rao,1978) and have a high 
promotional activity (Cattley and Popp,1989). On the 
other hand, some chemicals do not show significant 
promotional activity (Popp et al,1985). Peroxisome 
proliferation and mitogenicity seems to be two 
properties of these chemical agents as some 
induce in vitro DNA synthesis in cells without inducing
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peroxisome proliferation or beta oxidation (Bieri et 
al,1988).
Tumour development is seen with a number of peroxisome 
proliferators like clofibrate, nafenopin, Wy-14,643, 
tibric acid, Br-931, methyl clofenapate, bezafibrate, 
gemfibrozil, fenofibrate, ciprofibrate, DEHP, DEHA, etc 
(Reddy and Lalwani,1983). The available information 
indicate that almost all peroxisome proliferators are 
capable of inducing tumours in rodent experimental 
systems. This gives us sufficient evidence and reason 
to believe that they should be regarded as presenting a 
potential carcinogenic risk to humans as well.
1.3.3.2 TUMOURS INDUCED BY PEROXISOME PROLIFERATORS: 
Tumours-induced are usually multiple, capable of 
metastasizing to lungs and can be transplanted 
successfully in syngenic hosts (Reddy and 
Lalwani,1983). These tumours are indistinguishable, in 
morphology (gross appearance) and histopathology 
(microscopic and electron microscopic appearance), 
from those induced by other etiological agents. The 
sites of tumour development in chronological order 
liver, pancreas, stomach, kidney, lungs, urinary 
bladder and parotid gland (Reddy and Lalwani,1983).
The usual cells influenced in liver are binucleated 
ones (Styles et a2,1988). There is an increase in 
tetraploid: diploid ratio due to conversion of newly 
formed binucleate cells to tetraploid mononucleates by
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prolong drug administration (Lock et a l , 1989 ).
Hepatocytes of rats transplanted in nude mice are also 
responsive (Reddy et al,1984). Peroxisome proliferation 
is noticed in cells within 24 hours after drug 
administration. It reaches its zenith in about 14 days 
(Reddy and Lalwani,1983). Hyperplasia (increase in 
number) and hypertrophy (increase in size) of 
hepatocytes starts in a few days causing liver 
®^ls^Q©nient. Prolong administration of drug or chemical 
leads to marked hepatomegaly (enlargement of liver) in 
5 weeks time. This stimulation of cell proliferation is 
necrogenic (not associated with cell necrosis) 
l^^^icating that it is not a repair at ive hyperplasia 
(Reddy et al,1979). The effect is dose dependent and 
remains as long as the chemical agent is administered. 
Liver returns to normal in 10-14 days if the chemical 
agent is withdrawn. Acidophilic altered areas are seen 
in the liver of treated animal in 21 weeks. At 26-52 
weeks neoplastic nodules start appearing in liver. 
Hepatocellular carcinomas develop at 30 weeks and by 
week 60 almost all animals (100%) show well developed 
hepatocellular carcinomas (Lalwani et al,1981a : Rao et 
al,1984b : Reddy et al,1982). In 24-28 months carcinoma 
pancreas, leiomyoma of intestines and 
dermatofibrosarcoma are seen in addition to 
hepatocellular carcinomas (Reddy and Qureshi,1979 ).
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1.3.3.3 MECHANISM OF ACTION OF PEROXISOME 
PROLIFERATORS:
Most of the known chemical carcinogens are mutagenic 
and genotoxic (Ames,1979). In chemical carcinogenesis, 
usually there is alkylation of DNA alongwith reaction 
with cell membrane resulting in a transformed benign 
cell. Further alkylation cause?progression from benign 
to malignant state (Yano et al,1988). Some chemical 
carcinogens are non-mutagenic and non-genotoxic ( lype 
et al,1985) and some actually inhibit DNA synthesis 
(Novicki et al,1985). This interesting group of 
chemical carcinogens consist of chemicals like 
phenobarbitol, chloroform, ether, carbon tetrachloride, 
steroids, pesticides, etc (Hermann et al,1983). A new, 
substantial and significant addition to this group is 
that of peroxisome proliferators which are 
non-genotoxic and non-mutagenic (Glauret et al,1984 : 
Goel et al, 1985 : Warren et al,1980). There are no 
specific hepatic peroxisome proliferation receptors but 
they can bind to serum proteins (Lalwani et al,1987) 
without any gene activation (Milton et al,1988). There 
is ,however, no significant binding to RNA or DNA in 
both in vivo and in vitro (Goel et al,1985). No 
unscheduled DNA synthesis was seen by these chemical 
carcinogens in rat hepatocyte in vitro DNA repair assay 
or in in vivo (Cattley et al, 1988 ). There is
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progressive increase in 8-hydroxydeoxyguanosine, an 
adduct resulting from oxidative DNA damage. This is the 
most recent and only found evidence of any DNA damage 
(Kasai et al,1989 : Reddy and Rao,1989). Some
alterations in nucleic acid synthesis are reported 
(Seifert and Mostecka,1989). At the cell membrane level 
they are proposed to be acting at déacylation - 
reacylation cycles between phosphatidylcholine and 
lysophosphatidylcholine (Crane and Masters,1986). They 
are mitogenic to cells (Bieri et al,1988) but DNA 
synthesis alone can not account for carcinogenicity. 
Although all of them cause similar degrees of peroxisome 
proliferation, there isadifference in oxidative damage 
caused and carcinogenic potential (Conway et al,1989). 
There are reports of an inhibitory effect or 
accelerated regression by peroxisome proliferators on 
pre-neoplastic initiated cells by other chemicals 
(Staulbi et al, 1984). This indicates an entirely 
^tfforent mechanism of action as compared to other 
chemical carcinogens.
The field of peroxisome proliferator-induced 
carcinogenesis is in its early stages. There is very 
Little information available on the detailed aspect of 
metabolic activation, the DNA damage and subsequent 
repair, and macromolecular interactions associated with 
individual chemicals in this very broad group. 
Peroxisome proliferation is a tissue specific 
phenomenon restricted largely to hepatocytes (Reddy and
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Rao,1987) and carcinogenicity is not directly 
attributable to the chemical but to adoptive responses 
of the host. Hepatocytes respond irrespective of their 
location (Reddy et al,1984). Peroxisome proliferation 
can be used as an indicator of carcinogenic potential 
of a chemical (Rao et al, 1988a). It is suggested that 
peroxisome proliferators and other non-mutagenic 
chemicals only promote already existent initiated pre­
neoplastic cells (Hermann et al,1983) as compensatory 
cell proliferation to a necrotizing agent or partial 
hepatectomy can enhance the growth of initiated 
hepatocytes (Columbano et al,1990).
It is believed the carcinogenic effect? are due to 
reactive species such as hydrogen peroxide and free 
oxygen radicals derived from enhanced peroxisomal 
B-oxidation of fatty acids (Horton and Fairhurst,1987). 
Hydrogen peroxide and hydroxyl radicals themselves are 
capable of DNA damage (Allam et al,1988), and can lead 
to increased lipid peroxidation (Kornburst et al,1984). 
Carcinogenic effect is mediated either directly by 
carcinogenic hydrogen peroxide (generated by 
peroxisomal oxidases) or indirectly by free radicals 
produced from hydrogen peroxide (Rao et al,1984b). The 
result is an increase in free radical production 
retarding mixed function oxidase system (Miles et 
al,1980).
The exact mechanism remain intriguing but they
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apparently overload the cellular defences against 
peroxidative damage like catalase and glutathione 
peroxidase by stimulating hydrogen peroxide production. 
There are natural antioxidant defence systems in the 
body like vitamin E, glutathione, selenium, albumin, 
transferrin, lactoferrin and ceruloplasmin
(Halliwell,1988). Antioxidants could retard neoplasia 
by scavenging active oxygen superoxide radical 0(2), 
hydrogen peroxide, hydroxyl radical HO, and singlet 
oxygen (Rao et al,19 84a). During peroxisome 
proliferator-induced carcinogenesis there is depletion 
of vitamin E, elevation of oxidised glutathione, 
decrease in superoxide dismutase, depletion of 
selenium, and accumulation of excessive autofluorescent 
lipofuscin (Borek et al,1986b : Ciriolo et al,1982 : 
Lake et al,1989 : Lalwani et al,1981a : Reddy et 
■^L/ 1982). Ciprof ibrate and other peroxisome 
Proliferators irreversibly inhibit glutathione S 
transferase (antioxidant) both in vivo and in vitro 
(Foliot et al,1986). All this indicate?an oxidative 
stress. Severe impairment of antioxidant system is also 
seen in human hepatoma (Corrocher et al,1986). 
Antioxidants (e.g,ethoxyquin) markedly inhibit hepatic 
tumourigenic effect of ciprofibrate as evidenced by 
decrease^ tumour incidence, & decreased number of tumours 
per liver and a reduced tumour size (Rao et al,1984a).
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1.3.3.4. BIOCHEMICAL CHANGES INDUCED BY PEROXISOME 
PROLIFERATORS DURING CARCINOGENESIS:
Peroxisome proliferators induce a number of biochemical 
changes in rodent cells during carcinogenesis (Reddy 
and Lalwani,19 83). There is marked change in the 
profile of specific hepatic proteins and increased 
levels of mRNAs encoding for peroxisomal beta oxidation 
and microsomal-w-oxidation enzymes (Lock et al, 1989). 
The regulation of expression of peroxisomal and 
microsomal genes appear to be linked (Lock et al, 
1989). Lipid peroxidation can also activate oncogenes 
as myc is described (Dianzani, 1989). These changes are 
induction of new molecules, loss of an existing 
^^olecule or quantitative changes in already existing 
molecules. These changes may involve proteins, enzymes, 
hormones, receptors, etc. There is absence of gamma 
Glutamyl transpeptidase in altered areas, pre­
neoplastic nodules and hepatocellular carcinomas (Rao 
et al,1984b : Rao et al,1988b). This GOT negativity 
persists upto 8 weeks after withdrawl of the chemical 
is a common feature in hepatic lesions (Rao et 
al,1986b). GGT negative phenotype is stable and is not 
modulatable following treatment with other chemicals 
(Yeldani et al,1989). Lung metastasis of hepatic 
tumours induced by peroxisome proliferators are also
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GGT negative (Milano et al,1987). There is signifcant 
increase in peroxisome proliferation associated 
polypeptide (mol wt.80,000) PPA-80 (Bartles et al,1990 
: Lalwani et al,1981b : Watanabe et al,1985). There is 
quantitative change in 15 peroxisomal proteins studied 
in liver homogenates. Six proteins show increase while 
three show decrease in acidic gels. Six proteins show 
an increase in basic gels as well (Watanabe et 
al,1985). Placental form of glutathione S transferase 
is found negative in altered areas, pre—neoplastic 
lesions, neoplastic nodules and hepatocellular 
carcinomas (Rao et al,1986a : Rao et al,1986b : Rao et 
al,1988b). There was down regulation of five plasma 
membrane proteins (EGF receptor, asialoglycoprotein 
receptor, HA 321, HA 4 and dipeptidylpeptidase IV) by 
immunoblotting, immunoprécipitation and
immunofluorescence (Bartles et al,1990). There was also 
induction of a more basic lower mol.wt. isoform of 
basolateral plasma membrane protein CE 9. These changes 
3^© first observed on day 1—5 and these effects 
reverse 2-3 weeks after termination of treatment. 
Glucose 6 phosphatase activity was decreased in altered 
areas and neoplastic nodules but some reports have 
indicated a marked increase (Rao et al,1984b). A 
decrease in ATP-ase activity is reported after 
peroxisome proliferator treatment (Rao et al,1984b). 
Mitochondrial isomerase is induced greatly in treated 
rat livers (Yokota et al,1989). Carnitine acetyl
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transferase is greatly induced (Moody and Reddy ,1978). 
Catalase is increased two fold (Reddy et al,1974). 
Enoyl-CoA hydratase is increased 30-50 fold in liver 
and 3-5 fold in kidney (Lalwani et al,1981b). A highly 
specific paramarker induced in kidney is 1-acyl 
glycerophosphocholine (GPC) acyltransferase (Kawashima 
et al,1989). There is induction of peroxisomal fatty 
acyl-CoA oxidase (FACO) and microsomal 1aurate 
hydroxylase (LH). (Kocarek and Feller,1989). Increase 
in the activity of cytosolic epoxide hydro1ase and 
lauric acid hydrolase, peroxisomal beta oxidation 
enzymes, is reported with tiadenol (Thomas et al,1989). 
There is lack of expression of alpha fetoprotein 
messenger RNAs in hepatocellular carcinomas (Rao et 
1988b) although alpha fetoprotein is strongly 
associated with cell proliferation (Reddy et al,1979).
Peroxisomal enzymes are also regulated by other 
chemical carcinogens but probably through a very 
different mechanism (Nemali et al,1989). Most of these 
molecules which are induced or regulated by peroxisome 
proliferators are in a molecular weight range of 30,000 
to 50,000 with an exception of PPA-80.
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1.4.TUMOUR ANTIGENS:
1.4.1.INTRODUCTION:
Tumour cells , like other cells, are bound by a complex 
1ipid membrane which is traversed by glycoprotein 
molecules protruding from the surface. The 
immunodominant prosthetic groups are both protein and 
carbohydrate sections of molecule giving great 
diversity and polymorphism due to complexity and 
variations. The cell surface is thus a forest of 
inolecular stumps which serve a variety of functions 
e.g, maintenance of structure, the reception, fixation 
and enzymatic modification of molecules prior to their 
transport into cell, cellular recognition, cell union, 
immunological reactions, and the export of excretion 
products from cells. Tumour cells share many antigens 
'^ Lth normal cells e.g, differentiation antigens, tissue 
specific antigens, species specific antigens, MHC 
^^^Lgens, receptors, and blood group antigens 
(^Lg 1.4). Normal cell surface molecules, alone or in 
combination, are recognized as self and do not initiate 
an immune response.
Tumour cells possesses features distinct from 
comparable normal mature cells. One important change 
associated with cell transformation is a change in cell 
surface molecules. The surface of a transformed tumour 
cell differs from its normal counterpart in its 
molecular composition and immunological make up
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(Bhavandan and Davidson,1982 : Edelman,1983 :
Farber,19 84). The cell surface is involved in 
neoplastic change and determines behaviour of the cell 
(Prime et al,1987). If these abnormalities can be 
identified and related to specific behavioral 
properties, it will be helpful in revealing the 
molecular mechanism of cancer. Additionally, changes in 
these molecules may represent target sites to be 
exploited for screening, diagnosis, therapy, monitoring 
and prognosis (Friedman and Skehan,1981). Development 
of an absolutely new molecule, drastic modification of 
s^^ucture or total deletion of a molecule, causing 
alteration of profile of adjacent molecules or 
unmasking of normally covered molecules may create a 
non-self stimulus (Fig 1.5). Any new or modified 
^olQCule which renders a cell auto—immunogenic is 
regarded as a neoantigen, regardless of whether the 
change results from an endogenous alteration of 
cellular activities or is extraneously imposed by 
factors such as viruses or chemicals.
1.4.2 NATURE OF ANTIGENIC CHANGE:
Cell surface antigenic changes resulting from cell 
transformation may be of two types:
a) Quantitative changes in pre-existing antigenic 
molecules like in tissue specific antigen, species 
specific antigen, receptors etc (Brown et al,1981 : 
Prime et al,1987).
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b) Qualitative changes.
i. deletion of an existing antigen (Becker et 
al,1986 : Bowen and Baldwin,1979 : Hixson et al,1983 :
Holmes et al,1982).
ii. appearance of a totally new antigen 
(Baldwin,1973 ; Baur et al,1977).
Tumour antigens can elicit an immune response in host 
as shown by lymphocyte infiltration of tumour bed 
(Edelson et al,19 7 5), hypersensitivity to tumour 
Gxt^acts (Bluming et al,1972) and antibody production 
( Irie et al,1979) which can react with tumours of 
similar histology (Embleton et al,1980). Immune 
response can also be triggered by deletion of a normal 
cell surface antigen (Karre et al,1985). The immune 
response may not be strong enough to cause tumour 
regression but even then tumour antigens are important 
markers, being the raw material of refined diagnosis, 
rational therapy and long term monitoring. An ideal 
tumour antigen must have following features:
1. Present only and specifically on tumour cells.
2. should be in sufficient quantity to be detected.
3. should be very characteristic of tumours of the same 
etiology or same histology.
4. should indicate tissue of origin and tumour type.
5. should indicate state of differentiation.
6. must be at the cell surface for therapeutic 
exploitation but not for diagnostic use.
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7. should not be transiently expressed. If phase 
specific, during carcinogenesis, it should be present 
throughout the whole phase.
1.4.3 HISTORIC BACKGROUND OF TUMOUR ANTIGENS:
The search for specific tumour antigens and markers has 
been the longest un-interrupted line and direction of 
cancer research. Hybridoma derived monoclonal 
BH^lhodies and molecular genetics techniques have made 
it easier to analyse tumour cells in finer detail. 
Today we know more about principles and processes of 
helper cells, suppressor cells, antigen presentation by 
macrophages, soluble regulatory or growth factors, 
associative recognition, idiotype — antidiotype 
networks etc (Old,1981). Historically the search for 
tumour antigens focused initially on tumour specific 
^^^Lgens common to all cancers. Although such "common" 
tumour antigens are not yet been detected, these 
studies led to important discoveries of transplantation 
and differentiation markers (Old,1982). In early 1900 
tumour transplantations were attempted and the 
resulting graft rejection lead to optimism. Efforts 
were put to develop a tumour vaccine without a full 
understanding of the specificity of the immune response 
(Baldwin,1955). The inconsistent results caused 
contusion and skepticism, but this provided an impetus 
for further research. The existence of tumour specific
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antigens was later proved beyond any doubt, with the 
development of inbred animal strains sharing identical 
cell surface antigenic determinants (Bray, 1978 :
Foley,1953 : Gross,1943). These tumour antigens were 
able to elicit an immune response in host leading to a 
protective effect against subsequent tumour challenge 
(graft) even in the same animal where the tumour 
originated (Foley,1953 : Gross,1943 ; Klein et al,1960 
: Prehn and Main,1957). This demonstrated that immunity 
was specific for the tumour tissue and implied that new 
markers had developed in cancer cells which were 
recognized as foreign by the immune system. They were 
referred to as tumour antigens.
immune system, cellular and humoral working 
synergistically, is capable of identifying and 
destroying any cells, organisms or molecules which are 
foreign and alien to the body with a few exceptions 
like fetus, graft and parasites (Old,1981). Burnet 
proposed the concept of immunologic surveillance 
against cancer, based on the idea of tumour antigens. 
He proposed that the immune system was able to 
recognize and eliminate foreign antigens like those of 
tumours and malfunctioning of immune system was 
responsible for tumour development (Bray,1978). This is 
probably why a tumour develops more frequently in 
immunosuppression and it may be an explanation for 
spontaneous tumour regression (Carlsen,1990 : Gaffey 
Michael et al^1990). Later studies supported Burnet's
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hypothesis (Moller and Mol1er,1976) and it was 
concluded that tumours were immunogenic (Klein,1969) 
and tumour antigens were capable of eliciting both B 
and T cell responses (Fidler,1985). It is difficult to 
say what the effect and role of immune system is on 
tumour development of any given etiology.
It was found, in experimental systems, that as the dose 
of a carcinogen was increased the incidence of 
corresponding tumours increased , the latent period 
shortened and immunogenicity was much greater 
(Bray,1978 : Prehn,1975). Generally human tumours are 
weakly antigenic and have a higher potential to 
metastasise probably because the human exposure to 
carcinogen is over a longer duration and in a low dose. 
It has been proposed that a high dose of tumour 
antigens evokes a high immune response but a low and 
prolonged dose lead to evasion of immune system and 
tolerance (Hewitt et al,1976). Human cancer evokes a 
specific immune response under strictly controlled 
conditions (Nairn et al,1971). The antigenic strength 
of tumour cells may be increased by the in vitTO 
culture of cells (Jamasbi and Nettesheim,1977). 
A^ffhodies were found against malignant disease as 
df^oot evidence (Bodurtha et al,1975). Auto—antibodies 
are also a common feature of the tumour state (Swissa 
al,1990). Epithelial tumours may not be strongly 
immunogenic as shown by lack of serum antibodies
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(Swissa et al, 1990) but they may have been neutralized 
by circulating free antigens or may disappear with the 
onset of metastasis (Bray,1978).
A further source of immunogenic molecules is from the 
interior of cells (cytoplasm, nuclei, nucleoli and 
other organelles) released as secretions or after cell 
disintegration. They are not strongly immunogenic 
because of enzyme degradation, self tolerance or 
masking of determinant sites. Anti-cytoplasmic, anti- 
nuclear and anti-nucleolar antibodies are seen in 
cancer (Bray, 1978) in addition to old age and 
autoimmune diseases (Flood et al,1981). They are higher 
at later stages of disease but it is unclear whether 
they influence progress of disease or are result of 
tumour necrosis, antigen being released from dead 
cells.
Efforts have been expanded to produce a vaccine on the 
basis of the tumour specific antigens (Reif,1982). This 
is also because surgery, chemotherapy and radiotherapy 
have serious adverse effects (Andersson et al,1990 : 
Pohjola-Sintonen et al,1990) although they are very 
successful provided that the cancer is detected early. 
In spite of much effort, an ideal tumour specific 
antigen has not been found so far (Daar, 1987a : Old, 
1982) but it is now possible to do things immunologists 
and clinicians want to do without the identification of 
the ideal tumour specific antigen or marker. Tumour 
antigens have proved a success in screening, diagnosis,
59
monitoring and prognosis. They are used in therapeutic 
applications widely but their potential has not yet 
been fully exploited.
1.4.4 CHEMICAL NATURE OF TUMOUR ANTIGENS:
Proteins, lipids and carbohydrates are integral parts 
of the cell membrane and are involved , directly or 
indirectly, with all cellular functions and processes 
(Friedman and Skehan,1981 ) . Some regard tumours as a 
disease of cell membranes (Wallach,1976). Cell surface 
changes associated with malignant transformation 
include changes in glycoproteins, altered cell surface 
enzymes, altered sugar transport, changes in 
glycolipids and increased lectin agglutinibility. 
Membrane fluidity is increased while cell surface 
fihronectin and calcium requirement for growth are 
decreased. Invasion, metastasis and many other 
properties of tumour cells are associated with cell 
surface changes (Daar,1987a). It is reasonable to 
^oiiove that many of these have a common underlying 
basis. Numerous comparative studies of normal and 
transformed tumour cells have been made highlighting 
the differences between them (Hynes,1976).
Tumour antigens can be glycoproteins, glycolipids, 
carbohydrate antigens, proteoglycans or gangliosides, 
growth factor receptors (Prehn,1989) or altered growth
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factor receptors (Jones et al,1990). The examples of 
glycoprotein antigens are melanoma, colorectal 
carcinoma and melanoma (Albino and Houghton,1985 : 
Reisfeld and Cheresh, 1987 : Steplewski and Koprowski, 
1982). The examples of glycolipid antigens are seen in 
melanoma, colorectal carcinoma, Burkitt's lymphoma and 
other solid tumours (Albino and Houghton, 1985 : 
Blaszczyk et al, 1984 : Feizi, 1985b : Nudelman et al, 
1983 : Springer, 1984 : Steplewski and Koprowski,
1982). Carbohydrate antigens are present, alone or 
attached to glycoproteins and glycolipids, in a number 
of human cancers like gastrointestinal and bladder 
cancers (Feizi, 1985a : Feizi, 1985b). Proteoglycan 
antigens are described mainly in melanomas (Couchman 
and Ljubimov, 1989 : Ross et al, 1983). Gangliosides 
(composed of neutral sugars, sialic acids and lipids) 
function as receptors for toxins, binding sites for 
hormones, lymphokines and interferons and as antigenic 
determinants (Friedman and Skehan, 1981). Ganglioside 
tumour antigens are described in melanomas, 
neuroblastoma and carcinoma colon (Feizi, 1985b : 
Reisfeld and Cheresh, 1987). In addition sialoprotein 
(Bresalier et al, 1990), sialomucin or fibronectin 
(Friedman and Skehan, 1981) and an antigenic complex of 
glycoprotein - proteoglycan (Bumol and Reisfeld, 1982) 
are described in various tumours.
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1.4.5.TYPES OF TUMOUR ANTIGENS:
Tumour antigens can be classified by their tissue 
distribution. The different types can be distinguished 
by analysing their specificity (Baldwin,1978).
(1) TUMOUR SPECIFIC ANTIGEN (TSA): Tumour specific
antigens , according to definition, are ones which are 
present specifically on tumour cells while being absent 
from all other fetal or normal cells of comparable age 
and histology. They were described on a number of 
tumours initially by transplantation assays (Baldwin et 
/19 7 2 : Foley,1953 : Gross,1943 : Wortzel et
^^^1985). These TSA are called tumour specific 
transplantation antigens (TSTA) or tumour rejection 
antigens (TRA), when they are capable of eliciting an 
immune response leading to graft rejection and 
transplantation immunity (Klein, 1968 ) . TSA are 
described in a number of spontaneous and induced tumour 
system in animals as well as in human tumours like 
melanoma, astrocytoma and renal tumours (Albino and 
Houghton,1985). Multiple TSA are described as present 
on a single tumour cell (Wortzel et al,1983 : Wortzel 
et al, 1985) with each one playing an individual role. 
TSA are not always expressed on transformed tumour 
cells (Baldwin,1978). An endless polymorphism and 
diversity of such antigens has been described but 
little is known about the nature and complex
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antigenicity of any single tumour (Baldwin,1973). TSA 
is still a fundamental , but unresolved , question of 
tumour immunology.
(2) TUMOUR ASSOCIATED ANTIGEN (TAA); The antigen most 
close to TSA are the class 1 antigens on melanomas 
(Albino and Houghton,1985). Most TSAs, which were 
thought to be tumour specific initially, were later 
found to be present at a lower concentration in normal 
tissues. The term tumour associated antigen was thus 
introduced. TAA are present widely in different tumour 
systems (Chang et al,1981). They can be phase specific, 
being present transiently at some stage of 
carcinogenesis. They are mostly localized on the plasma 
membrane and may be capable of inducing transplantation 
resistance being then called tumour associated 
transplantation antigens or TATA ( Baldwin, 1978 ) . 
Examples of TAA are carcino-embryonic antigen (Gold and 
Freedman,1965), alpha-feto protein (Abelev,1971), human 
chorionic gonadotrophin (Cole et al,1983) and prostatic 
acid phosphatase (Daar et al,1981).
(3) ONCOFETAL ANTIGENS: De-repression of fetal antigens 
is a generalized response to malignant transformation 
with de-differentiation of tissue (Alexender,1972). 
These cross-reacting antigens may be present at various 
fetal developmental stages. They are a promising tool 
for diagnosis or therapy but are difficult to control. 
They are seen in a number of chemically-induced tumours 
(Baldwin,1973). In chemically-induced hepatomas these ,
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unlike alpha-feto protein, are immunogenic in the 
tumour bearing host (Baldwin,1978). They are different 
from TSA biochemically. They are in the cell cytosol 
fraction being released following cell rupture while 
TSA are intimately related to the cell membrane 
released only by papain or glucoronidase digestion 
(Baldwin,1978). They do not induce transplantation 
resistance and may be non-immunogenic. Some of the 
examples of oncofetal antigens are 5T4 (Hole and 
Stern,1988), GICA or gastrointestinal cancer associated 
antigen (Raux et al,1983), FC10.2 antigen of
teratocarcinoma (Gooi et al,1983), fetal-sulpho- 
glycoprotein in carcinoma stomach, pancreatic oncofetal 
antigen, and beta oncofetal antigen in carcinomas of 
colon, lung, breast, liver and kidneys.
(4) MAJOR HISTOCOMPATIBILITY ANTIGENS: These are 
polymorphic cell surface glycoprotein molecules. MHC 
class I antigens (HLA-A, B, C) are present on most 
nucleated cells. MHC class II antigens (HLA-DR, DP, DQ) 
are present on a wide range of tissues. Some murine 
tumours present alien inappropriate MHC antigens like 
TL antigen in T-cell tumours (Parmiani,1980). There are 
strong reasons to believe that tumours express 
inappropriate class I MHC antigens as tumour antigens.
(5) ONCOGENES AND ONCOGENE PRODUCTS: An oncogene is a 
genetic sequence coding for specific information 
required for cellular growth or differentiation. Viral
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oncogenes (v-onc) were acquired by retroviruses during 
evolution from normal cellular genes (c-onc) by 
transduction i.e., proximal integration followed by 
aberrant transcription. For each retroviral v-onc 
identified, there is a corresponding c-onc or 
proto-oncogene which codes for vital cellular 
functions. During normal growth, embryogenesis or 
differentiation proto-oncogenes of cells are not 
oncogenic but may be activated to an oncogene form 
causing aberrant growth. Activated proto-oncogenes and 
the products they encode may be detected (altered or 
excessive) and thus serve as antigenic markers of 
malignant disease. An example is the specific 
chromosomal translocation and activation of a 
proto-oncogene in Burkitt’s lymphoma, the c-myc 
oncogene is translocated from its normal position on 
chromosome 8 to Ig loci on 22, 2, or 14 in
B-lymphocytes (Taub et al,1982) presenting an excessive 
expression. The myc or ras are active in normal fetal 
tissues but stop acting in adult ones. Some oncogene 
products are secreted in blood and serve as circulating 
antigenic markers e.g. platelet derived growth factor 
PDGF, the c-sis gene product (Robbins at al,1983).
(6) BLOOD GROUP ANTIGENS: Blood group antigens, being 
altered chemically , are also potential tumour 
antigenic markers (Thorpe et al,1983). A slight change 
in normal glycosylase level or sugar pool composition 
might lead to such aberrant expression e.g. A, Lewis^
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(Le^) antigen of lung carcinoma and T-antigen (Thomsen 
- Friedenreich antigen) may act as TSA from a minor 
change in its structural chemistry (Springer,1984).
1.4.6.TUMOUR ANTIGENS ON TUMOURS OF DIFFERENT 
ETIOLOGIES:
Many of the tumour antigens are described in 
experimental animal systems for two reasons. Firstly, 
artificial tumour induction is not possible in humans 
because of obvious ethical reasons and secondly, it is 
impossible to identify the etiological agent in any 
human tumour with certainity. TAs showvarlability in 
their immunological and biochemical features in 
accordance with their etiology.
1.4.6.1.TUMOUR ANTIGENS ON VIRUS-INDUCED TUMOURS:
Genetic information for neo-antigens is introduced into 
cells from extrinsic oncogenic virus. Neo-antigens are 
common and cross-reactive among tumours induced by the 
same virus (like shared antigens in Burkitt's 
lymphoma), but not with tumours induced by a different 
virus (Klein et al,1960 : Klein,1968) with a few 
exceptions (Ball et al,1984). This applies to tumours 
^^Ising in different members of the same strain, 
members of a different strain or even in members of a 
totally different species (Bowen and Baldwin,1979).
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Tumour transformed cells induced by DNA viruses are 
generally non-permissive and do not produce infectious 
virus. TAs are usually cellular, separate from the 
viruses. DNA viruses are usually necrogenic, but when 
oncogenic, their transformed cells express 4 type of 
antigens. (1) T-antigen which is nuclear, coded for by 
the virus and has a molecular wt.70,000. (2) S cell 
surface antigen (3) U nuclear antigen and (4) viral 
TATA capable of rejection response, specific for virus 
but not a virion antigen.
Tumours induced by RNA viruses are permissive and 
release infectious virus continuously. RNA viruses can 
transform and replicate within the cell at the same 
time. The transformed tumour cells express: (1) viral
envelope glycoprotein antigen gp70. Antibodies against 
this protect against subsequent tumour challenge (2) 
intra-viral antigens (3) virally-induced cell surface 
antigens, as demonstrated by rejection or in vitro 
assays, e.g.GSA (a) gross cell surface antigen - a, in 
feline leukemia type C virus transformed cells.
A number of other TAs in virus-induced tumours have 
been described (Ball et al,1984 : Friedman and
Skehan,1981 : Old,1981 : Rogers and Galetto,1985).
1.4.6.2 TUMOUR ANTIGENS ON TUMOURS INDUCED BY 
PHYSICAL AGENTS:
New cellular antigens are demonstrable (DeWitt,1981)
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and each individual neoplasm may posses its own 
characteristic specific antigen regardless of 
histogenic or etiologic similarity (Daynes et al,1985 : 
Wortzel et al, 1985 ) and show polymorphism and 
heterogeneity (Kripke,1977). They may be capable of 
inducing transplation immunity seen even in
early stages of carcinogenesis (Seilstad et al,1985) or 
in, in vitro transformed cells (Fisher and 
Kripke,1984). Multiple antigens can be expressed 
simultaneously on a single cell (Wortzel et al,1985). 
The antigenicity of tumours is variable but they may be 
highly immunogenic. The antigenicity depends on culture 
condition and passage level in, in vitro systems.
1.4.6.3 TUMOUR ANTIGENS OF CHEMICALLY-INDUCED TUMOURS:
Tumour antigens of chemically-induced tumours were the 
first TAs described in 1950s (Baldwin,1955 :
Foley,1953 : Prehn and Main,1957). They are diverse and 
polymorphic (Baldwin,1973) and are believed to result 
from complex and not fully understood DNA — carcinogen 
interactions (Bowen and Baldwin,1979). Most of the 
chemically-induced tumours (induced by the same 
chemical in the same histogenic tissue of different 
animals) exhibit distinct and unique antigens of their 
own which fail to show any cross —reactivity 
(Baldwin,1973 : Baldwin,1978). A number of chemically- 
induced tumours, on the other hand , show cross-
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reactive TAs (Embleton et a l ,1980 : Hellstrom et 
al,1985 : Holmes et al,1971). Every tumour begin as 
multi focal areas of transformed cells (which may be 
responsible for tumour heterogeneity) but usually one 
focus supplants the rest. One explanation for the 
uniqueness of TAs is that they are derived from one 
single transformed tumour cell, the monoclonal origin 
(Fialkow, 1976).
Some of the TAs on chemically-induced tumours are: ( 1 ) 
defined by transplantation assays (2) extremely 
polymorphic with rare cross-reactions (3) stable 
through cell culture or animal passage - specificities 
can not change but may be lost (4) un-related to MHC 
(DuBois et al,1982) (5) seen unrelated to normal 
differentiation antigens (6) may be multiple 
(Wortzel et al, 1983 ) .
TAs may be expressed on pre-neoplastic lesions like 
skin papilloma (Lappe,1968), bladder tumours (Hellstrom 
et al, 1985) and tumours of the oral mucosa (Prime et 
31,1987). TAs can be found on carcinogen treated 
tissues without any obvious transformation 
(Trejdosiewicz et al,1984). TAs and antibodies to them 
are found in the blood and lymph of animals with 
tumours (Chang et al,1981). Immune responses to 
chemically-induced tumours have T, B and null-cell 
components and are tumour specific (Calderwood et 
al,1981). Antigenicity of tumours is variable like very 
weak in mammary tumours and very high in squamous cell
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carcinomas (Old ,1982). There is even a great
difference of antigenicity between tumours induced by 
the same chemicals in different tissues. TAs of 
chemically-induced tumours are described in a number of 
tumour systems (Baldwin,1973 : Baldwin,1978 : Bowen and 
Baldwin,1979 : DeLeo and Srivastava,1985 : Klein et 
al,1960).
1.4.7 NGN-ANTIGENIC TUMOURS:
Many spontaneously-arising tumours in animals, which 
are close analogues of human disease, are 
non-immunogenic or weakly immunogenic (Baldwin and 
Embleton,1969 : Baldwin,1978 : Bray,1978 : Hewitt et 
al,1976). However, some may be strongly antigenic 
(Morton et al,1969). There is a large volume of 
conflicting results and thus situation is confusing. 
Most of the evidence is from in vitro studies and this 
is where the problem arises. The antigenicity of 
carcinogen-induced tumours is determined largely by 
factors other than immunoselaction (Prehn,1975) as 
already described in section 1.4.1 and 1.4.3. Antigen 
deficiency may be inherent or related to biological 
factors such as antigen stability, modulation, 
solubility, cell membrane distribution or blocking 
factors. Non-immunogenic tumours can elicit an immune 
response under certain conditions which would indicate 
the possible presence of blocking factors in the host
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(Herberman et al,1972).
1.4.8 IMPORTANCE OF TUMOUR ANTIGENS;
Each antigen, present on a tumour cell, has an 
individual and unique role to play (Wortzel et 
al,1985). Sometimes there are multiple TAs present on a 
single tumour cell (Wortzel et al,1983). Inter-tumour 
and intra-tumour antigenic heterogenity may be found 
(Kennedy et al,1987). TAs play a role in tumour cell 
behaviour e.g., growth (Stauder et al,1989), and 
metastasis (Shestowsky et al,1990) as also described in 
section 1.2.1. Glycoprotein TAs are important and play 
a role in drug resistance of tumour cell (Belli et 
al,1990). A 95-120 kd glycoprotein in hepatomas is 
believed to be responsible in cell - substratum 
adhesion (Neumeier et al,1984). A number of TAs are 
associated with and involved in cell proliferation and 
transformation (Milner and Cook,1986) and their 
presence correlates well with tumour type in a 
proliferating tumour mass (Wong and Tattersall,1989). 
Addition of purified TAs to culture can cause cell 
proliferation (Armitage et al,1989). Free TAs shed from 
tumours bind antibodies in serum and block the immune 
response (Pimm et al,1989). This is more marked with 
tumours of higher metastatic potential (Currie and 
Alexander, 1974). TAs can be lost from cells when they 
are cultured (Payne and Coggin,1985). Mutagen treatment 
of cancer cells in vitro increase their immunogenicity
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by unmasking TAs, appearance of neo-antigens or 
selection of neo-antigenic cells (Boon and 
Maryanski,1985). Tumour cells, under attack from 
antibodies, can undergo antigenic modulation and 
antigen negative mutants can arise (Stevenson,1989). 
Antibodies start developing in carcinogen exposed 
animals against TAs well before the appearance of 
tumour, indicating the significance of TAs in early 
diagnosis (Bentvelzen et al,1983). TAs may be sensitive 
to physical and chemical modification (Jansson et 
al,1989) like trypsin affects the cell surface TAs 
which re-express after about 12 hours (Pontesilli et 
al,1989). Neuraminidase treatment increase antibody 
binding to TAs (Greenfield et al,1989). Alpha 
interferon can increase serum levels of TA markers and 
is helpful in sero-diagnosis (Scambia et al,1990). The 
pH and oxygen concentration influence expression of TAs 
quantitatively and that is how hypoxia and abnormal pH 
make tumours susceptible to killing by MoAbs and 
immunoconjugates (Davies et al,1989).
1.4.9 MONOCLONAL ANTIBODIES AND TUMOUR ANTIGENS:
A number of methods have been used over last 50 years 
or so to study and identify TAs. These included tumour 
transplantation assays (Baldwin, 1955 ) , leucocyte 
migration inhibition (Bloom et al,1969), polyclonal 
serum (Bray,1978), spontaneous tumour regression
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(Bodurtha et al,1967), colony inhibition, 
microcytotoxicity assays, complement dependent cell 
cytotoxicity (Baldwin,1978) and identification of 
tumour-specific antibodies or tumour antigens in serum 
(Herlyn et al,1987). The development of the hybridoma 
technology (Kohler and Milstein,1975) and production of 
monoclonal antibodies (MoAbs) has totally 
revolutionized the field of tumour immunology. This is 
because of the high specificity, easy production, and 
abundant continuous supply of stable standard titre of 
such antibodies. These are some of the advantages of 
MoAbs over polyclonal sera (Teh et al,1985). MoAbs have 
emerged as the most popular tool for the study of TAs. 
It may, however, sometime&be difficult to produce MoAbs 
against weaker antigens because of the presence of 
immunodominant antigens (but the new antigens may be 
^ f er ent from these antigens). Also physical 
conditions may affect the affinity, reactivity and 
functional activity of MoAbs in different assays 
(Haskell et al,1983). MoAbs are now available or being 
developed against TAs of many of the known human or 
experimental tumours (Proceedings of an international 
workshop on MoAbs to TAs,1981 : Abstracts from the 13th 
congress of European Society for Medical 
Oncology,1989). MoAbs can help greatly in more detailed 
dissection of antigens to examine their molecular 
composition, genetic origin and structural complexity.
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The original attempts to detect TAs with MoAbs were 
carried out in leukemias (Steplewski and 
Koprowski,1982), using antibodies which reacted 
preferentially with tumour cells and indicated the 
stage of lymphoid development and differentiation. Work 
since that time has shown that there may be great 
inter- and intra-tumour heterogeneity of TA expression. 
Thus it is better to use a panel of MoAbs rather than a 
single antibody for this type of work (Durrant et 
al,1989).
1.4.10 USE OF TUMOUR-SPECIFIC MONOCLONAL ANTIBODIES 
IN THE FIELD OF ONCOLOGY:
Specific MoAbs raised against TAs are potentially a 
potent and powerful tool, both in research and applied 
medicine. Their use ranges from in vitro tumour cell 
characterization to screening, diagnosis, therapy and 
prognosis (Daar,1987b : Sikora and Smedley,1984 :
Wawrzynczak and Thorpe,1988).
(A) SCREENING: TAs are present in pre-neoplastic 
lesions, early cancer or even carcinoma in situ 
(Giwercman et al,1990). They are thus very important in 
the screening and early diagnosis. The combined 
determination of two or more antigenic markers will 
increase the efficacy and reliability of screening 
systems (Begent and Rustin,1989). Circulating TAs are 
important in this respect (Sears et al,1982).
(B)DIAGNOSIS OF TUMOURS: MoAbs can be used to localise
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tumourgin vivo, for histological diagnosis or for serum 
assays of TAs.
Radiolocalization (Radioimmunodiagnosis, radioimaging 
or immunoscintigraphy) is the localization of a tumour 
in vivo after injecting a radioactive-labelled MoAb 
into the circulation. Primary or secondary tumours of
o
up to 1.5 cm can be detected easily. Examples are 
colorectal and breast carcinoma (Teh et al,1985), 
bladder tumour (Yu et al,1987), ovarian (Kenemans et 
al,1988), urinary, breast, gestational tumours 
(Epenetos et al,1982b) and other human solid tumours 
(Britton and Granowska,1987 : Markham and
Sikora,1987).
MoAbs are an important aide to histological diagnosis 
(Sloane and Ormerod,19 8 7). Micrometastasis and 
carcinoma in situ can be diagnosed with MoAbs 
(Giwercman et al,1990 : Teh et al,1985). Poorly
differentiated anaplastic tumours can be identified 
(Gatter et al,1984). Benign and malignant tumours can 
be distinguished (Boerman et al,1990). MoAbs in 
histological diagnosis are helpful in determining the 
tissue of origin, identifying specific cell types 
(Chilosi et al,1988), objective tumour classification 
(Armitage et al,1988), differentiation grade (Albino 
and Houghton,1985), metastatic potential, prognosis 
prediction and possibly etiological agent (Reisfeld and 
Cheresh,1987). Metastatic cells from secretions.
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effusions or body fluids can be identified as tumourous 
(Epenetos et al,1982a : Teh et al,1985).
Some tumours can cause a persistent release of TAs into 
the circulation. These can be found in serum, urine, 
meconium and cerebrospinal fluid (Chang et al,1981 : 
et al,1985 : Sears et al,1982). Serum TA assays 
3^® important in early detection of localized disease, 
onset of malignant change in pre-malignant lesion, 
differential diagnosis and clinical classification. 
Serum assays are available for CEA, gastrointestinal 
cancer antigen (GICA), CA-125 for ovarian cancer, 3E1.2 
for breast cancer and many others (Bast et al,1983 : 
Del Villano et al,1983 : Rogers et al,1981 : Teh et 
al,1985).
(C)MoAbs IN THE TREATMENT OF TUMOURS: MoAbs reactive 
^i"th tumour cells can be useful in the treatment of 
tumours. For example MoAb-coated tumour cells are 
easily lysed with leucocytes (Greenberg et al,1975). 
MoAbs can also suppress in vivo growth of certain 
tumour (Herlyn et al,1980) and have been shown to be 
cytotoxic in vitro (Pontesilli et al,1989 : Reisfeld 
and Cheresh, 1987). MoAbs can also destroy tumour cells 
3fter exposure to chemotherapeutic agents (Davies and 
O Neill,1973), or can trigger antibody and complement 
dependent cell cytotoxicity (Herlyn and 
Koprowski,1981), reticulo—endothelial phagocytosis, or 
direct anti-proliferative effect (Hu et al,1989). 
However, murine MoAbs can cause immune reaction in
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humans (Byers and Baldwin,1988) and thus have a limited 
role for therapeutic purposes. Human MoAbs and 
immunized mouse MoAbs are now available (Kjeldsen et 
al,1988) and are used in vivo with minimal side effects 
and marked clinical improvement in the treatment of 
many tumours.
The therapeutic applications of MoAbs are bone marrow 
clearance and transplantation (Prentice et al,1987), 
therapy with MoAbs alone (Hu et al, 1989 : Ritz et
al,1981), therapy with MoAb-drug conjugate (Aboud Pirak 
al,1989 : Deguchi et al,1986), therapy with MoAb- 
^^^in conjugate (Brusa et al,1989 : Thorpe and
Mason,1987) and therapy with MoAb-linked radionucleides 
(Colapinto et al,1990 : Sharkey et al,1988). Some of 
these successes are only at in vitro level and are 
®i^her yet to be tried in vivo or are in the process of 
clinical trials.
— idiotype antibodies are now being developed and 
are available against different tumours for 
immunization (Austin et al,1989 : Glennie and
Stevenson, 1987 ) . Bi-specific antibodies are also 
developed having specificity against a TA and a 
therapeutic agent (Pimm et al,1990).
(D) MoAbs IN TUMOUR PROGNOSIS: MoAbs which react with 
tumours can be used to monitor treatment and evidence 
recurrences (Abelev,1989 : Allen March,1987 : Bast et 
al,1983 : Klapdor et al,1984 : Pecchio et al,1986).
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They can be used to predict the likely success of 
treatment and to monitor any change of an apparent 
benign lesion into a malignant one (Giwercman et 
al,1990 : Markham and Sikora,1987 : Tate,1982). Serum 
TAs can be an early indicator of treatment failure and 
the extent of disease (Kenemans et al,1988).
1.4.11 SOME IMPORTANT TUMOUR ANTIGENS USED AS MARKERS:
(1) ALPHA FETO-PROTEIN (AFP): This tumour marker of 
mol.wt. 70,000 was first described by Abelev 
(Abelev,1971). Its levels decline gradually after 
birth. Hepatocytes in vitro secrete AFP but normal 
liver architecture inhibits its secretion. It is an 
important marker of primary liver tumours (Al-Sarraf et 
31/1974), testicular and ovarian teratomas, ovarian 
yolk sac tumours, bronchial, gastric and pancreatic 
carcinomas (Wardmann and Mclntire,1974), seminoma, 
neuroblastoma, Wilm's tumour and chorio-epithelioma. 
AFP is present on cell surface and can cause 
immunosuppression (Gold and Freedman,1965). Immuno- 
ugates of MoAbs against AFP, with drugs or 
radionucleides, are used for diagnostic and therapeutic 
purposes (Sell,1981 : Tsukuda et al,1982). AFP levels 
fall after tumour resection or therapy (Heyward et 
al,1983) and are a useful screening, monitoring and 
prognostic indicator. It is also a maternal serum 
marker of fetal distress or intra—uterine death.
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(2) CARCINO EMBRYONIC ANTIGEN (CEA): This TA marker of 
mol.wt. 180,000-200,000 was described by Gold and 
Freedman (Gold and Freedman,1965). It is normally found 
in fetal intestines, liver and pancreas. It is a marker 
for tumours of liver, pancreas, lung, stomach and 
breast. Higher levels are also found in renal 
impairment, collagen diseases, smoking, cirrhosis, 
emphysema, infection, trauma, infarction and 
inflammatory lesions of intestines (Lowenstein and 
Zamchek,1978). It is valuable in monitoring therapy, 
detecting early recurrence and prognosis (Tate,1982). 
It is not highly specific as a serum diagnostic marker 
but with immunocytochemistry it can be demonstrated on 
virtually all colonic carcinomas (Bagshawe,1983).
(3) HUMAN CHORIONIC GONADOTROPHIN (H C G ): It is a 
pi3c®ri'tal hormone which maintains the corpus luteum in 
pregnancy, first described by Zondek in 1930. Its alpha 
subunit has a mol. wt. of 14,900 and beta subunit has a 
mol.wt.23,000. Its levels are increased many fold in 
trophoblastic tumours like hydatidiform mole and 
choriocarcinoma. Higher levels are also found in germ 
®®ii tumours of testis and ovary and islet cell tumours
of the pancreas (Cole et al,1983).
(4) CA-125: It is an important tumour marker antigen of 
ovarian cancer (Teh et al,1985). Higher serum levels 
are found even in stage I disease and fall after 
successful therapy (Heinonen et al,1985). Its combined 
use with CA19-9 is more useful (Kenemans et al,1988).
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Higher levels are also found in tumours of lung, 
breast, cervix, endometrium and in benign conditions 
like chronic liver or biliary disease and peritonitis.
(5) CA19-9: A glycolipid antigen comparable to CEA but 
is less specific giving false negative results (Del 
Villano et al,1983). Its combined determination with 
CEA is more useful in tumours of the intestines, 
stomach and pancreas (Pecchio et al,1986).
(6) CA12-5; It is useful, with CEA and CA19-9,in 
detecting carcinoma of intestines (Klapdor et al,1984).
(7) PROSTATIC ACID PHOSPHATASE (PAP): A marker for 
prostatic cancer (Blick et al,1983).
(8) PLACENTAL ALKALINE PHOPHATASE (PLAP): A marker of 
seminoma and dysgerminoma (Lange et al,1982).
(9) Ca - ANTIGEN: An antigenic tumour marker with a 
mol.wt. 75,000, useful in diagnosing atypical cells in 
tumours of breast and the urinary system (Harris,1987).
(10) NEURON-SPECIFIC ENOLASE: It is a marker in small 
cell carcinoma of lung, neuro-endocrine tumours and 
metastatic neuroblastomas as a staging, prognostic and 
monitoring index (Zeltzer et al,1983).
(11) Bl-SPl: It is a pregnancy specific beta-1
Glycoprotein whose level is raised and serves as a 
marker for trophoblastic tumours (Bagshawe et al,1978).
(12) PANCREATIC CANCER ASSOCIATED ANTIGEN (PCAA) AND 
PANCREATIC ONCOFETAL ANTIGENS: These are glycoprotein
markers of pancreatic and gastro intestinal tumours
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(Maruyama et al,1983).
(13) GASTRO-INTESTINAL CANCER ANTIGEN (GICA): It is an 
oncofetal monoganglioside antigen, defined by MoAbs, 
worthwhile in assessing the behaviour of colorectal 
carcinoma (Raux et al,1983).
(14) PROSTATE SPECIFIC ANTIGEN (PSA): This is a useful 
tumour marker for monitoring radiotherapy responses and 
as an aid to diagnosis, in addition to PAP (Kuriyama et 
al,1982).
(15) MH-A6 ANTIGEN: A glycoprotein marker for gastric 
carcinoma (Ogasawara et al,1988).
(16) HMFG ANTIGEN: A glycoprotein marker of breast, 
ovarian and intestinal tumours (Ashorn et al,1988).
(17) EPITHELIAL MEMBRANE ANTIGEN (EMA): A marker of 
bladder carcinoma (Asamoto et al,1989).
(18) CA-242 and CA-50: These, with CA19-9, are markers 
of pancreatic cancer. They are used for serum assays
immunocytochemica 1 diagnosis, detecting pre 
neoplastic lesions as well (Haglund et al,1989).
(19) SQUAMOUS CELL CARCINOMA ANTIGEN: It helps in 
diagnosis but is important in the follow up of oral and 
facial squamous cell carcinomas (Fischbach et al,1990).
(20) MELANOMA ANTIGENS: A number of antigens are 
described as markers in melanomas (Albino and 
Houghton,1985 : Herlyn and Koprowski,1988 : Reisfeld 
and Cheresh,1987).
(21) 3E1.2: A tumour marker for breast carcinoma (Teh 
et al,1985).
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(22) EPITHELIAL LI ANTIGEN: A histochemical marker of 
lung carcinoma (Dale and Brandtzaeg,1989).
(23) TISSUE POLYPEPTIDE ANTIGEN (TPA): A marker
preferentially present on ovarian tumours but also on 
benign tumours (Ghazizadeh,1989).
In addition to the above described antigens a number of 
other markers are described like renal tumour antigen 
(Ueda et al,1979), blood group precursor T-antigen in 
bladder cancer (Coon et al,1982), Bramwell Harris 
glycoprotein (Friedman and Skehan,1981), CX-1 antigen 
and galactosyl transferase for ovarian adenocarcinomas 
(Gauduchon et al,1983 : Wass et al,1981), immuno-
supressive acidic protein in ovarian ascites tumour 
(Sawada et al,1983), Human cervical cancer antigen 
(Ermoshina et al,1986), leukemia antigen markers 
(Janson et al,1987), TSP-ISO antigen (Falconi et 
al, 1988), brain tumour antigen ( Pfreundschuh et 
al,1978), M protein of myeloma and B cell malignancies 
(Salmon, 1973 ) , Lymphoma and Hodgkin's antigen 
(Stein,1987), etc. Ectopically secreted hormones can be 
useful tumour markers like calcitonon (medullary 
thyroid carcinoma), catecholamines (pheochromocytoma, 
neuroblastoma and adrenal tumours), specific gut 
polypeptides (intestinal tumours), serotinin 
(carcinoid), C-reactive proteins, 1-acid glycoprotein, 
haptoglobin, antychymotrypsin, beta-2-microglobulins, 
polyamines, spermidine, putrescine, pteridines, LDH and
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HBD hydroxy butyrate dehydrogenase .
Multiple tumour markers are more useful and increase 
the efficacy of diagnosis or therapy. In breast cancer 
the following can be simultaneously used as markers 
(Coombs and Powles,1982):
A) CEA, B-OFA, Ferritin (onco fetal products).
B) HOG, SPl (hormones).
C) Sialyl transferase, PLAP, Aik. Phosphatase (enzyme).
D) Putrescine, spermidine (polyamines).
E) Dimethyl guanosine, amino-isobutyric acid, methyl 
inosine, pseudouridine (pucleosides).
F) PAM, C-reactive protein, alpha acid glycoprotein, 
alpha antitrypsin, haptoglobin, haemoprexin, lysozyme, 
ceruloplasmin (acute phase proteins).
G) Alpha lactalbumin, k-casein (milk proteins).
H) Misc. like KH2 prostaglandin, hydroxy proline.
1.4.12 MoAbs CROSS-REACTIVE WITH DIFFERENT OR IDENTICAL 
TUMOUR ANTIGENS OF DIFFERENT TUMOURS:
MoAbs identifying TAs, on various tumours, can cross- 
react with other TAs of similar or different tumours of 
different histology, etiology or in similar tumours of 
different species. They can cross-react with tumours of 
totally different tissue or histologic type, other 
tumours of similar etiology in similar or different 
tissues, normal tissues or fetal tissues and sometimes 
in tumours of totally different species. Some examples
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are as follows:
(1) Tumour specific MoAb cross-reactivity is seen in 
human tumours of similar histology. This is shown in 
Wilm’s tumours, neuroblastomas, Burkitt’s lymphomas, 
choriocarcinomas, malignant melanomas, sarcomas, 
bladder cancer, colorectal carcinomas, ovarian 
carcinomas and breast cancers (Reif,1982).
(2) MoAbs against ovarian TAs show cross-reactivities 
with endometrial, cervical, breast, colorectal and 
other carcinomas (Kenemans et al,1988).
(3) MoAbs identifying TAs of malignant melanoma can 
cross-react with astrocytomas, epithelial tumours, 
adrenal medulla, pancreatic islet cells, parotid gland, 
nervous tissue, endothelial cells and smooth muscle 
cells of blood vessels (Albino and Houghton,1985 : 
Reisfeld and Cheresh,1987 : Steplewski and
Koprowski,1982).
(4) MoAb specific to small lung carcinoma TAs were 
found cross-reactive with adrenal, thyroid, pituitary, 
parathyroid, Leydig cells of testis, islet cells of 
pancreas and occasional bronchial and pancreatic cells. 
Rete testis, mammary epithelia and gastric mucus cells 
were partly positive. Neurons were found weakly 
positive. Supportive cells of nervous system like 
9iisi/ Schwann and ganglionic cells were found 
positive. Mesenchymal cells like smooth and cardiac 
muscle, pia, arachanoid and ovarian stromal cells were
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found positive (Schol et al,1988).
(5) Similar antigens were found, as defined by antibody 
assays, on chemically-induced experimental sarcomas 
(Invernizzi and Parmiani,1975).
(6) Radiation-induced tumours of skin and bone exhibit 
similar TAs as indicated by cross-reactivity of 
antibodies identifying them (Daynes at al,1985).
(7) MoAbs identifying TAs of solid tumours cross-react 
with blood group antigens (Blaszczyk et al,1984 : Coon 
et al,1982).
(8) MoAbs identifying TAs of myeloid leukemia can 
react with other myeloid 1eukemias (Wortzel et 
al,1983).
(9) Cross-reactive antibodies identifying oncofetal TAs 
are identified in spontaneous tumours as well as 
2-acetyl-aminofluorene and other chemical-induced 
hepatomas and mammary carcinomas (Baldwin,1978 : Bowen 
and Baldwin,1979).
(10) MoAbs defining TAs of ovarian adenocarcinomas , 
cross-react with renal, breast, pancreas, epididymis 
and renal carcinomas (Mettler et al,1990).
(11) A MoAb-defined trophoblastic glycoprotein (72 kd) 
is found on a number of tumours like bladder, breast, 
cervix, ovary, endometrium, lung, oesophagus, pancreas, 
stomach and ovary. This marker is not found in serum 
but is found useful in immunocytological diagnosis and 
staging (Hole and stern,1988 : Southall et al,1990).
(12) Gastrointestinal cancer associated antigen (GICA)
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is also associated with cancers of lung, thyroid, 
ovary, prostate and urinary bladder (Raux et al,1983).
(13) Antigens are identified in leukemias and lymphomas 
whose specific MoAbs show cross-reactivity (Armitage et 
al,1988).
(14) MoAb defined MH-A6 antigen of gastric tumours is 
also associated with other tumours and tissues 
(Ogasawara et al,1988).
(15) MoAb, defining embryonic antigen (EA), cross-react 
with a number of human and rodent tumours but not with 
normal human tissues. There is also inter-species 
cross-reactivity between tumours of different 
histologies. Human, mouse, hamster and other rodents 
seem to share a common epitope on EA (Payne and 
Coggin,1985).
(16) A human TA marker, which is a membrane-associated 
urothelial differentiation antigen, is cross—reactive 
with other species (Trejdosiewicz et al,1984).
(17) Antigens of mouse and human mammary tumour viruses 
are cross-reactive (Smorodinsky et al,1988).
(18) Ovarian tumour marker TA is cross-reactive with 
carcinoma breast, carcinoma lung, lung, breast, 
thyroid, fallopian tube, uterus, ovarian cyst, fibroid 
uterus and endometriosis (Ohkawa et al,1989).
(19) Rat tumour matrix proteoglycan antigens are also 
seen in muscle, nerve, epithelia and endothelium. 
Cross-species reactivity was found with bovine, avian
86
and human tissues (Couchman and Ljubimov,1989).
(20) Some epitopes of progesterone receptors, defined 
by MoAbs, can serve as TA markers and are cross­
reactive in many species like human, rodent, chicken 
and livestock (Groyer-Picard et al,1990).
(21) Human proliferation associated antigen is present 
on lamb, calf, dog, rabbit and cat (Falini et al,1989).
(22) Human tumour nucleolar protein antigens are also 
associated with tumours of different histology 
(Greenfield et al,1989).
(23) MoAbs against equine HOG also bind to alpha 
subunit of human HOG (Bidart et al,1989).
(24) Human MoAbs against human breast tumours cross- 
react with carcinomas of colon, stomach, lung and 
normal epithelium of kidney and colon (Imam and 
Taylor,1989).
(25) Pancreatic TA is also found in gall bladder, 
colouic and gastric cancer and goblet cells (Maruyama 
et al,1983).
(26) SV 40 T tumour antigen is also associated with 
papova virus antigen (Ball et al,1984).
(27) MoAb against human kidney gamma glutamyl 
transpeptidase cross-react with many human organs 
(epididymis, prostate, seminal vesicle, pancreas, liver 
and hepatoma) and with mouse, rat, rabbit, pig and 
guinea pig kidneys (Shiozawa et al,1990).
Uncommonly tumours can express a differentiation
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antigen absent on the tissue of origin but found on 
other normal tissues like the antigen of small cell 
lung carcinoma and normal nervous tissue, antigen of 
melanocytes and breast tumours etc. The HLA-II antigen 
of colorectal carcinoma is absent from normal 
colorectum but is found in some benign conditions like 
coeliac disease (Daar et al,1982). Sometimes jumping 
specificities are seen like CEA found on colonic 
®pi"thelium and also on granulocytes and lymphocytes. 
Identical antigens may be found on short sections of 
differentiation pathways in different tissues.
A number of other antigens, which may serve as TAs, can 
cross-react extensively within or outside the species 
barrier e.g., S-antigen of the retina (Broekhuyse and 
Kuhlmann,1989 ), osteonectin (Bolander et al,1989), 
apolipoprotein (Leroy et al, 1989), LFA-1 (Hildreth et 
al,1989), islet cell pancreas antigen (Yamashiro et 
al,1990), human and monkey glomerular epithelial cells 
(Fukatsu et al, 19 89 ) and connective tissue and 
streptococcus (Abyzov et al,1989).
1.4.13 TUMOUR ANTIGEN MARKERS IN LIVER TUMOURS:
Principal surface proteins of normal rat liver 
epithelial cells are in the mol.wt. range 40,000 -
70.000, 100,000 and 140,000 - 160,000. Long term 
cultured cells show decrease in proteins of 40,000 -
70.000. Almost all in vitro transformed and tumour cell
88
lines show appearance of a 135,000 mol.wt. protein 
(Bannikov et al,1980).
In hepatocellular carcinoma (HCC), a common human 
tumour with multiple etiologies including hepatitis B 
virus infection, a number of antigenic markers are 
often found (Chedid et al,1990):
(1) AFP (alpha feto protein)
(2) AAT (alpha 1 antitrypsin)
(3) HbsAg (hepatitis B surface antigen)
(4) HbcAg (hepatitis B core antigen)
(5) HDdeltaAg (hepatitis D delta antigen)
(6) MB (Mallory bodies)
MoAbs raised against the HCC cells indicate that while 
antigens are often shared with normal cells, not all 
the antigens expressed on HCC cells are demonstrable on 
normal cells (Chedid et al,1990). Surface glycolipid 
antigens have also been described in human HCC (Hiraiwa 
et al,1990).
Several distinct types of TAs may be expressed. HCC 
cells, compared to normal hepatocytes, also show 
enhanced expression of class I HLA-A, B, and C in 
either the cytoplasm or membrane accompanied by beta 2 
microglobulin expression. Class II antigens (HLA-DR or 
DQ) are much less persistent, positive cells being 
sparse and heterogenous. The expression is usually 
cytoplasmic but occasionally membranous. There does not 
appear to be any relation to differentiation state or 
tumour size (Paterson et al,1988). In the
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carcinogen-induced rat liver tumours (Baldwin,1973). 
Some may be strictly tumour-specific (even different 
nodules in same liver can be antigenically dissimilar) 
while others can be cross-reactive (Baldwin,1978). In 
addition a variety of abnormal transient TAs may be 
demonstrated during various stages of carcinogenesis. 
These are usually normal liver components modified by 
covalent interaction with carcinogens or their 
metabolites (Baldwin,1978). A number of liver tumour 
antigens are described like 150,000 mol.wt. D23 antigen 
(Baldwin et al,1973 : Dunk et al,1987 : Hill et
al,1973). Nuclear antigens (non-histone proteins) also 
exhibit remarkable tumour specificity as shown in 
chemically-induced hepatomas using MoAbs (Babin and 
Anderson,1988 ) . They can be multiple, specific or 
cross-reactive and are important markers of 
transformation.
A number of oncogenes are also associated with 
hepatocellular carcinomas includind ras, raf, myc, etc 
(Buchmann et al, 1989 : Huber et al, 1989 : Lee et al, 
1990a ; Rao et al, 1989 : Watatani et al, 1989 : 
Norland et al, 1990). They are either activated by 
intrinsic or extrinsic mechanisms (Embleton et al, 1989 
: Fitzgerald et al, 1989 : Hellstrom et al, 1989) and 
can serve as important markers of HCC.
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1.5 SUMMARY OF INTRODUCTION AND REASONS FOR THE PRESENT 
STUDY:
Most of the tumour cells, irrespective of the 
etiological agent and whether transformed in vitro or
vivo, are significantly different from their normal
^ differences
counterparts. These r vary in different tumour
systems depending upon the tissue of origin,
etiological agent, dose of etiological agent, duration
of exposure and physiological status of the exposed
tissues.
The tumour system of peroxisome proliferators is 
relatively new. There is no study or data available, at 
the present time, which highlights differences between 
peroxisome proliferator-induced tumour cells and their 
normal counterparts. Another important factor which 
makes this study interesting is that peroxisome 
proliferator chemicals are non-genotoxic and non- 
mutagenic in contrast to most of the chemically-induced 
tumour systems studied so far. Their mechanism of 
action for tumour development is not very well 
understood. It, therefore, will be fascinating to know 
how a non-genotoxic and non-mutagenic chemical 
(peroxisome proliferator) changes a normal cell to a 
transformed cancer cell and what is the extent and 
degree of changes in the tumours induced.
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1.5.1 ANTIGENS OF THE CIPROFIBRATE (PEROXISOME 
PROLIFERATOR)-INDUCED RAT LIVER TUMOURS;
Peroxisome proliferator-induced carcinogenesis causes 
many biochemical, enzymatic, genetic, protein, etc 
changes in the liver tumour cells induced (Dianzani, 
1989 : Lock et 9.1, 1989). Many of these changes may 
well involve antigenic make up of the cells. There is 
no study or data available, at present, which highlight 
these antigenic changes in the tumour cells induced by 
peroxisome proliferators, with the possible exception 
of PPA-80 (Lock et a.1, 1989). It is believed that most 
of the protein antigen changes in tumour cells are a 
direct result of carcinogen-DNA interaction, which is 
lacking in peroxisome proliferator system. A number of 
enzyme changes are described as a result of peroxisome 
P^olifs^âtor carcinogenesis and a lot more are believed 
to be associated (Lock et al, 1989). There are marked 
changes in the profile of specific hepatic proteins and 
increase in levels of mRNAs encoding for peroxisomal 
beta oxidation and microsomal w—oxidation enzymes 
(Lock et al,1989 : Reddy and Lalwani, 1983). There is 
also expression of peroxisomal and microsomal genes 
(Lock et al, 1989). Some oncogenes are also believed to 
be activated as a direct result of lipid peroxidation 
(Danziani, 1989).
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1.5.2 AIMS OF THE WORK PRESENTED:
The aims of this study were:
( 1 ) to look into the specific in vitro characteristic 
features of Ciprofibrate (peroxisome proliferator)- 
induced rat liver tumour cells in comparison with the 
normal rat liver cells (like in vitro growth potential, 
agglutinibility with lectins and growth in semisolid 
media with colony formation).
(2) To assess the degree or grade of transformation of 
tumour cells induced by Ciprofibrate.
(3) To study the non-genotoxic and non-mutagenic system 
of chemical carcinogenesis.
(4) To study the gross and histological appearance of 
rat liver tumours induced by Ciprofibrate peroxisome 
proliferator.
(5) To raise monoclonal antibodies against rat liver 
tumour cells induced by Ciprofibrate.
(6) To study the cell antigen changes in rat liver 
tumour cells induced by Ciprofibrate.
(7) To study the reactivity of Ciprofibrate-induced rat 
liver tumour specific monoclonal antibodies with other 
normal and fetal rat tissues.
(8) To study the reactivity of raised monoclonal 
antibodies with peri-neoplastic tissue and chemically- 
treated rat liver tumours with Ciprofibrate without any 
apparent neoplastic change.
(9) To study the reactivity of tumour-specific
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monoclonal antibodies in a cross-species system (i.e., 
human tissues and tumours).
(10) To study the location of target antigens in the 
rat liver tumour cells.
(11) To study in detail and characterise the antigens 
identified by the raised monoclonal antibodies.
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SECTION-2 
MATERIALS AND METHODS
2.1. ISOLATION OF HEPATOCYTES :
2.1.1. INTRODUCTION:
Over the past decades a number of attempts have been 
made and many methods were devised, to isolate 
parenchymal liver cells as viable single cells with 
maximum viability and minimum contamination from other 
cell types. The earliest techniques used were those of 
mechanical dispersion and partial homogenization 
(Alexander and Grisham,1970). Then removal of calcium 
and potassium was attempted with citrate, 
©"thylenediaminetetraacetate (EDTA),and tetraphenylboron 
(TPB) perfusion. Attempts were made to dissolve 
intercellular junctions using trypsin, papain, 
lysozyme, neuraminidase and pepsin (Hole and Stern, 
1988 : Leffert and Sell, 1974 : Osagwara et al, 1988 : 
Reif, 1982). These enzymes digest or partially damage 
plasma membrane and affect binding of antibodies to 
cells (Grisham,1980 : Martin et al, 1989) thus limiting 
their use. A major step forward was the introduction of 
collagenase and hyaluronidase to digest cellular 
junctions without damaging plasma membrane structure 
(Martin et al, 1989 : Peters et al, 1979). The cells 
isolated by use of collagenase based methods are almost 
exclusively hepatocytes. Perfusion of liver or 
incubation of liver slices , without mechanical 
disruption and damage, under physiological conditions 
yields a fairly significant number of intact cells
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(Berry and Friend,1969). Later, in situ perfusion 
techniques were developed and used (Seglen,1973).
2.1.2. MATERIALS:
(1) Hanks balanced salt solution (Flow).
(2) Calcium and magnesium free Hanks balanced salt 
solution. (Flow)
(3) Collagenase type IV (Seglen,1976). (Sigma)
(4) L-Glucose. (BDH)
(5) Calcium chloride. (BDH)
(6) Heparin 1000 units/ml. (Roche)
(7) Fischer F344 male rats 8-12 weeks.
(8) Medium RPMI-1640 with glutamine (2 mM), penicillin 
(6 mg%) and streptomycin (10 mg%), with no serum added.
(9) Waterbath at 37°C.
(10) 35% Bovine serum albumin fraction V solution. 
(Sigma)
2.1.3 ISOLATION OF HEPATOCYTES:
(1) A rat was anaesthetized by ether. 1000 units of 
heparin was injected into the femoral vein.
(2) The animal was killed by cervical dislocation.
(3) The animal was swabbed with 70% alcohol.
(4) The abdomen was opened and the liver removed 
quickly and aseptically. The liver was immediately put 
in 15 ml Hanks balanced salt solution contained in a 
sterile plastic universal bottle. The HBSS contained 
100 mg% glucose, 6 mg% penicillin and 10 mg%
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streptomycin.
(5) Universal bottles containing the liver were 
transferred to a sterile laminar air flow cabinet. The 
liver was washed 2-3 times in calcium and magnesium 
free HBSS at room temperature.
(6) The liver was dissected into small pieces of 
0»5-1.0 mm size with a scalpel, scissors and forceps. 
The same procedure could be carried out on liver tissue 
thawed after storage in liquid nitrogen.
(7) About 10 to 20 pieces of liver were placed in a 
^^^v®^sal bottle containing 15 ml of calcium and 
magnesium free Hank's balanced salt solution.
(8) The Universels containing liver slices were kept in 
a waterbath at 37^C for 10-15 minutes and then returned 
to the laminar air flow cabinet.
(9) Supernatant fluid (containing any single cells) was 
removed by gentle aspiration through a pipette leaving 
behind large undigested fragments.
(10) 10-15 ml freshly prepared HBSS containing 5 mM 
calcium chloride, 100mg% glucose, 6 mg% penicillin, 10 
mg% streptomycin and 0.04% collagenase type IV was 
added to each of the universels.
(11) Universels were incubated in a waterbath at 37°C
for 20 minutes while shaking intermittently by 
hand and oxygenated as well with a mixture of 95% 
oxygen and 5% carbon dioxide.
(12) The liver suspension was gently expressed through 
a 10 ml pipette for one minute, to aid cell dispersion.
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The bigger fragments of tissue were allowed to settle. 
Supernatant fluid was removed by gentle aspiration and 
collected in a separate 50 ml centrifuge tube.
(13) 15 ml of HBSS containing collagenase was added and 
the mixture incubated at 37°C for 15 minutes in a water 
bath.
(14) The same process was repeated 3-4 times collecting 
the supernatant fluid and replenishing collagenase 
containing HBSS solution each time. Finally all liver
parenchymal tissue was digested and only white fibrous
tissue was left in the universal.
(15) The collected supernatant fluids or cell
suspension was filtered through an 80 uM filter mesh or 
double layered sterile gauze. The undigested tissue 
fragments and multicellular clusters were thus removed.
(16) Bovine serum albumin was added to the collected 
supernatant fluid to obtain a final concentration of 
1%. This prevents damage and provides a cushioning 
action to freshly isolated hepatocytes (Jeejeebhoy and 
Phillips,1976).
The method described above for the isolation of 
hepatocytes was a modification of the methods described 
elsewhere (Fry et al,1976 : Belleman et al,1977).
2.1.4. PURIFICATION OF HEPATOCYTES:
A very low speed repeated centrifugation is often used 
to purify hepatocytes. The pooled cell suspension from
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the collagenase digestion with added 1% bovine serum 
albumin was centrifuged at 50 g for 3-5 minutes. A 
loose pellet was formed from which supernatant fluid 
was removed by gentle aspiration. The pellet was 
resuspended in medium RPMI-1640 with 1% bovine serum 
albumin and centrifuged twice as described above. 
Finally the cells were again resuspended in RPMI-1640 
medium. This repeated centrifugation at low speed 
leaves almost all cell debris, dead cells and all other 
cells in the supernatant fluid which was removed and 
discarded. A pellet of relatively pure viable 
hepatocytes was thus obtained.
The concentration of cells and their viability was 
carried out by trypan blue dye exclusion using a 0.2 mm 
modified Fuchs-Rosenthal haemocytometer. 0.1% w/v
trypan blue was used and the cells were exposed to it 
for less than a minute because of the tendency of even 
viable hepatocytes to take up the dye. Exposure to the 
dye of up to 5 minutes can be well tolerated by liver 
cells (Dr. D. Benford, Roben’s Institute, personal 
communication). The results are shown in section 3.1.
2.1.5 MTT ASSAY FOR CELL VIABILITY:
MTT is a quantitative and versatile colorimetric assay 
for detecting viability and proliferation of cells 
(Al-Rubeai et al, 1990 : Denizot and Lang, 1986 : Lamb 
et al, 1989 Î Mossmann, 1983 : Twentyman and Luscombe, 
1987). It is rapid, convenient, simple, cost effective
99
and precise. Radioisotopes are not used and 
scintillation or gamma counter is not required. Only an 
ELISA plate reader is required and many samples can be 
assayed at the same time. It depends on the reduction 
of tétrazolium salt MTT [3-(4,5-dimethylthiazol-2-yl) 
-2,5-diphenyl tétrazolium bromide], by living cells, to 
form a blue formazan product which is read in an ELISA 
reader at 540-570 nm. Tétrazolium is cleaved in 
mitochondria, by dehydrogenase enzymes (usually absent 
in serum), of metabolically active living cells. It 
actually measures energy metabolism of cells and not 
the amount of DNA as in the thymidine uptake assay. The 
amount of formazan produced, and in turn the colour 
reaction, is directly proportional to viable cell 
number in a particular cell density range having a 
linear relationship. Dead cells are absolutely negative 
and do not give any reaction.
The following protocol was used for the assay (Denizot 
and Lang, 1986 : Twentyman and Luscombe, 1987):
1. The medium was gently aspirated from the culture 
vessel. Cells were dissociated by adding 1-2 ml of non- 
enzymatic dissociation solution and incubating at 37°C.
2. The cells were centrifuged at 50 g (400 rpm) for 3-5 
niinutes and re suspended in 200 uL of serum free RPMI 
(as described in section 2.3.5) medium (serum proteins 
precipitate and fetal calf serum is better than new 
born calf serum).
3. Samples were put in wells of an ELISA plate
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(Falcon). The plate was centrifuged at 200 g or 1000 
rpm for 3 minutes and the supernatant was aspirated 
gently using a multichannel pipette.
4. 50 uL of 1 mg/ml MTT solution, diluted in phenol red 
free RPMI medium, was added to each well and mixed by 
gently touching the plate to a vibrating mixer (LKB).
5. The plate was covered and incubated at 37°C for 3 
hours in a 5% CO2 incubator.
6. The plate was centrifuged again as in step 3 and the 
supernatant aspirated gently without disturbing the 
precipitates.
7. 200 uL of dimethyl sulfoxide [DMSG] (Sigma) was 
added to each well. DMSG dissolves the formazan 
crystals more effectively (Twentyman and Luscombe,
1987). The formazan crystals were solubilised by 
mixing, as the plate was gently touched to a vibrating 
mixer for 5 minutes. Acid isopropanol (100 uL of 0.04 N 
HCl in isopropanol) can also be used but it precipitate 
proteins.
8. The plates were read within an hour in the ELISA 
plate reader (Dynatech MR600), at 540 nm with reference 
filter at 630 nm (The plate was read at 570 nm if acid 
isopropanol was used).
9. Negative controls were run. A standard calibration 
curve was made by running the assay with a dilution 
range of known starting concentration of cells. 
The results are described in section 3.1.
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2.2. PRESERVATION OF TUMOUR TISSUE:
2.2.1. INTRODUCTION:
It is often impractical to utilize or to take advantage 
of a large tumour biopsy. Such material is valuable. 
Moreover, the same biopsy material can be needed at 
different times for a series of experiments. It would 
be an advantage if such material could be stored for 
future use. The storage of the intact tumour tissue 
from the biopsy material has been tried using a variety 
of techniques with success (Freshney,1988b : Sikora and 
Smedley,1984 ). The primary cells from tumours can be 
cryopreserved effectively without affecting their 
antigenicity (Peters et al, 1979). The storage of 
single cell suspension of primary cultures give 
relatively poor results in terms of viability and 
function on revival (Reif,1982).
2.2.2 MATERIAL:
(1) Dissected material from normal or tumour tissue.
(2) Sterile instruments(scalpel,scissors and forceps).
(3) HBSS (Flow) containing 100 mg% glucose, 6 mg% 
penicillin and 10 mg% streptomycin.
(4) Medium RPMI-1640.(Flow)
(5) Dimethyl sulphoxide (DMSG). (Sigma)
(6) Fetal calf serum.(Sigma)
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2.2.3 METHOD:
(1) Necrotic, fatty and fibrous tissue was removed from 
the biopsy material by dissection. The tumour or the 
normal liver tissue was chopped into 3-4 mm size small 
pieces. These pieces were washed in HBSS 2-3 times.
(2) The preservative medium was prepared freshly (see 
appendix).
(3) 4-5 pieces of tumour tissue were put in each 
plastic round bottom 2 ml cryotube/freezing ampoules.
(4) Preservative medium was added to these ampoules 
upto the required level of 1.8 ml as marked. They were 
closed tightly and labelled.
(5) They were left for 10 minutes at room temperature.
(6) They were placed overnight at -70°C for slow 
freezing of the material.
(7) The cryotubes were transferred next day over liquid 
nitrogen and a record of their location was kept.
(8) To thaw they were taken out from the liquid 
nitrogen and quickly put in a waterbath at 37°C for a 
few minutes-until thawed.
(9) The ampoules were swabbed thoroughly with 70% 
alcohol in a laminar air flow cabinet. They were opened 
and the medium removed. The tissue was placed in a 
tissue culture dish of 60 X 15 mm size, and fresh 
medium added slowly.
The results are described in section 3.2.
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2.3. CULTURE OF LIVER CELLS IN VITRO ;
2.3.1. INTRODUCTION:
biver tissue was first cultured about seventy years 
ago. Liver, in addition to predominant parenchymal 
hepatocytes, also contains other cells such as 
fibroblasts, epithelial cells of biliary ducts, 
endothelial and smooth muscle cells of blood vessels, 
Kupffer cells and sinusoidal cells. Selective culture 
of individual cell types has become possible only in 
last 10-15 years. Lobular parenchymal cells are 
harvested selectively by collagenase digestion and 
^o^“P^^®richymal cells are separated out by enzyme 
treatment (Mills and Franklin, 19 69 ) or low speed 
centrifugation (Knook et al,1977).
Isolated hepatocytes have been cultured using a 
variety of culture conditions. Efforts to produce long 
term adult hepatocyte culture have met with limited 
success (Grisham,1980 : Koch and Leffert,1979 : McGowan 
et al,1981) . Autologous serum from partially
hepatectomized rat has been used with limited success 
for hepatocyte culture (Michalopoulos et al,1982). 
Serum has been found to be cytostatic and cytotoxic by 
some workers (Enat et al,1984) contrary to the others 
(Draghi et al,1980). Serum free formulations have also 
been used (Barnes and Sato,1980 : Gatmaitan et al,1983 
: Paul et al, 1988). Although past studies of liver 
cultures have shown some in vitro proliferation, it is
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likely that any cell growth in culture with medium 
containing serum was due to the predominant non- 
parenchymal cells (Grisham,1980 : William and
Gunn,1974). Cells in long term culture are simple both 
functionally and morphologically. Equating identity of 
cells in long term culture with any of the liver cells 
f^ vivo is often difficult. There are reports that 
epithelial liver cells in long term propagatable 
culture are not derived from mature hepatocytes but 
from the incompletely differentiated hepatocyte 
precursor cells. These stem cells are the most likely 
cells of origin of long term cultures of hepatic 
epithelial cells that retain some hepatocyte like 
function in vitro (Grisham,1980).
Although hepatocytes replicate readily in vivo in 
response to partial hepatectomy, it has been extremely 
difficult to culture adult hepatocytes under conditions 
that permit cell multiplication. However, fetal 
(Leffert and Paul,1972) or newborn animal hepatocytes 
(Draghi et ai,1980) were shown to multiply in culture. 
Recently several reports have indicated that adult 
hepatocyte cultures can be maintained in serum free or 
serum supplemented formulations in the presence of 
hormones and other supplements (Enat et al,1984 :
Friedman et al,1981 : McGowan et ai,1981 : Paul et ai,
1988).
Thymidine incorporation studies have shown many fold 
increases in DNA synthesis but these DNA synthesizing
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cells frequently do not proceed through cell cycle to 
mitosis. Actual cell division is a rare and 
infrequent phenomenon (Enat et al,1984). Mouse 
hepatocytes show an increased potential for 
proliferation in culture compared to rat hepatocytes 
(Sawada et al,1988) indicating the possibility of 
involvement of some yet undetermined species specific 
factors. A number of approaches have been tried to get 
hepatocytes to grow in culture. The effect of various 
chemical compounds (Francavilla et al,1987), culturing 
adult and neonatal rat hepatocytes together (Nakamura 
et al,1987), varying seeding density and matrix 
(Bissell et al, 1987 : Enat et al, 1984 : Fleig et 
al,1984 : Sawada et al, 1986 ; Schuetz et al, 1988) 
have been tried.
A number of growth promoting and growth inhibiting 
factors have been identified and studied (Carr et 
al,1986 : Francavilla et al,1984 : Francavilla et
al,1985 : Higgins and Borenfreund,1986 : Strain et 
al,1986). In tissue culture system of hepatocytes and 
hepatoma cells a number of hormones, growth factors and 
trace elements have been found effective in 
maintenance and proliferation of cultures. Some of the 
important factors are insulin, glucagon, epidermal 
growth factor, growth hormone, prolactin, hepatocyte 
growth factor, parathyroid hormone, thyroxine, 
transferrin, hydrocortisone, copper, zinc, selenium.
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iron and linoleic acid (Barnes and Sato,1980 :
Gatmaitan et al,1983).
Many transformed, fetal or normal cells secrete a 
number of growth promoting (Coffey at al,1986 : Klein 
at al, 1987 : Liu at al, 1988 : Rowe at al, 1986) and/or 
growth inhibiting (Dittmer at al,1984 : Fryling at
al,1985 : Gaffney at al,1983 ; Shirasune at al,1988) 
macromolecular factors.
Despite attempts to establish various tumours as 
permanent cell lines in culture, only a few examples of 
permanent cell lines are in existence (Rafferty,1975). 
Solid epithelial tumours are much more difficult to 
grow and adapt compared to the culture of blood 
malignancies. There are reports of cell lines 
established from tumours or pre-neoplastic lesions (Hsu 
at al,1988 ; Kawaguchi at al,1987 : Langdon at al,1988 
: Lin at al,1985 : Sacks at a l ,1988 : Willson at 
al,1987). Some of the neoplastic or pre-neoplastic 
growths show very slow progression or simply just 
maintain themselves in culture for months or years 
(Kerler and Rabes,1988). Many tumour cells show a very 
limited survival or growth in culture (Chang at al,1980 
: Steplewski at al, 1981 : Steplewski and
Koprowski,1982 ). A recent review on the cell culture 
of human metastatic breast carcinoma shows a wide range 
of growth/survival potential from 2-4 days to 
continuous growth in culture (Pettengill and 
Lewko,1989). It should be remembered while looking at
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reports of establishment of cell lines from tumours, 
that only the successful attempts are reported in 
literature.
2.3.2. EFFECT OF FETAL CALF SERUM, LOW PROTEIN SERUM 
REPLACEMENT, AND AUTOLOGOUS RAT SERUM ON HEPATOCYTES:
The media were prepared based on RPMI-1640 with 
glutamine ( 2 mM ), penicillin (6 mg% ) and 
streptomycin (10 mg%) as described in table 2.1.
Six groups of tissue culture dishes (Falcon Primaria 
size 60 X 15 mm) were set up. 5 ml of the respective 
media A, B, C, D, E and F were put in each of one dish 
of these groups as described in table 2.1 and labelled 
accordingly. Fischer F344 male rat liver cells were 
isolated as described in section 2.1 and plated out in 
these dishes at a concentration of 5 X 10^ viable 
cells per tissue culture dish. Medium was changed every 
third day by gentle aspiration through a pipette and 
replaced by an equal volume of the respective fresh 
medium. Cell concentration was measured on alternate 
days. The experiment was carried out for fourteen days. 
All the measurements were recorded and a graph plotted. 
The results are shown in section 3.3.2.1.
2.3.3. EFFECT OF DIFFERENT GROWTH PROMOTING FACTORS ON 
THE VIABILITY OF HEPATOCYTES:
The growth promoting factors were added to RPMI-1640 
medium containing glutamine (2 mM), penicillin (6 mg%)
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TABLE 2.1
EFFECT OF FCS, LPSR and RAT SERUM ON HEPATOCYTES
MEDIUM FCS INSULIN * 
HYDROCORTISONES
3% LPSR 5% RAT SERUM
5% 10% 15%
A + - - + - -
B - + - + - -
C - - + + — -
D - - + - - -
E - - - - - +
F - - - - + -
* Insulin (Sigma) 50 ug/ml.
$ Hydrocortisone (Sigma) 0.36 ug/ml.
1 0  3
and streptomycin (10 mg%) as described in table 2.2. 
Tissue culture dishes were prepared in groups A, B, C, 
to H. 5 ml of the respective media were added to every 
dish in each group from A to H. The cell seed for each 
dish was 5 X 10^ viable freshly isolated rat 
hepatocytes (as described in section 2.1). The medium 
was changed every third day by aspiration and 
^©plsnished with the same volume of the respective 
media. Cell counting of the viable hepatocytes was done 
on alternate days. A graph was plotted showing number 
of viable cells against time. The results are shown in 
section 3.3.2.2.
2.3.4. CUMULATIVE EFFECT OF GROWTH FACTORS:
The media were prepared to study the cumulative effect 
of some important growth factors as described in table
2.3.
Tissue culture dishes were prepared in groups from A to 
G. 5 ml of the respective medium were put in each dish 
^^ these groups. The cell seed for each dish was 
5 X 10^ freshly isolated viable rat hepatocytes (as 
described in section 2.1). Medium was changed every 
third day and replaced by equal amount of the 
respective medium. Cell counting of the viable 
hepatocytes was done on every third day and results 
recorded. The results are described in section 3.3.2.2.
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TABLE 2.2
EFFECT OF GROWTH PROMOTORS ON HEPATOCYTES
MEDIUM INS* HC$ HGF" EGFL PL" GH# GL@ Sl+Cu+Zn!
A + - - - - - - -
B - + - - - - - -
C - - + - - - - -
D - - - + - - - -
E - - - - + - - -
F - - - - - + - —
G - — - - - - + -
H - - - - - - - +
INS* Insulin (Sigma) 50 ug/ml.
HC$ Hydrocortisone (Sigma) 0.36ug/ml.
HGF" Hepatocyte growth factor (Sigma) 50 ng/ml
EGFL Epidermal growth factor (Sigma) 50 ng/ml.
PL" Prolactin (Sigma) 20 mU/ml.
GH# Growth hormone (Sigma) lOuU/ml OR
Pituitary extract (Sigma) 15 ug/ml.
GL@ Glucagon (Sigma) 10 ug/ml.
SL+Cu+Zn! Selenous acid (BDH) 3 nM +
Copper sulphate (BDH) 0.1 uM +
Zinc sulphate (BDH) 50 pM.
N.B. Basic medium was RPMI-1640 + glutamine 2 
penicillin 6 mg% + streptomycin 10 mg%.
mM
1 1 1
TABLE 2.3
CUMULATIVE EFFECT OF GHROWTH FACTORS
MEDIUM RPMI* INS$ HCL EGF" GL" PL# Cu+Se+Zn@
A + - - - - - -
B + + - - - - - -
C + + + — - - -
D + + + + - — -
E + + + + + - -
F + + + + + + -
G + + + + + + +
RPMI* RPMI-1640 + glutamine 2 
streptomycin 10 mg%.
mM + penicillin 6 mg% +
INS$ Insulin (Sigma) 50 ug/ml.
HCfc Hydrocortisone (Sigma) 0.36 ug/ml.
EGF" Epidermal growth factor (Sigma) 50 ng/ml.
GL" Glucagon (Sigma) 10 ug/ml.
PL# Prolactin (Sigma) 20 mU/ml.
Cu+Se+Zn@ Copper sulphate (BDH) 0.1 uM + Selenous acid 
(BDH) 3 nM + Zinc sulphate (BDH) 50 pM.
1 1 2
2.3.5. SERUM FREE MEDIUM:
After studying the effect and cumulative effect of a 
number of growth promoting chemicals, a serum free 
hormonally and chemically defined medium was prepared 
with the formulation described in table 2.4.
2.3.6. EFFECT OF THE SEEDING DENSITY:
This experiment was carried out to find out the optimal 
seeding density of the hepatocytes. Four groups of 
Falcon Primaria tissue culture dishes 60 X 15 mm size 
were set namely E, F , G and H. 5 ml of serum free 
medium made in RPMI-1640 (section 2.3.5) were put in 
all these dishes. Freshly isolated Fischer F344 male 
rat hepatocytes (see section 2.1) were seeded in the 
following manner:
E = 5 X 10^ cells per dish.
F = 1 X 10^ cells per dish.
G = 5 X 10^ cells per dish.
H = 1 X 10^ cells per dish.
The medium was changed and cell counting of viable 
hepatocytes was done every third day up to a period of 
fourteen days. The results are shown in section
3.3.2.3.
2.3.7. EFFECT OF CONDITIONED MEDIUM (BY GROWTH OF F344 
FISCHER RAT EMBRYO FOR 7 DAYS) ON HEPATOCYTES:
Fetal and embryonic tissues show more potential for 
survival and growth in culture than adult tissues
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TABLE 2.4 
SERUM FREE MEDIUM
SUBSTANCE FINAL CONCENTRATION SOLVENT
Bovine Insulin 
(Sigma)
50 ug/ml or 
10"^-10“'^ M
0.01 M HCl.
Hydrocortisone 
(Sigma)
0.36 mg/L, 0.36 ug/ml 
or 10~^M
H2 O.
Penicillin 100 U/ml or 6 mg% H2 O.
Streptomycin 100 ug/ml H2 O.
Fungizone 250 ug/ml H2 O.
Glucagon 10 ug/ml O.OIM NaOH.
Epidermal Growth 
Factor (Sigma)
50 ng/ml PBS.
Prolactin 20 mU/ml 0.01 M HCl.
Growth hormone or 
Pituitry extract
10 uU/ml 
15 ug/ml
PBS.
Linoleic Acid 5 ug/ml 1 mg/ml BSA
Copper Sulphate 
CuS04.5H20(BDH)
0.1 mM H2 O.
Zinc sulphate 
ZnS04.7H20(BDH)
50 pM H2 O.
Selenous acid 
H2Se03 (BDH)
3 nM H2 O.
Ferric citrate (BDH) 100 ug/ml HgO.
Transferrin (Sigma) 5 ug/ml H2 O.
Hepatocyte growth 
factor (Sigma)
50 ng/ml HgO.
Triiodothyronine 10"9 M 0.01 M NaOH.
.
Bovine serum 
albumin (Sigma)
0.1% HgO.
i
1 1 4
(Leffert and Paul, 1972). This may well be due to some 
growth promoting factors produced by these fetal or 
embryonic tissues. Conditioned medium has a positive 
influence on various cells grown ±n vitro (Chang et al, 
1985 : Ove et al, 1989). In this experiment Fischer 
F344 rat embryonic cells were cultured in RPMI-1640 
containing 15% fetal calf serum for 7 days and then 
this condition medium was used to grow hepatocytes. 
Preparation of the conditioned medium; Fischer F344 rat 
embryos (13 days old) were collected in HBSS 
(containing 100 mg% glucose, 6 mg% pencillin and 10 mg% 
streptomycin) after aseptically dissecting the pregnant 
female rat and taking out the uterus. Embryos were 
chopped into about 3 mm size pieces and then 
transferred to a plastic universal bottle by a pipette 
and allowed to settle. The supernatant fluid was 
discarded and the pieces of rat embryos washed in HBSS 
2-3 times. 5 ml of 0.25% trypsin-EDTA solution at room 
temperature was added to each universal containing 
tissues of 2-3 embryos. The material was left overnight 
at 4°C and then trypsin was removed by gentle 
aspiration. Then the universal bottle was 
incubated at 37°C for 20-25 minutes. 10 ml of medium 
(RPMI-1640 15% FCS) was added to each Universal bottle. 
The tissue was dissolved by gentle pipetting and 
solution was filtered through a double layer of gauze. 
The cell suspension was washed twice in medium by 
centrifugation at lOOg for 5 minutes each. Then the
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pellet was resuspended each time by pipetting. Cells, 
obtained from two embryos, were seeded in one 75 cm^ 
flask with 50-60 ml of RPMI medium. These flasks were 
incubated in an incubator under an atmosphere of 5%CÛ2 
and 37°C. After 18-24 hours, medium was changed in all 
the flasks by gentle aspiration and replaced by an 
equal volume of RPMI medium. These cells were cultured 
for one week after which a variety of cell types were 
present. The medium was then removed and cell debris 
separated by centrifugation.
Seven groups of tissue culture dishes (Falcon Primaria 
60 X 15 mm) were set up from A to G. Seven medium 
preparations were made as described in table 2.5.
To all groups of tissue culture dishes 5 ml of the 
respective medium from A to G were added. Each dish was 
then seeded with 5 X 10^ freshly isolated hepatocytes 
(Fischer F344 male rat). The medium was changed every 
third day and replaced with the respective medium at 
the same volume. Cell counting of viable hepatocytes 
was done at the same time as the change of medium. The 
results are described in section 3.3.2.4.
2.3.8. EFFECT OF CONDITIONED MEDIUM (BY GROWTH OF F344 
FISCHER NEONATAL RAT LIVER CELLS FOR 7 DAYS) ON 
HEPATOCYTES:
Gollagenase digestion and low speed centrifugation 
gives a cell yield of pure hepatocytes (Fry et al, 1976 
; Jeejeebhoy and Phillips,1976 ) . However, if the rat
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TABLE 2.5
EFFECT OF CONDITIONED MEDIA ON HEPATOCYTES
MEDIUM % OF RPMI* INS+HC$ COND.MED" % % OF SFM"
A 100% + Nil Nil
B 100% - Nil Nil
C 90% + 10% Nil
D 50% + 50% Nil
E Nil - Nil 100%
F Nil - 10% 90%
G Nil 50% 50%
RPMI* RPMI-1640 + 15% FCS -f■ glutamine 2 mM +
INS+HC$
COND.MED
SFM"
penicillin 6 mg% + streptomycin 10 mg%
Insulin (Sigma) 50 ug/ml + Hydrocortisone (Sigma)
0.36 ug/ml.
Conditioned medium by growth of rat embryo or” 
fetal rat liver cells.
Serum free medium as described in section 2.3.5.
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liver cells are isolated by trypsin digestion and 
relatively high speed centrifugation, a product is 
obtained containing all the cells of liver i.e, 
hepatocytes, fibroblasts, epithelial cells, endothelial 
cells, smooth muscle cells and Kupffercells. The 
neonatal tissues exhibit a higher growth potential than 
the adult cells which may be due to some growth 
promoting factors produced by these neonatal tissues or 
other cell types.
Preparation of the conditioned medium: Liver of a new 
born Fischer F344 rat was taken out by aseptic 
dissection. It was washed in HBSS and cut into small 
pieces. These pieces were then dissociated with 
trypsin-EDTA for 3-4 hours at 4°C and then by 
incubation at 37°C as in section 2.3.7. Cells were 
isolated and seeded to tissue culture flasks in 50-60 
ml RPMI medium (containing 15% FCS) at a density of 
5 X 10^ cells per ml. Flasks were incubated and cells 
cultured as described in section 2.3.7. The grown cells 
represented all types of liver cells. The cultures were 
carried out for 8-10 days and the medium was then used 
as conditioned medium.
The same experiment was carried out, as described in 
section 2.3.7, using the medium conditioned by growing 
neonatal liver cells. The results are described in 
section 3.3.2.4.
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2.3.9. NORMAL AND CIPROFIBRATE PEROXISOME PROLIFERATOR- 
INDUCED HEPATIC TUMOUR CELLS IN SERUM FREE AND SERUM 
SUPPLEMENTED MEDIUM:
Liver tumours were induced in Fischer F344 male rats by 
feeding them one of the peroxisome proliterators 
(Ciprofibrate) from the fibrate group for 105 weeks. 
These liver tumour tissues from separate animals were 
provided by Dr Frank Bonner and Dr Sue Wilson (Sterling 
Winthrop Research Centre, Alnwick). On overall gross 
examination at dissection the livers were extensively 
enlarged, and surfaces were nodular and irregular. 
Greyish white areas were seen against much darker 
colour of liver than normal. In addition there were 
areas of necrosis and haemorrhage. Some of the greyish 
areas were hard to cut. No evidence of calcification 
was found. Histopathology of these tumours, carried out 
Alnwick, showed them to be hepatocellular 
carcinomas (non metastatic). The tumour tissue was 
transported rapidly to this laboratory in the serum 
free medium at 4°C in an insulated container. On 
receipt, this tumour tissue was stored over liquid 
nitrogen 6 hours after dissection as already described 
in section 2.2 .
Four groups of tissue culture dishes were prepared 
namely A, B, C and D. A serum free medium (as 
described) and a serum supplemented medium (containing 
15% Fetal calf serum, 50 ug/ml insulin and 0.36 ug/ml
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hydrocortisone) were prepared. To the dishes of group A 
and C, 5 ml of serum free medium were added while to 
the group B and D, 5 ml of serum supplemented medium 
were added (see table 2.6). Hepatocytes were isolated 
from normal livers and tumour tissue of Fischer F344 
male rats. To dishes of group A and B, 5 X 10^ normal 
hepatocytes were seeded per dish. Hepatic tumour cells 
at 5 X 10^ cells per dish, were seeded to the dishes 
of group C and D. Medium was changed twice weekly by 
gentle aspiration and replenished by exact volume of 
the respective medium. Cell count of viable cells was 
done every third day. The results are described in 
section 3.3.2.5.
2.3.10. GROWTH OF CELLS ON SUBSTRATE:
Substrates like collagen (Gatmaitan et al, 1983 :
Michalopoulos and Pitot, 1975), nitrocellulose filters 
(Savage and Bonney, 1978), floating gel membranes 
(Sattler et al, 1978) and liver biomatrix (Enat et al, 
1984) are shown by many to have a positive influence on 
hepatocytes in culture. Some, on the other hand, found 
better results with a serum free medium without a 
substrate.
COATING THE SURFACE WITH SUBSTRATE : Collagen,
fibronectin, laminin and poly-L-lysine were used.
1. 0.01% collagen type I from rat tail (Sigma) solution 
was made in 0.1 M acetic acid, by dissolving for 2-3 
hours at room temperature. A small amount remained
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TABLE 2.6
NORMAL AND TUMOUR CELLS OF RAT IM VITRO
EXPERIMENT GROUP MEDIA USED CELL TYPE
SFM* SSM" NRLC$ RLTC#
A + - -f -
B — + + -
C + - - +
D - + - +
SFM*
SSM"
NRLC$
RLTC#
Serum free medium as described in section 2.3.5 
RPMI-1640 + 15% FCS + glutamine 2 mM + 
penicillin 6 mg% + streptomycin 10 mg% + 
insulin 50 ug/ml + hydrocortisone 0.36 ug/ml.
Normal rat liver cells (Fischer F344 male). 
Ciprofibrate (peroxisome proliferator)-induced 
rat liver tumour cells (Fischer F344 male).
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undissolved. Sterilized by filtration through Nalgene 
filter (Flow). Tissue culture dishes 60 X 15 mm (Falcon 
Primiria) were coated as 6 uG/cm^ (0.6 ml of solution 
per dish). They were left to dry overnight and rinsed 
with PBS before use.
2. Fibronectin (Sigma) solution was made, as 1 mg/ml, 
by adding milli Q water and allowed to mix at room 
temperature for 30 minutes without agitating. It was 
further diluted 1:25 in PBS. 1 ml was added to each 
60 X 15 mm tissue culture dish (Falcon Primiria) to 
give about 4 uG/cm^ (range 1-5 uG/cm^). It was allowed 
to stand for 45 minutes at room temperature. Solution 
was removed and dishes dried as described.
3. Laminin (Sigma) was thawed slowly to prevent gel 
formation and diluted in PBS as 3.0 mg/ml. 0.5 ml 
(1.6 uG/cm^) was added to each dish for 45 minutes at 
room temperature. Solution was removed and dishes 
dried.
4. Poly-L-lesine (Sigma) solution was made as 
0.1 mg/ml. 0.2 ml (2.0 uG/cm^) was added to each tissue 
culture dish. Solution was removed after 2 minutes and 
dishes washed with PBS.
groups of tissue culture dishes were prepared as:
U = 60 X 15 mm tissue culture dishes (Falcon Primiria)
V = same as above.
W = collagen coated dishes.
X = fibronectin coated dishes.
Y = laminin coated dishes.
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Z = poly-L-lysine coated dishes.
Serum free medium (section 2.3.5) was used for group U 
while serum supplemented medium (15% FCS + 50 uG/ml 
insulin + 0.36 uG/ml hydrocortisone) was used for the 
rest. 5 X 10^ freshly isolated hepatocytes were seeded 
to each dish in every group in 5 ml of the medium as 
mentioned above. Medium was changed every third day and 
cell counting effected as described in section 2.1. The 
experiment was repeated with Ciprofibrate peroxisome 
proliferator-induced hepatic tumour cells as well. The 
results are described in section 3.3.2.6.
2.3.11. EFFECT OF TRYPSIN ON TUMOUR CELLS:
Trypsin is the enzyme usually used to dislodge cells 
from culture vessels when confluency is reached and 
cells stop growing. It is immediately after 
trypsinization that subcultured cells start to grow 
rapidly. Trypsin, as already mentioned in section 2.3, 
causes various changes in the cell membranes at the 
molecular level (Grisham,1980). It is possible that it 
is also involved in the mechanism of induction of cell 
proliferation. This experiment was performed to find 
out the effect of trypsin treatment on hepatic tumour 
cells induced by Ciprofibrate peroxisome proliferator. 
Trypsin was prepared in five dilutions using phosphate 
buffered saline. The dilutions were X/IO, X, 5X, lOX 
and 50X where X is 0.05% w/v concentration of trypsin. 
Tissue culture dishes (Falcon Primiria) 60 X 15 mm size
123
were used and serum free medium (5 ml/dish) was put in 
each of these dishes. The seed was 5 X 10^ freshly 
isolated tumour cells in each dish. These dishes were 
divided in groups as following (see table 2.7):
A = Control 
B-1, B-2, B-3 
C-1, C-2, C-3 
D-1, D-2, D-3 
E-1, E-2, E-3 
F-1, F-2, F-3
To group B-1, B-2 and B-3 1 ml of X/10 trypsin was
added for 2 minutes, 10 minutes and 30 minutes 
respectively. The reaction was stopped by adding 1 ml 
of soybean trypsin inhibitor (Sigma) and cells were 
washed by centrifugation at 50 g for 2-3 minutes. Then 
the cells were seeded in fresh serum free medium in 
new dishes with the same marking. The same procedure 
was repeated for dishes of group C, D, E and F using X, 
5X, lOX and 50X trypsin. The medium was changed by 
aspiration and adding equal volume of the same medium. 
Cell count of viable hepatocytes was done on day 3, 6, 
9 and 12. The results are described in section 3.3.2.7.
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TABLE 2.7 
EFFECT OF TRYPSIN ON TUMOUR CELLS
GROUP TRYPSIN CONCENTRATION* EXPOSURE TIME
X/10 X 5X lOX 50X 2 Mins 10 Mins 30 Mins
A - - - - - - ; - -
B-1 + - - — - + -, -
B-2 + - - - - - + —
B-3 + - - - - - - +
C-1 - + - - - + - -
C-2 - + - - - - + —
C-3 - + - - - - - +
D-1 - - + - - + - -
D-2 - - + - - - + -
D-3 - - + - - - - +
E-1 - - - + - + - -
E-2 - - - + - - + —
E-3 - - - + - - - +
F-1 - - - - + + - -
F-2 - - - - + . - + -
F-3 — - - - + - - +
* X indicate 0.05% w/v of trypsin.
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2.4 AGGLUTINATION OF TUMOUR CELLS BY LECTINS :
2.4.1. INTRODUCTION:
Lectins or agglutinins are naturally occurring chemical 
compounds of plant origin. They cause clumping or 
agglutination of malignant, transformed or neoplastic 
tumour cells when incubated with such cells at 
appropriate concentrations. There are molecular 
receptors on cells for lectins, which cross link cells 
through these receptors. They usually do not 
agglutinate normal cells or agglutination of normal 
cells is much lower compared to corresponding tumour 
cells (Inbar and Sachs,1969 : Kapeller and Doljanski, 
1972 : San et al, 1979 : Sharon and Lis,1972). This 
agglutinibility is because of some changes in cell 
membrane (usually in the glycosidic side chains) during 
transformation and carcinogenesis. Normal cells can 
also be made more susceptible to the action of lectins 
by treating them with proteolytic enzymes.
2.4.2. MATERIALS AND METHODS:
A variety of cells, including the hepatic tumour cells 
(i^^uced by Ciprofibrate peroxisome proliferator) and 
normal counterparts, were treated with various 
concentrations of wheat germ agglutinin and 
concanavilin-A (based on the method of San et al,1979) 
to compare the agglutination of these cells by the 
lectins. The different cells used were:
(1) Fischer F344 rat normal liver cells.
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(2) Fischer F344 rat hepatic tumour cells induced by 
Ciprofibrate peroxisome proliferator.
(3) Fischer F344 rat hepatic tumour cells kept in 
culture in a serum free medium for 20-25 days.
(4) HeLa cells.
(5) BHK 21 monolayer cells.
(6) BHK 21 suspension culture cells.
(7) MAK hybridoma, a hybridoma cell line secreting a 
murine monoclonal antibody.
(8) MRC-5, a lung fibroblast, cell line.
Tumour cells and normal hepatocytes were freshly 
isolated as already described in section 2.1 while the 
other cells were taken from growing cultures. Two sets 
of six small bijou 5 ml plastic bottles were prepared 
for each cell type. 0.5 ml of serum free medium was 
dispensed in to each bottle and 2 X 10^ cells added. 
The bottles were marked in group one as lA, 2A, 3A, 4A, 
5A and 6A and in second group from IB to 6B in the same 
way. Wheat germ agglutinin (Sigma) solution was 
prepared in PBS at a concentration of 200 ug/ml. 
Similarly a solution of concanavalin-A (Sigma) was 
prepared in PBS at a concentration of 1600 ug/ml. 
Appropriate volumes of these stock solutions were added 
to each bottle in such a way to get the desired 
concentrations (see table 2.8).
The total volume in each bottle was made up 1.0 ml by 
adding PBS. After mixing, by shaking gently, the
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TABLE 2.8 
AGGLUTINATION OF CELLS WITH LECTINS
EXPERIMENT
GROUP
WHEAT GERM AGGLUTININ 
IN uG/ML
CONCANAVALIN-A 
IN uG/ML
0.1 1.0 10 50 100 50 100 200 400 800
lA - - - - - - - - -
IB - - - - - - - - - . -
2A + - - - - - - - - -
2B - - - - - + - - - -
3A - + - - - - - - - -
3B - - - - - - + - - ■ -
4A - - + - - - - - - -
4B - - - - - - + - -
5A - - - + - - - - -
5B - - - - - - - - + -
6A - - - - + . - - - - -
6B - - - - - V - - - — +
..—*
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bottles were incubated at 37°C for 30 minutes. Cell 
counts were carried out in a haemocytometer after 
gently mixing with trypan blue. Only single viable 
cells (and not clustered or agglutinated cells) were 
counted. The calculation of percentage agglutinability 
was carried out, for all cells, as follow:
A - B
% Agglutinibility = 100 X
where A = Number of single cells in the absence of 
agglutinin (control).
and B = Number of single cells in the presence of 
agglutinin (test).
A-B = Number of cells agglutinated.
The results are described in section 3.4.
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2.5. GROWTH OF TUMOUR CELLS IN SEMISOLID MEDIA:
2.5.1. INTRODUCTION:
One of the properties of transformed or tumour cells is 
anchorage independent growth in semisolid medium. This 
phenomenon of growth in semisolid medium is poorly 
understood and a variety of factors are believed to 
regulate it (Crowe et al,1978). Freshly isolated tumour 
cells from biopsy materials show a broad spectrum in 
terms of their potential to grow and form colonies in 
semisolid medium (Courtenay et al,1977 : Ottestad et 
al,1988 : Pretlow et al,1986 : San et al,1979). On the 
other hand, most of the established cell lines have a 
much higher potential of growth in semisolid medium. It 
is also seen that many solid tumours, although they are 
malignant both morphologically and histologically In 
vivo, are not capable of showing growth in semisolid 
^®dium. Success in obtaining colony growth is not 
achieved in each and every case (Ahmann et al,1986 : 
Pavelic et al,1980).
2.5.2. GROWTH IN SOFT AGAR:
Stock solutions of 1.2% and 0.6% agar (fine purified 
gum agar from Sigma) in distilled water were prepared. 
They were autoclaved to dissolve and sterilize. These 
sterilized solutions were then stored at room 
temperature. 2X and IX serum free media were prepared 
according to the formulation mentioned in section
2.3.5. 500 ml Duran bottle each containing 200 ml of
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1.2% and 0.6% agar was melted in a 650W microwave oven. 
Bottles of 2X and IX serum free medium were warmed up 
to 37° C in a water bath simultaneously. 100 ml serum 
free medium and 100 ml 1.2% agar were quickly mixed to 
give a final concentration of 0.6% agar for base of the 
dishes. By rapid gentle pipetting 6 ml of the above 
mixture was dispensed into one 100 X 20 mm tissue 
culture dish (Falcon) avoiding air bubbles. The sides 
of the dish were coated by swirling and then left to 
harden at room temperature for 15 minutes. These 
prepared dishes can be stored at 4°C for future use. A 
number of dishes were prepared in this way.
100 ml 0.6% agar was quickly mixed with 100 ml 2X serum 
free medium to give a 0.3% agar for the cell 
suspension. It was kept warm at 37°C before use. 
The following cells were used:
(1) HeLa cells from a growing culture.
(2) BHK 21 monolayer cells from a growing culture.
(3) MRC 5 cells from a growing culture.
(4) BHK 21 suspension cells.
(5) MAK hybridoma, a hybridoma cell line secreting 
murine monoclonal antibodies.
(6) Fischer F344 rat hepatocytes freshly isolated.
(7) Fischer F344 rat hepatoma cells freshly isolated.
(8) Fischer F344 rat hepatoma cells cultured for 20-25 
days.
The cells were washed in PBS by centrifugation for
131
these experiments. Prepared tissue culture dishes were 
set up in groups as lA, IB, 1C; 2A, 2B,
2C; ..... 8A, 8B and 80. 1 X 10^, 1 X 10^, and
1 X 10^ cells of each type were prepared in 6 ml of
0.3% agar medium and then put into respectively lA, IB,
1C; 2A, 2B, 2C;......... 8A, 8B, and 8C. After seeding
the cells, the dishes were allowed to gel for a few 
minutes at room temperature. The dishes were placed in 
a 5% 002-95% air incubator. The cultures were fed twice 
weekly with 3-4 ml of freshly prepared 0.3% agar 
rnsdium. Cell colonies were counted at weekly intervals. 
Colonies with greater than 30 cells were taken as 
positive (San et al, 1979). The results are described 
in section 3.5.
2.5.3. GROWTH IN METHYL CELLULOSE (METHOCEL):
Three grams of methyl cellulose (Sigma 4000 ops) was 
added to 200 ml double distilled water at 80-90°C with 
continuous stirring. The solution was sterilized by 
autoc 1 aving in 200 ml aliquots. Then the solution was 
slowly cooled to 4°C with continuous shaking of the 
bottle otherwise methocel will not stay in solution and 
will settle out as a powder. At or around 4°C a 
semisolid transparent jelly like solution is obtained. 
Fot the growth experiments methocel media was prepared 
as described (see appendix).
The medium was stored at -20°C as it can be stored for
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long periods (Methocel solidifies at -20°C but gels at 
room temperature). For use, 100 ml fetal calf serum was 
added to each bottle of methocel giving a final serum 
concentration of 30% and the final concentration of 
methocel becomes as 0.9%. 1 X 10^, 1 X 10^, and
1 X 10^ cells of each type were prepared in 10 ml 
methocel. This was dispensed in 100 X 20 mm tissue 
culture dishes as described in the previous section. 
The cultures were fed twice weekly with freshly 
prepared methocel medium 3-4 ml per dish. Cell colonies 
were counted each week for three weeks as described 
above. The same experiment was repeated using lOX serum 
free medium and omitting the fetal calf serum. The 
results are described in section 3.5.
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2.6. ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA):
2.6.1. INTRODUCTION:
Enzyme linked immunosorbent assay (ELISA) is the method 
employed to detect antibodies in hybridoma supernatant 
cultures or ascitic fluid with the help of antigen. 
ELISA is comparable to radioimmunoassay or 
immunoflurescence in sensitivity, reproducibility, 
automatability and applicability. In addition , it 
gives results independent of human error and bias. 
ELISA chemicals have a longer shelf life and expensive 
equipment is not required making it economical to use 
(Reif, 1982) . Intact whole cells can be used as
sri'tig©ns in ELISA to screen for cell surface antigens 
(Becker et al,1986 : Campbell,1987 : Douillard et
al,1980 : Trejdosiewicz et al, 1984). When cells attach 
to the surface in a solid phase they may change their 
antigenic configuration. The coating chemicals 
(gluteraldehyde, paraformaldehyde, acetaldehyde, 
acetone or coating buffer) can chemically alter the 
antigen (Campbell,1987 : Saladino et al,1985). Better 
results may be obtained using liquid phase ELISA 
although this is a difficult method to develop and 
standardize. In the liquid phase cells present antigen 
in a native form with maximum antigen antibody binding.
2.6.2. ELISA PROTOCOL:
(1) A cell suspension was prepared at a suitable 
cell density for feeding a 96 well plate as 50-100 uL
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per required cell number for each well. The required 
number of cells per well were seeded, in 50-100 uL PBS 
or medium, in a U-bottom ELISA 96 well plate (Falcon).
(2) 100 uL of hybridoma supernatant or ascitic fluid, 
at an appropriate dilution, was added to each well.
(3) The plate was incubated at room temperature for 30 
minutes. Longer incubation can be done at 4°C to reduce 
cellular uptake of antibodies by pinocytosis into the 
cells and may give a high background.
(4) To remove unbound antibodies, and to wash cells, 
plates were centrifuged at 1000 rpm (212.8 g) in a 
Beckman GPR Centrifuge for 4-5 minutes at 10-15°C.
(5) Supernatant fluid was aspirated carefully, from 
each well, with a multichannel pipette using separate 
tips for each well. 150-200 uL of PBS at 37°C was added 
to each well. The cell pellet was resuspended by gently 
touching the plate against a vibrating mixer. It is 
necessary to keep the cells alive as non-specific 
uptake of antibodies can occur in the dead cells.
(6) B-galactosidase-linked conjugate (Amersham) was 
diluted, in the freshly prepared diluting conjugate 
buffer (see appendix), in the desired dilution 1:200, 
1:300, 1:400, 1:500 or 1:1000.
(7) Plates were incubated at 37°C in a humid atmosphere 
for 2-3 hours or preferably overnight at 4°C.
(8) Plates were washed twice as in step 4.
(9) 100 uL of freshly prepared substrate solution
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ortho-nitrophenyl-B-D-galactopyranoside (ONPG) was 
added to each well and incubated in a humid atmosphere 
at 37°C until the desired bright yellow colour 
developed, usually in 30-40 minutes. The substrate ONPG 
(Amersham) solution was prepared at a concentration of
0.9 mg/ml or 3 mM in the ELISA substrate buffer (see 
Appendix).
(10) The reaction was stopped by adding 50 uL of 1 M 
solution of Na2C0g to each well. This also enhances 
intensity of the developed yellow colour. (Fig. 2.1)
(11) Centrifugation was done again at 1000 rpm 
(212.8 g) in Beckman GPR Centrifuge at 15°C for 4-5 
minutes. 150 uL of coloured supernatant fluid was 
transferred to another ELISA plate to the corresponding 
wells carefully. The cells were thus left out to avoid 
any interference in absorbance reading (O.D).
(12) Absorbance or optical density (O.D) value was read 
in the ELISA plate reader (Dynatech MR 600) at 410 nm.
2.6.3. CHEQUER BOARD ELISA EXPERIMENTS:
A number of ELISA experiments were run in order to 
find out the optima for cell concentration, the 
conjugate dilution, and efficacy of test system. Cell 
number per well, dilution of conjugate and 
dilution of antiserum were varied in these experiments. 
A number of negative and positive controls were run and 
any cross-reactivity in the system was also checked. 
Preparation of Antiserum: Antirat (Fischer F344 male)
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Fig. 2.1
DIAGRAMATIC REPRESENTATION OF ELISA REACTIONS
Substrate converted 
to chromatic compound
41'
Ooo Substrate
2nd Antibody (Conjugate)
1st Antibody (Monoclonal)
Cell
(Campbell, 1987)
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hepatocyte antiserum was raised in balb/c mice. The 
mice were injected with 5 X 10^ viable freshly isolated 
hepatocytes intra-peritoneally in 0.5 ml PBS per 
animal. The injections were given three times with an 
interval of two weeks between each injection. Three to 
four days after the last injection, blood was collected 
aseptically by terminal bleeding through cardiac 
puncture. It was allowed to clot at 37°C for 1 hour. 
The clot was freed from walls of the container by a 
sterile needle. The sample was left overnight at 4^C 
for the clot to retract. Serum was drawn off carefully 
with a pipette to reduce to a minimum the number of red 
blood cells. Centrifugation was done at 200 g for 20 
ininutes to remove red blood cells. The supernatant 
fluid was collected carefully. Sodium azide (BDH) can 
be added as a preservative at this stage at a 
concentration of 0.1% w/v. Thiomersal or merthiolate 
may also be used at a concentration of 1:10,000. This 
antiserum was stored at -20°C in 100 uL aliquots. 
Preparation of Negative Serum; Negative serum was also 
obtained from cardiac puncture and terminal bleeding of 
un-immunized balb/c mice. Serum was separated out and 
stored in the same manner as described above.
A number of chequer board ELISA plates were run as 
described (Campbel1,1987) varying the cell 
concentrations per well, dilution of the conjugate and 
various dilutions of the antirat hepatocyte antiserum. 
The cell numbers used per well were 1 X 10^, 1 X 10^,
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5 X 10^, 1 X 10^, and 5 X 10^. The dilutions of the
conjugate used were 1/100, 1/200, 1/300, 1/400 and
1/800. The various antirat hepatocyte antiserum 
dilutions used were 1/100, 1/400, 1/800, 1/1600, 1/6400 
and 1/12,800.
2.6.4. EXPERIMENTS TO TEST SENSITIVITY OF THE ASSAY TO 
POSSIBLE CROSS-REACTIVITY OR INTERFERENCES:
The following were tested.
(A) Complete HAT medium was used in place of antiserum.
(B) 1/1600 negative serum was used in place of 
antiserum.
(C) 1/1600 antirat hepatocyte antiserum was used as 
positive control.
(D) Cells (Antigens), conjugate and substrate were used 
but antiserum omitted to find any cross-reaction.
(E) Only cells (Antigens) and substrate were allowed to 
react and conjugate and antisera were omitted in order 
to detect any cross reactivity in the system.
(F) Antiserum, conjugate and substrate were allowed to 
react and cells (antigens) were omitted.
(G) 1/6400 antirat hepatocyte antiserum.
(H) 1/12800 antirat hepatocyte antiserum.
These experiments were done to find any cross- 
reactivity in the system and to detect any false 
positive results. The cell number used was 5 X 10- per 
well, conjugate dilution was 1:300 and the volume of 
supernatant was 100 uL/well.
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2.7. MONOCLONAL ANTIBODIES PRODUCTION AGAINST THE RAT 
LIVER TUMOUR CELLS :
2.7.1. INTRODUCTION:
Monoclonal antibodies are an ideal tool in experimental 
and clinical oncology due to their potential to achieve 
high degree of specificity, ready availability for an 
indefinite period and a standard titre. They can be 
produced more consistently. There are, however, 
problems of antigenic modulation, loss of target 
antigen, emergence of antigen negative 
subpopulations of tumour cells, inactivity of 
antibodies due to combination with free tumour antigens 
in serum and difficulties in accessing solid tumours. 
In addition, monoclonal antibodies have considerable 
applications in cardiology, autoimmune diseases, 
metabolic malfunctions and organ transplants. They are 
also used for separation and isolation of antigens 
(see section 1.3).
When an animal is immunized with an antigen, this leads 
to clonal expansion of B-lymphocytes which recognize 
the antigen and their differentiation to antibody 
secreting plasma cells. If individual 
3'^^iU®ri“i'csponding cells from lymphoid tissue of an 
immunized animal could be propagated continuously in 
vitro the culture supernatant would contain homogeneous 
antibody molecules (monoclonal antibody) which 
recognize only one or a few closely related antigens.
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In 1975 Kohler and Milstein (Kohler and Milstein, 1975) 
immortalized antibody-secreting lymphocytes by fusing 
them with cells from a continuously growing myeloma 
cell line and then cloned individual hybrid cells to 
produce cell lines (hybridoma) each of which secretes 
one particular antibody molecule.
An antibody-secreting cell line is produced by fusing 
an antibody-secreting cell from lymphoid tissue of an 
immunized animal and a cell from a myeloma 
(plasmocytoma) cell line which represent a similar 
differentiation stage. The resultant hybridoma retains 
the 'ability of one parent (B-lymphocyte) to secrete a 
particular antibody and continuous growth 
characteristics of the other parent (myeloma cell). The 
non-fused HGPRT- negative myeloma cells are selected 
out in HAT (Hypoxanthine, Aminopterin and Thymidine) 
medium and do not survive in that medium. The non-fused 
lymphocytes, on the other hand, die out in due course 
because of their finite life span. Only the hybrids 
survive and grow in HAT medium, (see Fig. 2.2)
2.7.2. ISOLATION OF TUMOUR-SPECIFIC MONOCLONAL 
ANTIBODIES :
Monoclonal antibodies were raised against the rat 
hepatic tumour cells induced by Ciprofibrate — a 
fibrate peroxisome proliferator, in the exposed group 
of male Fischer F344 rats.
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Fig. 2.2
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2.7.2.1. IMMUNIZATION:
were
Three, young 8 week old, Balb/c mice _ immunized with 
rat hepatic tumour cells of Fischer F344 rat. 5 x 10^ 
tumour cells, freshly isolated from tumour tissue, in
0.5 ml PBS were injected intra-peritoneally into each 
animal. Three such inoculations, each two weeks apart, 
were given to each animal. The results are described in 
section 4.1.
Cells as whole, membranes, extract, spent culture 
medium or purified medium all have been used for MoAb 
production against tumour cells (Chang et al, 1980 : 
Davis and Preston, 1981 : Kenemans et al, 1988 : Martin 
et al, 1989 : Ohkawa et al, 1989 : Teh et al, 1985).
2.7.2.2. MYELOMA CELLS:
Cells of the SP2/0 myeloma cell line were grown in 
Minimum Essential Medium containing 10% Fetal calf 
serum. This was done with the aim of having 10® myeloma 
cells with greater than 95% viability in log phase on 
the day of the fusion.
2.7.2.3. B-LYMPHOCYTES:
Three to four days prior to fusion, the immunized 
animal was boosted with 5 x 10® tumour cells in 0.5 ml 
PBS injected intra-peritoneally. On the day of fusion, 
the animal was anaesthetized and killed by cervical 
dislocation. It was swabbed thoroughly with 70% 
alcohol. The abdominal cavity was opened and the spleen 
was removed aseptically using sterile scissors and
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forceps. The spleen was immediately transferred to a 
universal bottle containing 10 ml of serum free medium 
L-15.
2.7.2.4. FUSION PROTOCOL:
(1) SP2/0 myeloma cells were centrifuged at 1000 rpm 
(200 g) for 5 minutes and resuspended as 10^ cells in 5 
ml serum free medium L-15.
(2) The spleen of immunized animal was transferred 
quickly to a sterile petri dish in laminar air flow 
cabinet. It was washed with serum free L-15 medium. 
Fibrous or any other fatty tissue was dissected away 
from it. The spleen was skewered with a 25G sterile 
disposable needle in place. It was gently teased with a 
second 25G sterile disposable needle. The process was 
continued till all the spleen cells were separated out 
in the medium of petri dish. Spleen carcass was left 
behind which was of much lighter colour but of the same 
size.
from the petri dish
(3) The medium r containing B-lymphocytes
was drawn in a 10 ml pipette and transferred to 
u^^versal bottle. Cell suspension was expressed gently
2-3 times through a 10 ml pipette to break the large 
cell clumps.
(4) The spleen cells were counted. They were in the 
order of 10® cells. (Spleen cells are difficult to see 
under the microscope due to their small size. 0.05 ml 
spleen cell suspension was taken in an Eppendorf tube
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containing 0.3 ml Of 0.9% ammonium chloride solution. 
Cells swell and became easily visible for counting)
(5) 10® spleen cells were centrifuged at 1000 rpm 
(200 g) for 3 minutes and resuspended in 5 ml serum 
free L-15 medium.
(6) 5 ml spleen cell suspension (10® cells) and 5 ml 
SP2/0 cell suspension (10? cells) were mixed gently (at 
a ratio of 10:1). The mixed cell suspension was 
centrifuged at 1000 rpm (200 g) for 3 minutes.
(7) Supernatant was discarded and pellet loosened by 
gently tapping the bottom with finger. Cells spread to 
make a thin layer over the walls of universal.
(8) 1 ml of 40% v/v (made with serum free L-15 medium) 
warmed (at 37°C) polyethylene glycol (PEG) was added 
dropwise to the universal bottle, through its walls 
over a period of 1 minute. The Universal was kept warm 
and mixing by holding it in hand and gently rotating 
it.
(9) The universal was kept in a water bath at 37°C for 
one minute.
(10) 10 ml of serum free L-15 medium was added to the 
universal slowly over a period of 10 minutes. It was 
then left at room temperature for 5 minutes.
(11) It was then centrifuged at 1000 rpm (200 g) for
3-4 minutes. The supernatant was discarded and the 
pellet resuspended in 50 ml of L-15 medium containing 
IX HAT and 15% fetal calf serum.
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(12) Two drops (approximately 150 uL) was added to each 
well of four 96-well tissue culture plates by a 
pipette. Wells lA, IB and 1C were not used and left out 
for controls in the ELISA assay. The volume in each 
well was made up to 200 uL by adding 50 uL of HAT L-15 
medium.
(13) The plates were covered and sealed by plastic tape 
and incubated at 37°C in a 5% COg incubator.
(14) Plates were inspected daily using an inverted 
microscope to observe death of myeloma cells and 
lymphocytes and appearance of clones.
(15) On day 4, wells were fed by taking out 100-150 uL 
of medium from each well and replacing it with freshly 
made IX HAT medium (in L-15 medium containing 15% FCS). 
Medium was changed every 6-7 days in the same way. The 
results are described in section 4.2.
2.7.2.5. ASSAY OF WELLS:
Inspection of wells was performed daily using an 
inverted microscope. When colonies appeared and were 
visible (usually between 8-14 days) as distinctive 
colonies, wells showing clonal growth were assayed for 
antibody productivity. ELISA was carried out as 
described in section 2.6.2, using 100 uL of well 
supernatant, with both normal Fischer F344 rat 
hepatocytes and rat hepatic tumour cells.
On each plate a negative control (serum of Balb/c mice 
1/1600 dilution) and a positive control (antirat
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Fischer F344 rat hepatocyte antiserum in Balb/c mice 
1/1600 dilution) were included. The clones of interest 
were identified and selected for cloning. The results 
are described in section 4.3.
2.7.3. CLONING OF HYBRIDOMAS:
Hybridomas of interest, as selected by ELISA, were 
cloned by limiting dilution. Hybridomas from a well, of 
interest, were diluted serially on a 96-well tissue 
culture plate (Fig. 2.3) and grown into colonies or 
populations. Medium used was 50% 2X HAT L-15 medium 
containing 15% FCS and 50% L-15 medium containing 15%
FCS conditioned by growth of SP2/0 myeloma cells. 
Single colonies whose supernatant fluid gave the most 
positive/distinctive reaction between normal and tumour 
cells were selected for growth amplification. The 
results are described in section 4.4.
2.7.4. AMPLIFICATION OF CLONES:
The cloned hybridomas were amplified carefully from 
96-well microtitre tissue culture plates to 150 cm^ 
flasks going through 6-well plates, 25 cm^ flasks and 
75 cm flasks. Hybridomas were then stored over liquid 
nitrogen for long term storage, as already described in 
section 2.2 .
2.7.5. PRODUCTION OF ASCITES:
Tissue culture supernatant of hybridomas contain 
microgram quantities of antibody per ml while ascitic
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Fig. 2,3
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fluid contains milligram quantities of antibody per ml 
of ascitic fluid. It was, therefore, necessary to 
produce some ascitic fluid in order to get a 
reasonable quantity of antibody for experiments. 
5 X 10® hybridoma cells were injected to each young 
male Balb/c mouse (8-10 weeks) intra-peritoneally in
0.5 ml PBS, after priming the animal with pristane. 0.5 
ml pristane or 2,6,10,14-tetramethyl pentadecane 
(Sigma) was injected to each mice intra-peritoneally 
one week before injecting hybridoma cells. Hybridomas 
usually grow as ascitic tumours. Animals were examined 
daily and ascitic fluid was withdrawn when the 
peritoneal cavity showed maximal distension. Ascitic 
fluid was tapped, from peritoneal cavity after 
anaesthetizing the animal, and stored at -70°C. The 
results are described in section 4.6.
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2.8 CHARACTERIZATION OF ANTIGENS IDENTIFIED BY THE 
MONOCLONAL ANTIBODIES RAISED AGAINST CIPROFIBRATE 
PEROXISOME PROLIFERATOR-INDUCED HEPATIC TUMOUR CELLS:
2.8.1 HISTOLOGY, HISTOPATHOLOGY AND IMMUNOCYTOCHEMISTRY 
(IMMUNOHISTOLOGY) OF TISSUE SECTIONS:
2.8.1.1 INTRODUCTION:
Immunocytochemical techniques have the potential to 
localize antigens in cells and tissues with strongly 
improved diversity, selectivity and specificity of 
staining reactions, as compared to standard staining 
methods for demonstration of tissue morphology 
(Vandesande, 1979). Immunocytochemical techniques are, 
sometimes, more sensitive and accurate than other 
assays as seen in colorectal carcinomas (Bagshawe, 
1983) and they are also very helpful in difficult cases 
and early histological diagnosis.
Immunocytochemistry was started in 1950 with 
fluorescent techniques and fluorochxomes (Coons and 
Kaplan, 1950) but it has certain limitations. One need 
an expensive and complex fluorescent microscope, 
o^i®ritation with background details is not visualized 
and preparations are not permanent. Enzyme labels like 
horseradish peroxidase, alkaline phosphatase, glucose 
oxidase and urease are found better for this purpose 
(Nakane and Pierce, 1966). They are more sensitive and 
convenient with tissues of complex morphology. They 
produce permanent chromatic precipitates, in both
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paraffin fixed and cryostat sections, that can be 
viewed by an ordinary light microscope. 
Immunocytochemistry has a wide range of applications 
like differential diagnosis of tumours, determining 
tissue of origin, grading of tumours, difficult and 
problematic diagnosis, typing of specific hormone 
secretions, characterization of antigens (cell surface 
antigens and the molecules involved in cell-cell or 
cell—surface interactions), study of receptor 
molecules, electron microscopy, localization of 
Intrinsic amines, detection of neuropeptides and 
hormones, autoimmune diseases, different cell and 
tissue markers, kidney and heart transplantations, 
tumour markers, detection of the oncogenes and their 
products, dermatology, haematology, microbiological 
specimen examinations, study of cells in culture or 
cell lines and detection of metastatic tumour cells in 
ascitic, pericardial or pleural effusions (for details 
look Immunocytochemistry - modern methods and 
applications., eds. Polak, J.W. and Van Noorden, S., 
1986., Wright Bristol).
Immunocytochemical examination of tissue sections can 
be done using both direct and indirect methods. The 
indirect methods are used more often as they save the 
trouble of conjugation of primary antibody. In the 
direct method (Guesdon et al, 1979 : Heggeness and Ash, 
1977) a labelled primary antibody is applied which
151
identifies an antigenic site. In the indirect method 
(Warnke and Levy, 1980) an unlabelled primary antibody 
is used to bind the antigen in tissue section. 
Excessive primary antibody is washed off and a second 
enzyme-conjugated antibody is applied from another 
species. This second enzyme-conjugated antibody 
combines to the first antibody to visualize specific 
^^^ig®riic sites. A label system or bridge can be used 
additionally which increases the sensitivity of test 
many fold. The examples of such label systems are 
peroxidase-antiperoxidase, alkaline phosphatase- 
antialkaline phosphatase, avidin-biotin, gold, 
ferritin, luciferase and phycoerythrin. A number of 
different bridge and double bridge systems are 
described (Ordronneau and Petrrusz, 1980) which may 
increase sensitivity but, sometimes, at the cost of 
specificity.
Avidin-biotin is a label system which enhances the 
sensitivity of a test involving antigen—antibody 
reaction (Coggi et al, 1986). Avidin is a large egg 
white glycoprotein molecule which bind with great 
affinity to the vitamin biotin. The avidin-biotin 
system was first used in 1977 (Heggeness and Ash, 1977) 
and was further developed and modified (Guesdon et al, 
1979 : Hsu et al, 1981 : Warnke and Levy, 1980). 
Primary unlabelled antibody is applied as the first 
step. A biotinylated-antibody is allowed to react with 
the primary antibody in the second step. This
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biotinylated antibody can be visualized with labelled 
avidin, with avidin acting as a bridge with 
biotinylated enzymes or with avidin-biotin enzyme 
complex (ABC). In the third step there is a reaction 
between the complex of enzyme-conjugate biotin and 
avidin, using free sites on the avidin molecule to bind 
“to biotinylated second antibody. This causes an immense 
amplification of the result, often many fold (fig 2.4). 
Avidin can be labelled with a marker like fluorochrome, 
enzyme, ferritin or gold which in turn is visualized in 
the next step. The endogenous biotin-avidin binding can 
be eliminated by blocking the sites first with free 
avidin or using extravidin from Streptomyces avidinii. 
The advantages of avidin-biotin system are sensitivity, 
versatility, detection of a low amount of antigens and 
low background. Higher dilutions of antibodies can be 
used and are especially useful with MoAbs. Pitfalls of 
it are non specific binding, endogenous avidin and non­
specific staining of mast cells.
iridirsct immunostaining of tissue sections have been 
used extensively in research and clinical applications 
(Chedid et al, 1990 : Dale and Brandtzaeg, 1989 :
Ghazizadeh, 1989 : Haglund et al, 1989 : Hole and
Stern, 1988 : Holmes et al, 1982 : Martin et al, 1989 : 
Paterson et al, 1988 : Prime et al, 1987 : Southall et 
al, 1990).
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Antigen-antibody reaction using avidin-biotin label 
system.
[Coggi, G., Dell’Orto, P. and Viak, G. (1986): Avidin- 
biotin methods. In Immunocytochemistry-modern methods
and application,, ed. Polak, J.M. and Van Noorden, S. 
Wright Bristol., p. 54-70]
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2.8.1.2 PREPARATION OF TISSUE SECTIONS:
TISSUE SAMPLES : Fischer F344 rats (5-6 month old and
250-300 gms) were obtained from the Animal Biology Unit 
(ABU), University of Surrey. Animals were killed by 
cervical dislocation. They were dissected out 
immediately and fresh tissues taken out as quickly as 
possible to prevent any post mortem changes. All the 
tissues were handled as gently as possible to avoid any 
mechanical damage and crushing.
Ciprofibrate peroxisome proliferator-induced liver 
tumours from Fischer F344 rats (tumours were developed 
by feeding rats this fibrate peroxisome proliferator 
for 105 weeks at a dose sufficient to induce 
hepatocellular carcinoma) were kindly provided by Dr 
Sue Wilson and Dr Frank Bonner of Sterling Winthrop 
Research Centre Alnwick, Northumberland.
Human tumour and normal tissues were kindly donated by 
Dr Bill Merchant and Dr B.T.B. Manners of the 
Histopathology Department of the Royal Surrey County 
Hospital Guildford and by Dr Julie Howarth of the 
Histology Unit, Department of Biochemistry University 
of Surrey.
FIXATION: The pieces of tissues were fixed in 10%
neutral buffered formalin (see appendix) for at least 
one week. Tissues can be kept safely in fixative 
solution for upto a period of 1 year. Fixation 
preserves the morphology and prevents autolysis of
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tissues. It may also affect the antigenicity. The
a
formol fixative does not mask antigens as do aldehyde 
fixatives so there is no need for an unmasking step 
later. It also allow a higher MoAb dilution to be used. 
PROCESSING OF TISSUE: Tissues were embedded in paraffin 
wax by the following method.
1. Tissue samples were taken to a fume hood. A piece of 
tissue, 2-3 mm in thickness, was cut from each sample 
and was freed of all fibrous tissue and fat. A sharp 
razor or blade was used to avoid mechanical damage and 
crushing of tissues which might cause diffusion of 
^^"tig©ns. It was placed in a metal processing container 
or a metal base mould (R.A.Lamb London). A reference 
number was given to each sample and it was labelled 
for a separate record.
2. The containers were placed in a tissue basket which 
was then fitted to the Histokinette automatic tissue
processor (British American Optical Co. Ltd., Slough
England).
3. Tissues were transferred automatically from one 
beaker of fluid to the next and processes of 
dehydration, clearing and impregnation with wax were 
carried out using the following schedule overnight. 
DEHYDRATION:
a) 70% Ethyl Alcohol   2 hours.
b) 85% Ethyl Alcohol   2 hours.
c) 95% Ethyl Alcohol   2 hours.
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d) 100% Ethyl Alcohol first r u n ............. 2 hours.
e) 100% Ethyl Alcohol second r u n ...........  2 hours.
f) 100% Ethyl Alcohol third r u n ............  2 hours.
Paraffin wax does not penetrate tissues in the presence
of water so dehydration is an essential step.
CLEARING:
i) Toluene first run  ......................  2 hours.
ii) Toluene second r u n ......................  2 hours.
Alcohol is not miscible with wax so it is necessary, 
after dehydration, to treat tissues with a chemical 
that mixes with both substances and may later be 
eliminated in wax impregnation step. These agents alter 
^®f^sctive index of tissues and render them 
transparent and are thus called clearing agents. Xylene 
and chloroform can also be used.
IMPREGNATION WITH WAX:
a) Paraffin wax first run at 5 8 ° C   2 hours.
b) Paraffin wax second run at 5 8 ° C .......  2 hours.
Tissue containers were then transferred to a third wax 
bath from which they were set into blocks.
The wax used (Fibrawax B.D.H. chemicals) had a melting
point of 56 C. A low melting point wax makes section
cutting very difficult. Wax polymerize when heated over 
60‘^C. The wax removes the clearing agent and completely 
permeate the tissues. It hardens on cooling so sections 
can be cut. Only thoroughly impregnated tissues give 
good quality sections. Under impregnated tissues do not 
cut easily and wash off the slides easily.
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4. Tissues were removed from the container using a pair 
of electrically heated forceps and were placed in a 
plastic or metal base mould (R.A. Lamb, London) filled 
with molten wax. The tissues were oriented in such a 
way that the surface to be cut rested on base of the 
mould. A plastic block was placed in the mould with the 
reference number label.
SECTION CUTTINGI Tissue sections of 3-5 uM thickness 
were cut from the wax blocks using an American Optical 
Spencer 820 Rotary Manual Microtome or an LKB 
Historange. Knife blade should be very sharp as pulling 
or ripping of section may give non specific positive 
staining. The sections were taken off the blade of 
microtome very carefully with a brush and forceps and 
floated on distilled water, heated at a temperature of 
5O^C, until creases on the section disappeared. 
Appropriate numbers of glass slides and cover slips 
(Chance propper Ltd U.K) were cleaned and degreased 
with alcohol. Slides were coated with poly-L-lysine 
(0.1 mg/ml), collagen or fibronectin (Sigma) for the 
immunocytochemical preparations otherwise tissue 
sections used to wash off the slide surface. The tissue 
sections were mounted on slides by half 
submerging a clean slide into the water near the tissue 
section and withdrawing it, so bringing the 
flattened section with it. The mounted slides were 
dried by gently pressing with filter paper. The
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reference number was etched onto the slide with a 
diamond pencil. The mounted slides were placed 
initially for drying on a hot plate (40-45°C) for 1-2 
hours and then left in an incubator at 37°C overnight 
to dry. The slides were then used immediately or stored 
in a slide box (R.A.Lamb, London) for future use.
2.8.1.3. PREPARATION OF BLOOD FILM SLIDES:
Fischer F344 rat blood was- withdrawn, in a disposable 
syringe coated with a thin film of anticoagulant 
(0.1 ml of 1000 units/ml), from the tail vein or by 
cardiac puncture after anaesthetizing it with ether. 
Glass slides were cleaned and degreased with alcohol. 
One drop of blood was put on each slide. Another slide 
was put at an angle of 45° to the surface of first 
slide and slid upto the other end so that a very thin 
film of blood was formed. The slides were allowed to 
dry at room temperature and stored at -20°C till used.
2.8.1.4 PREPARATION OF SLIDES OF ISOLATED CELLS:
Cells from normal liver and peroxisome proliferator 
induced liver tumours were isolated as described in 
section 2.1.3. Cells were suspended in HBSS at a 
concentration of 1 X 10  ^ cells per ml. Slides were 
made from the cell suspension as described in section
2.8.1.3. Slides were dried and stored at -20°C.
2.8.1.5. ROUTINE STAINING OF HISTOLOGICAL SECTIONS:
Tissue sections were stained, for routine histological
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examination, with Ehrlich's acid haematoxylin (BDH) and 
eosin (BDH) by the following protocol;
1. Slides were immersed in a container full of xylene, 
for 3 minutes, to remove the wax (dewaxing).
2. Slides were immersed in absolute alcohol for 
1 minute.
3. Slides were immersed in 70% alcohol for 1 minute.
4. Slides were immersed in 50% alcohol for 1 minute.
5. Slides were rinsed in distilled water. Sections were 
rehydrated in step 2-5 which is essential for the 
purpose of staining.
6. Slides were put for 15 minutes in Ehrlich's acid 
haemotoxylin (BDH).
7. Slides were de-stained (blue-ed) in tap water for 
5 minutes to remove extra stain.
8. Slides were differentiated in acid alcohol 
( l"^  Hydrochloric acid in 70% alcohol ) by agitating for 
5-10 seconds.
9. Slides were washed in tap water for 1-2 minutes.
10. Slides were reviewed using a microscope to ensure 
that sections were sufficiently differentiated. Steps 7 
or 8 were repeated, if required.
11. Slides were again de-stained (blue-ed) in tap water 
for 15 minutes.
12. Slides were counter stained for 2 minutes in 
1% aqueous solution of eosin (BDH).
13. Slides were rinsed in tap water for 30 seconds.
14. Slides were dehydrated in 85% alcohol for
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30 seconds.
15. Slides were dehydrated in 100% alcohol for 
30 seconds for first run.
16. Slides were dehydrated again as second run in 
100% alcohol for 30 seconds. In steps 13-16 slides were 
dehydrated again for preservation of the details.
17. Slides were cleared in xylene for 30 seconds.
18. Slides were cleared again in xylene for 30 seconds 
and were mounted directly from xylene.
19. Xylene container having slides was taken to the 
fume hood. Sections were mounted in DPX (BDH) by 
placing a drop of mountant DPX on a clean coversiip, 
taking the slide directly from xylene, inverting it 
over the coverslip and pressing gently so that the 
mountant spread under the coverslip. They were allowed 
to dry in the fume hood for 2 - 3 hours and were 
labelled.
20. Slides were examined at a magnification of X40, 
XlOO and X400 using a vickers M15c microscope. Slides 
were photographed for permanent record. The results are 
shown in section 5.1 , 5.2 and 5.4.
2.8 .1.6. IMMUNOCYTOCHEMISTRY OR IMMUNOSTAINING OF THE 
TISSUE SECTIONS :
immunostaining of tissue sections was done, 
with the developed monoclonal antibodies (section 2 .7 ), 
using the avidin-biotin labelling system (fig 2.4 on 
page 154). Optimal dilutions of antibodies and
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conjugates depend upon the temperature of incubation, 
time length of incubation, type of section whether 
frozen or fixed, length of fixation, type of fixation 
and any unmasking done. Excessive antibody relative to 
^^tigen may cause reduced binding; a phenomenon similar 
to prozone effect in agglutination test, so it is 
necessary to always run a number of negative controls. 
Each tissue has intrinsic controls and each section 
should show a different positive cell pattern. If the 
same cells are stained with every antibody then it 
indicate that some non-specific staining is present. A 
reliable positive result is the one where a maximum 
contrast is seen between specific staining and the 
background. A checker board titration can be set to 
find optimal dilutions, minimum back ground and best 
positive results. The protocol of the immuno-staining 
is as under:
1. Steps 1-5 were done as described in section 2.8.1.5. 
for dewaxing and rehydration of tissue sections.
2. Monoclonal antibody (ascitic fluid or tissue culture 
supernatant in an appropriate dilution) was applied to 
the tissue sections at room temperature for 45 minutes. 
This was done by either immersing the slides in a 
container having MoAb solution diluted in PBS or by 
putting the MoAb solution over the slide covering the 
tissue section.
3. Slides were rinsed gently with distilled water.
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4. Slides were washed in PBS bath for 5-10 minutes.
5. Antimouse IgG-biotin conjugate (Sigma) was applied
to the tissue sections, at a dilution of 1/4000, for
45 minutes at room temperature as in step 2.
6 . Step 3 of rinsing was repeated.
7. Step 4 of washing was repeated.
8 . Extravidin-Alkaline phosphatase (Sigma) was applied 
to tissue sections for 45 minutes, at room temperature, 
at a dilution of 1/1500.
9. Step 3 of rinsing was repeated.
10. Step 4 of washing was repeated.
11. Substrate solution of NBT (Nitro blue tétrazolium)
and BCIP (5-bromo-4-chloro-3-indolyl phosphate) was 
freshly prepared (see appendix) and applied to tissue 
sections for 30 minutes at room temperature. Alkaline 
phosphatase produces more reliable results and 
levamisole in the buffer inactivates endogenous 
alkaline phosphatase.
12. Step 3 of rinsing was repeated.
13. Step 4 of washing was repeated.
14. Sections were counter stained with 1.0% aqueous 
solution of neutral red (BDH) for 30 seconds at room 
temperature. It allowed the visualization of the 
general morphology of tissues.
15. Sections were washed three times in a PBS solution 
bath for 1 minute each.
16. Sections were mounted as in step 19 of section 
2.8 .1.5 but with aqueous base Univert mountant (BDH)
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because the chromogenic precipitates of substrate 
(brown to black coloured depending on intensity of 
reaction) are soluble in organic solvents.
17. Slides were allowed to dry at room temperature for 
about 4 hours, accordingly labelled and inspected using 
a light microscope. Slides of interest were 
photographed for permanent record. The results are 
shown in section 5.2 , 5.3 and 5.4.
2.8.2. IMMUNOBLOTTING/WESTERN BLOTTING;
2.8 .2.1. INTRODUCTION;
The antigenic mixture of interest is solubilised, 
usually with sodium dodecyl sulphate (SDS), urea, 
2-mercaptoethanol or any other reducing agent. Proteins 
are separated by polyacrylamide gel electrophoresis 
(SDS-PAGE). The separated protein (antigens) from gels 
are electrophoretically transferred to the 
nitrocellulose membrane, where they bind irreversibly. 
The non-specific sites on the nitrocellulose membrane 
are blocked and antigens are probed with antibody of 
interest using enzyme-labelled conjugates which are 
visualized later by an insoluble precipitatable 
chromogenic substrate.
Polyacrylamide gel electrophoresis gives high 
resolution and sensitivity and is simple to carry out. 
Gels are prepared as slabs, polymerized in a mould made 
from two sheets of glass separated by plastic spacers.
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Gels are robust and inert. Proteins are separated on 
the basis of both size and electrical charge. A gel is 
formed by polymerizing acrylamide and N,N'-methylene 
bisaery1amide, which is a bifunctional cross-linking 
reagent. Acrylamide and bisacrylamide should be handled 
very carefully as they are neurotoxins and can be 
absorbed through the skin. Polymerization is quick at 
room temperature using an initiator (ammonium per 
sulfate or a combination of riboflavin and u/v light) 
and a catalyst (TEMED N,N,N’,N '-tetramethylene 
diamine). Porosity of gel is adjustable by varying the 
concentration of acrylamide, usually between 3-30% w/v. 
Gels of lower concentration disintegrate while those 
with a higher concentration are brittle. Most large 
molecules experience a sieving effect due to gel 
porosity.
Gels, after electrophoretic separation of proteins, can 
be stained for protein, used for immunochemical studies 
or treated for autoradiography. High resolution SDS- 
PAGE combined with specificity of monoclonal antibodies 
can give considerable information on both antigens and 
sritibodies. SDS-PAGE can be followed by crossed 
Immunoelectrophoresis, at right angles to the first 
dimension into an agarose gel containing antibody. 
Separated proteins by SDS-PAGE can be fixed and a 
labelled antibody system can be applied directly. 
Proteins separated by SDS-PAGE can be transferred 
electrophoretically to nitrocellulose membrane and then
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probed with different antibodies. Antibodies can be 
coupled, on the other hand, to the blotting membrane 
and radiolabelled antigens blotted onto it being 
separated by SDS-PAGE.
Immunoblotting or western blotting is a favoured 
procedure due to speed and simplicity (Towbin and 
Gordon, 1984 : Towbin eù al, 1979). Proteins are easily 
transferred to nitrocellulose membrane by 
electrophoresis, where they bind irreversibly. The 
transfer takes a short time and there is minimal 
lateral diffusion thus avoiding diffuse bands. Western 
or immunoblotting has been used extensively for the 
detection of target antigens, monoclonal/polyclonal 
antibody reactivity, characterization of antigens and 
detection of antibodies with the help of known antigens 
(Babin and Anderson, 1988 ; Ogaswara et al, 1988 : Raux 
et al, 1983 ; Schol et al, 1988).
2.8 .2.2. SEPARATION OF PROTEINS OR GEL ELECTROPHORESIS 
(SDS-PAGE);
One dimensional gel electrophoresis under denaturing 
conditions (in the presence of 0 .1% sodium dodecyl 
sulphate) separates protein in accordance with their 
molecular size, as they move through a polyacrylamide 
gel matrix towards the anode (positive electrode). 
P^rotein samples are solubilized by boiling in the 
presence of SDS and 2-mercaptoethanol which reduces 
disulfide bonds. An aliquot of protein sample is
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applied to a gel lane and individual proteins or their 
subunits are separated electrophoretically (Hames and 
Rickwood, 1981 : Hunkapiller et al, 1983 : Laemmli, 
1970).
MATERIALS
1. Prestained molecular weight standards or markers 
26,600-180,000 (sigma).
2. Acrylamide solution 30% and bisacrylamide solution 
2% (National diagnostics New Jersey, U.S.).
3. Ammonium persulphate solution 10% w/v (BDH).
4. TEMED (N .N .N ’.N '-tetramethylethyl enediamine) 
(Bethesda Research Lab).
5. 4X Tris-Cl/SDS (separation or lower gel) buffer pH 
8.8 (1.5 M Tris-Cl +0.4% Sodium dodecyl sulphate) see 
appendix.
6 . 4X Tris-Cl/SDS (stacking or upper gel) buffer pH 6.8 
(0.5 M Tris-Cl containing 0.4% Sodium dodecyl sulphate) 
see appendix.
7. 2X SDS-sample buffer (see appendix).
8 . Electrophoresis buffer, pH 7.0-9.0 (see appendix).
9. 0.75 mm plastic spacers.
10. Teflon combs.
11. 25-100 uL syringes.
12. Power pack (Bio-Rad)
13. Protean electrophoresis cell (Bio-Rad)
14. Microprotein determination kit (Sigma)
15. Spectrophotometer Ultrospec 11 (LKB)
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16. Plastic boxes and cellophane membranes.
17. Orbital shaker Gyrotory (New Brunswick, USA)
18. Coomassie brilliant blue R (BDH)
19. Methanol and glacial acetic acid (BDH)
20. Spatula.
PREPARATION OF SAMPLE
Hépatocytes from Fischer F344 rat normal liver and 
Ciprofibrate peroxisome proliferator-induced liver 
tumour cells were isolated by collagenase digestion as 
described in section 2.1.3. Cells were resuspended in 
PBS and disintegrated by repeated freeze thawing. 
Protein content of both the samples was calculated 
using a microprotein determination kit, as described in 
the accompanied instructions, against a known standard 
calibration curve reading in a spectrophotometer at 
650 nm. Samples were prepared from both normal and 
tumour cell suspensions with protein contents of 
200 mg^, 100 mg% and 50 mg% respectively. Every sample 
was mixed , at a ratio of 1:1, with SDS-sample buffer 
containing bromophenol blue as tracking dye. Samples 
were boiled in a boiling water bath for 5 minutes. 
POURING THE GEL
1. Two glass plates (for 0.75 X 14 cm X 14 cm gel) were 
thoroughly washed and clean dried with acetone.
2. A glass plate gel sandwich was assembled using
0.75 mm spacers, firmly secured by bulldog clamps and 
sealed with agar.
3. The separating or lower gel (10%) solution was
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prepared as required (see appendix).
4. The above solution was transferred to the centre of 
the gel sandwich, by drawing a pasteur pipette of 
liquid gel, along an edge of one of the spacers. The 
sandwich was filled leaving a space of 2-3 cm at the 
top for the stacking or upper gel.
5. The space left at the top was filled with distilled 
water, poured gently without disturbing the interface 
of gel. This weight of the water at the top makes a 
linear smooth border for the separation gel.
6 . The gel was allowed to stand for 30-40 minutes at 
room temperature and then water was poured off.
7. The upper or stacking gel solution was prepared as 
described in appendix. This was mixed and used 
immediately.
8 . A teflon plastic comb cut for the desired tracks or 
wells was placed in the gel sandwich. Upper or stacking 
gel solution prepared in the previous step was poured 
into it. The sandwich was completely fillsd including 
spaces or wells of the comb avoiding any air bubbles.
9. Stacking gel was allowed to polymerize for 
10-15 minutes at room temperature.
LOADING THE GEL
1. Tracks or wells were marked on the outer surface of 
glass plate correspondingly with a marker pen. The 
teflon comb was removed carefully without tearing the 
edges.
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2. Wells or tracks were filled with electrophoresis 
buffer using a pasteur pipette and manipulated, with a 
flat tipped needle attached to a syringe, to make them 
upright if necessary.
3. The spacer at the bottom was removed with the help 
of a blunt spatula. The gel sandwich was placed in the 
buffer chamber in a way that the wells faced the upper 
buffer chamber and the bottom rested in the lower 
buffer chamber. It was secured in position with the 
help of bulldog clamps. Electrophoresis chambers, both 
upper and lower, were filled with electrophoresis 
buffer (600 ml in upper chamber and 900 ml in lower 
chamber). Air bubbles at the bottom of the gel were 
removed by manipulating with a flat syringe needle.
4. Samples were loaded in wells using 25-100 uL syringe 
by carefully applying the sample as thin layer at the 
bottom of the well. Prestained molecular weight markers 
were also applied in at least one well for reference. 
RUNNING THE GEL
The power supply was connected to the electrophoresis 
chamber in accordance with anode and cathode. It was 
initially run at 20 mA and when the tracking dye 
reached the separating gel it was increased to 40 mA. 
Electrophoresis was stopped and power supply 
disconnected when the tracking dye reached the bottom 
of gel, usually in 3-4 hours time.
DISASSEMBLING OF THE GEL
The gel sandwich was removed from the buffer chambers
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and placed on a sheet of absorbent paper. Spacers were 
carefully removed by gently sliding a spatula around 
edges of the gel. The upper glass plate was lifted to 
expose the gel. The stacking gel was removed off the 
plate with a spatula. The glass plate having the gel 
was inverted over a container of fixative solution and 
the gel was dropped into it by carefully separating it 
from the glass with a spatula. The fixative solution 
was prepared (see appendix). The fixative solution 
container (plastic box), having the gel, was put on an 
orbital shaker for 2-3 hours at room temperature at 
100 rpm.
The gel could then be used to stain and visualize 
protein bands or to transfer those separated proteins 
onto a nitrocellulose membrane by electroblotting. 
STAINING AND VISUALIZATION OF SEPARATED PROTEINS 
Detection of protein bands in a gel by coomassie blue 
depends on non-specific reversible binding of the dye, 
coomassie brilliant blue R, to proteins. The detection 
limit is 0.3 to 1.0 ug per protein band. Protein bands 
can also be visualized by irreversible silver staining, 
where silver binds to various chemical groups like 
sulfhydryl and carboxyl moieties in proteins. The 
detection limit is 2.0 to 5.0 ng per protein band. 
Coomassie blue staining solution was prepared (see 
appendix). Some staining solution was put in a plastic 
container box and gel was transferred into it. It was
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covered and shaken on an orbital shaker at 100 rpm, 
overnight at room temperature. The gel was stained 
entirely and intensely. It was then destained to a 
point where the separated protein bands are clearly and 
distinctly visible with least possible back ground. 
Destaining solution was prepared (see appendix). Some 
de staining solution was put in a new plastic box and 
the gel was transferred to it. The box was shaken on an 
orbital shaker at 100 rpm at room temperature. The 
destaining solution was removed and replaced with a 
fresh one every 30 minutes till the desired results 
were achieved. Protein bands were stained and examined 
with reference to known molecular weight markers. 
Results can be photographed and gels can be dried and 
stored in cellophane plastic membranes. Gels can also 
be stored at 4°C in 7% glacial acetic acid or water. 
The results are shown in section 5.6.
2.8.2.3. WESTERN BLOTTING/IMMUNOBLOTTING:
Antigens, after being separated by SDS-PAGE, were 
transferred to a nitrocellulose membrane. The 
nitrocellulose membrane was blocked for non-specific 
binding sites and probed with a MoAb of interest. The 
MoAb binding was in turn detected by biotinylated 
^r^timouse IgG and the extravidin alkaline phosphatse 
reaction sequence. Lastly it was visualized by a 
substrate which was converted to a precipitatable 
chromogenic substance.
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MATERIALS
1. Electroblotting buffer (20 mM Tris/150 mM glycine) 
[see appendix].
2. Ponceau S solution (0.5% Ponceau S/1% acetic acid) 
[see appendix].
3. Blocking buffer 1% BSA solution in distilled water.
4. Primary MoAb (ascitic fluid or culture supernatant) 
at an appropriate dilution.
5. Antimouse IgG biotin conjugate (Sigma)
6 . NBT and BCIP substrate (Sigma)[see appendix]
7. Extravidin alkaline phosphatase (Sigma)
8 . Phosphate buffered saline (BDH)
9. Whatman 3 MM filter paper
10. Scotch brite pads 3M
11. 0.45 uM nitrocellulose membrane (Sigma)
12. Transblot cell (Bio-Rad)
13. Power pack (Bio-Rad)
14. Plastic boxes and heat sealable plastic bags
15. Photographic equipment 
ASSEMBLING THE WESTERN BLOT SANDWICH
All the steps were carried out with gloved hands as oil 
and proteins from the fingers can contaminate and block 
protein transfer.
1. The plastic support of the sandwich was opened in an 
assembly tray or over a sheet of absorbent paper on a 
smooth surface. One scotch brite pad was placed over 
one of the plastic supports in the centre. A piece of
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3 MM Whatman filter paper was cut equal to the size of 
the gel. It was prewetted in electroblotting buffer and 
placed over the scotch brite pad.
2. The gel (after separation of proteins as described 
in section 2 .8 .2 .2 ) was placed on that filter paper 
carefully without tearing it. Its surface was moistened 
with electroblotting buffer. Air bubbles, between the 
gel and filter paper, were removed by gently rolling a 
glass rod or pushing a gloved finger across the surface 
and lifting the gel as needed.
3. A piece of nitrocellulose membrane was cut to the 
size of the gel, wetted with buffer and placed over the 
gel. Air bubbles, if found, were removed as described. 
*^ be lower side of the sandwich was cathode ( negative ) 
and upper side was anode (positive) in that situation.
4. Another piece of Whatman filter paper was cut, 
wetted with buffer and placed over the upper anode side 
of the nitrocellulose membrane. Air bubbles were 
removed.
5. Another scotch brite pad was placed over it.
6 . The plastic support was closed and secured 
carefully. The sandwich was placed in a transblott cell 
and oriented in a way so that nitrocellulose membrane 
faced the anodal (positive) side of the tank as shown 
in fig. 2.5 .
TRANSFER OF PROTEINS FROM GEL TO NITROCELLULOSE
1. The transblott cell chamber was filled with 
electroblotting buffer.
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Fig. 2*5
Western Blot Sandwich
Direction of current flow
Cathode Anode
Electroblotting buffei
Plastic support
Scotch brite pad
Whatman filter paper
Nitrocellulose membrane
Whatman filter paper 
Scotch brite pad 
Plastic support 
Electroblotting buffer
1 7 5
2. The power supply was connected to the corresponding 
positive (anode) and negative (cathode) of the 
transblott cell.
3. Proteins were transferred electrophoretically at
14-20 V constant voltage at 4°C overnight, which was 
reliable and convenient (High voltage can transfer 
proteins at room temperature within 1-4 hours). Voltage 
was increased to 25 V for 1 hour the following morning. 
REVERSIBLE STAINING OF TRANSFERRED PROTEINS
1. The blot sandwich was carefully dis-assembled after 
disconnecting the power supply. The nitrocellulose 
membrane was carefully recovered and the indicated 
transfer of proteins had occurred if bands of the 
prestained molecular weight markers were visible. The 
nitrocellulose membrane was placed in a plastic box 
containing Ponceau S solution for 5 minutes at room 
temperature to stain the proteins.
2. Destaining was done to reduce back ground by placing 
the nitrocellulose membrane in deionised distilled 
water for 2 minutes at room temperature. Red coloured 
protein bands were visualized and indicated that 
proteins were transferred successfully.
3. The nitrocellulose membrane was completely destained 
by soaking it in distilled water for 10-15 minutes.
The nitrocellulose membrane can then be dried at 37°C 
for 30 minutes and stored at -20°C in plastic bags till 
further use.
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PROBING THE TRANSFERRED PROTEINS WITH A MoAb OF 
INTEREST
1. The nitrocellulose membrane was placed in a plastic 
or glass box containing about 5-10 ml of blocking 
buffer to block the non specific binding sites on 
nitrocellulose. It was kept agitating on an orbital 
shaker (LKB) at 100 rpm for 1 hour at room temperature.
2. The nitrocellulose membrane was washed in PBS bath 
for 3-4 times for 1 minute each.
3. The nitrocellulose membrane was then placed in 
another plastic box containing MoAb solution in PBS, in 
appropriate dilution. 5-10 ml solution was sufficient 
for 2-3 nitrocellulose membranes. It was again put on 
orbital shaker ( 1 0 0 rpm) for 1 hour at room 
temperature.
4. Washing was done again as in step 2.
5. The nitrocellulose membrane was then placed in a 
plastic box containing 5 ml of antimouse IgG 
biotinylated antibody at a dilution of 1/4000. The box 
was put on orbital shaker for 1 hour as previously 
described.
6 . Washing was done as in step 2.
7. Nitrocellulose membrane was placed in a plastic box 
containing 5 ml of extravidin alkaline phosphatase at a 
dilution of 1/1500. Box was put on orbital shaker for 1 
hour at room temperature as already described.
8 . Washing was carried out as in step 2.
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9. The nitrocellulose membrane was placed in a plastic 
box containing 10-15 ml of NBT and BCIP substrate 
solution prepared as described in step 11 of section
2.8 .1.6. The box was shaken on an orbital shaker for 
30 minutes (or till the band developed) at room 
temperature at 100 rpm.
10. The nitrocellulose was removed from substrate 
solution as soon as band developed and washed in a bath 
of PBS as in step 2 to reduce the background.
11. The nitrocellulose was dried at 37° C for 30 
minutes, photographed for a permanent record and stored 
at -20°C in plastic sealed bags.
The results are shown in section 5.6. The bands which 
developed were brown to black in colour. The molecular 
weight of the protein band, with which MoAb reacted, 
was calculated in relation to prestained molecular 
weight markers blotted on i:iitrocellulosemembrane 
simultaneously. The time of incubation and dilution 
were optimised by repeated checker experiments to get 
optimum positive results with the least background and 
negative controls.
2.8.3. PHAST GEL SYSTEM;
2.8 .3.1. INTRODUCTION:
The programmable Phast Gel system (Pharmacia LKB 
Biotechnology) was used to run and develop minigels. 
Proteins were separated in separation unit and stained 
with silver staining in a development unit or blotted
178
on a nitrocellulose membrane as described in an 
instruction manual (Pharmacia LKB Biotechnology). Two 
gels can be separated or developed at the same time and 
the separation and development unit can be used 
simultaneously.
2.8 .3.2. SEPARATION OF PROTEINS:
12.5-^ homogenous gels (Pharmacia) were used with a 
mol.wt. range of 15,000 - 250,000 kd. Samples were 
prepared as in section 2 .8 .2.2 and similar prestained 
molecular weight markers were used. 1 uL of each sample 
was applied on gels with an 8 well sample applicator 
(Pharmacia) as described. SDS buffer strips were used. 
The separation was effected using the programme for 
SDS-PAGE for a homogenous 12.5% gel.
2.8 .3.3. DEVELOPMENT OF THE GEL:
The separated gels were stained (developed) with silver 
staining in the programmable development chamber. The 
separated gels were transferred to development chamber. 
Following chemicals were prepared fresh in bottles and 
attached to indicated port of the chamber. The system 
was run on the indicated programme.
1. To Port 0, Waste.
2. To Port 3, 10% ethanol, 5% acetic acid in 
distilled water (300 ml).
3. To Port 4, 5% gluteraldehyde (80 ml).
4. To Port 5, distilled water (300 ml).
179
5. To Port 6 , 0.4% silver nitrate (80 ml).
6 . To Port 7, 1 ml 2% formaldehyde in 150 ml of 2.5%
sodium carbonate (developer).
7. To Port 8 , 2.5 Gm sodium thiosulphate and 3.7 Gm
fris-HCl added to 100 ml distilled water (background
reducer).
8 . To Port 9, 5% glycerol in distilled water (80 ml). 
The results are shown in section 5.6. The developed 
protein bands were compared with molecular weight 
standards for characterisation.
2.8 .3.4. IMMUNOBLOTTING OF MINIGELS:
Minigels, after protein separation, were separated from 
their hard plastic base. The gel was secured with pins 
on a piece of wood. A very thin wire or thread was run 
through its entire length as close to the hard base as 
possible thus separating the gels from hard base. Gels 
were then blotted as described in section 2 .8 .2.3 .
2.8.4. CLONOTYPING OF MoAbs:
Clonotyping of MoAbs was done, using the Clonotyping 
system 1 (Sera-Lab), to determine the class of MoAb 
produced by the hybridoma cells. The following protocol 
was adopted for each MoAb:
1. 100 uL of the appropriate dilution of MoAb (ascites 
or culture supernatant) was added to the wells of a 96 
well ELISA plate (Falcon) from column 3-10. In column 1 
PBS (negative control) and in column 2 mouse serum
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1 / 1 0 0 0 dilution (positive control) was added in the 
same amount.
2. 100 uL of coating buffer (Don Whitley Scientific 
Ltd, UK) was added to each well. The plate was covered 
with plastic sealer (Flow) and put at 4°C overnight.
3. The plate was washed by immersing it in a container 
of PBS and shaking. It was dried by inverting it over 
tissue paper.
4. 100 uL of 1% ESA was added to each well and the 
plate was incubated for 1 hour at room temperature.
5. The plate was washed as in step 3.
6 . The alkaline phosphatase conjugate was prepared in 
PBS in a 1/300 dilution , of antimouse Ig, IgG^, IgG^a, 
IgGgb' IgGg, IgM, kappa and lambda. 100 uL was added to 
the wells in columns indicated as under and incubated 
for 4 hours at room temperature after covering it:
Ig ......................  column 1-3.
b) IgG^ ....................  column 4 .
c) IgG2a ................... column 5.
d) IgG2b ................... column 6 .
e) IgGg ....................  column 7 .
f) I g M .....................  column 8 .
g) kappa ...................  column 9 .
h) lambda ..................  column 1 0 .
7. The plate was washed as in step 3.
8 . The substrate, p-nitrophenyl phosphate was dissolved 
as 1 mg/ml in a buffer (see appendix).
9. 100 uL of substrate was added to each well. A bright
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yellow colour developed. The plate was read at 410 nm 
in an ELISA plate reader (Dynatech MR 600).
This was repeated with all the monoclonal antibodies. 
The results are shown in section 5.5.
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SECTION-3 
LIVER CELLS IM VITRO
3.1 ISOLATION OF HEPATOCYTES :
3.1.1 INTRODUCTION:
Isolation of pure viable, physiologically intact and 
biochemically active hépatocytes, free from other cells 
of liver architecture, was important and essential for 
further studies to be carried out on hepatocytes and 
hepatic tumour cells.
3.1.2 RESULTS:
Collagenase digestion of liver slices was used to 
disperse liver tissue and then low speed centrifugation 
was performed to obtain purified hepatocytes free from 
other cells and tissue debris. These remained in the 
supernatant while the hepatocytes formed a loose pellet 
at the bottom of centrifuge tube.
Cells were counted using the vital stain, trypan blue, 
and more than 90% were found viable, and 
morphologically intact. The yield of cells was about
15-20 million cells per gram of tissue.
In addition, MTT assay was done to confirm viability, 
physiological integrity and biochemical activity of the 
cells. A calibration curve was drawn from data with a 
known number of cells and used later to calculate the 
cell number (fig. 3.1). The MTT assay correlated well 
with the trypan blue viability within a range of + 10% 
(fig 3.2). The MTT assay also showed that the 
peroxisome proliterator-induced tumour cells were
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metabolically more active than the normal cells, as 
shown by the difference in reduction of the tétrazolium 
dye by a similar number of cells (fig 3 .1 ).
The isolated hepatocytes were a homogeneous population 
of large single cells, oval to polygonal in shape. 
Cells were often multinucleated, with regular cell 
membranes and numerous chromatic cytoplasmic granules. 
The cells were shiny, transparent and light yellow in 
colour. Dead cells, in contrast, were dull and dark 
without a regular cell membrane and were readily and 
easily identifiable in culture (fig 3.3 and fig 3 .4 ). 
Fibroblasts were not observed. Hepatocytes became more 
regular, circular and smaller in shape when put in 
culture after 1-2 days. They were loosely attached to 
the surface and were not firmly adherent. This has 
also been observed by others (Dr. P.Skett, Department 
of Pharmacology University of Glasgow, personal 
communication).
3.1.3 DISCUSSION;
The number of viable cells and total number of cells 
per gram of liver tissue obtained, by the method 
described, is comparable to the in situ perfusion 
techniques (Belleman et ai, 1977 : Berry and Friend, 
1969). The in situ perfusion techniques are difficult 
to perform and it is not easy to keep the whole process 
sterile. Moreover, in livers having tumours, the whole 
liver is digested and the cells dispersed thus making
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Fig 3.3 Cell suspension of liver cells after digestion 
of liver tissue (40X phase contrast).
Fig 3.4 Hepatocytes after separation. Some dead cells 
are also visible in the field (40X phase contrast).
it difficult to separate tumour cells exclusively at a 
later stage. On the other hand, morphologically 
distinct tumours can be cleanly dissected out from the 
liver, and the tumour cells separated by enzyme 
digestion with the minimal contamination from normal 
hepatocytes. The slicing method is thus more reliable 
for pure tumour cells than perfusion methods.
in situ perfusion techniques are said to give 
higher cell viability, low oxygen consumption, lower 
degradation of proteins, better protein synthesis and 
low leakage of enzymes. Most of these advantages, of in 
situ perfusion techniques over slicing methods, 
disappear with time of cell incubation and culture 
(Gustavsson and Mor1 and, 1980). The differences may 
thus reflect a temporary stress condition.
3.2 PRESERVATION OF TISSUE;
3.2.1 INTRODUCTION;
Tissue samples, as a source of peroxisome 
proliferator-induced tumour cells and normal cells, 
were cryopreserved over liquid nitrogen for use at 
different times and stages of the work.
3.2.2 RESULTS;
Peroxisome proliferator-induced rat liver tumour tissue 
was kindly provided by Dr. Sue Wilson and Dr. Frank 
Bonner of Sterling Winthrop research centre, Alnwick. 
Tumour tissue was recovered by sacrificing the animals
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followed by immediate dissection of the tumourous 
tissue from the affected livers. The tissue was 
transported in serum free culture medium at 4°C as 
advised (British organ transplant unit, Cambridge). 
Tumour tissue and normal liver tissue cryopreserved 
within 4-6 hours of excision (section 2.2). The 
tissues, when thawed and digested to isolate and 
recover viable cells (section 2 .1 ), gave almost the 
same recovery of total and viable cells as from fresh 
unfrozen tissues.
3.2.3 DISCUSSION:
It is difficult to take full advantage of a large 
tumour biopsy in one experiment or to use the material 
from the same biopsy at later times unless the material 
is stored appropriately. It is, therefore, an advantage 
to cryopreserve and store the tissue for later use. 
Cryopreservation of various human and animal tumour 
tissue has been described by many authors (Freshney, 
1988b : Sikdra and Smedley, 1984). Primary cells,
isolated from tumours by tissue digestion, can also be 
stored successfully with the preservation of 
antigenicity (Peters et al, 1979). However Reif (Reif, 
1982) found that tumour tissue preservation was better 
than isolated cell cryopreservation.
In view of the success of isolation of hepatocellular 
carcinoma cells and hepatocytes from frozen tissue in 
my experiments, cryopreservation of liver tissue and
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tumour tissue was used routinely.
3.3 IN VITRO CULTURE OF NORMAL AND TUMOUR CELLS:
3.3.1 INTRODUCTION;
Normal liver cells and peroxisome proliferator-induced 
tumour cells were propagated and grown In vitro to 
examine differences in cell survival, growth and 
proliferation potential, since differences in growth 
can be an important distinguishing feature of tumour 
cells. Initially the conditions for liver cells in 
vitro culture were defined and optimised (section 2 .3 ) 
and then normal and tumour cells were compared to 
determine difference in their growth potential. Many 
tumours have been shown to grow in culture indefinitely 
and give rise to cell lines (Langdon et al, 1988 : 
Sacks et al, 1988 : Willson et al, 1987). This
potential of in vitro survival and growth of tumour 
cells is however variable between different tumours 
(Chang et al, 1980 : Kerler and Rabes, 1988).
3.3.2 RESULTS:
3.3.2.1 Culture in LPSR, PCS and rat serum: Normal rat
liver cells were cultured in different concentrations 
of fetal calf serum (PCS), low protein serum 
replacement (LPSR) and autologous rat serum (section 
2.3.2). Cells in 15% PCS showed better growth as 
compared to 5% PCS, 10% PCS, 20% PCS, LPSR and 
autologous rat serum (fig 3 .5 ).
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Fig 3.6
Effect of PCS, LPSR & rat serum
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A is 5% fetal calf serum.
B is 10% fetal caff serum.
500 C is 15% fetal calf serum.
D is 15% fetal calf serum without
isulin and hydrocortisone.400
E is 10% rat serum.
F is 3% Low Protein Serum Replacement.
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3.3.2.2 Growth promoting factors and serum free medium: 
Different hormones and growth promoting factors were 
included to determine their effect on hepatocyte growth 
and viability in vitro (section 2.3.3 and 2.3.4). The 
results (fig 3.6) appeared to indicate that epidermal 
growth factor (EOF), prolactin, glucagon, insulin and 
hepatocyte growth factor (HOP) have a major supportive 
effect on hepatocytes in vitro, with EOF the strongest 
and HOF the weakest as determined by number of viable 
cells and % viability.
The overall supportive effect of these growth promoting 
factors is potentiated if they are combined together 
and allowed to interact with the cells (fig 3.7).
A serum free chemically defined medium was formulated 
based on the growth promoting factors and hormones as 
described in section 2.3.5 .
3'3'2.3 Cell seeding density: The optimal cell seeding 
density was determined for the hepatocytes. 5 X 10^ 
cells per 60 X 15 mm Falcon primiria tissue culture 
dish appeared to give the best results (fig 3.8).
3.3.2.4 Effect of conditioned medium: Media conditioned 
by the growth of rat embryonic cells or neonatal rat 
liver cells were also used for in vitro culture of the 
hepatocytes (section 2.3.7 and 2.3.8). The conditioned 
media, when combined with serum-supplemented medium at 
ratio of 10% and 50%, appeared to give better results
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Fig 3.6
Effect of growth promotors
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Fig 3.7 
Cumulative effect of growth factors
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Fig 3.8
Effect of cell seeding density
Viable Cells (X 10"3)
600
E “ 5 X  10^4 cells/dish.
F • 1 X  10^5 cells/dish.
"^3“—®—S'—
H - 1 X  10^6 cells/dish.
500
400
300
200
100
0 6 8 10 
Days in culture
12 14 16
-a - H
The cells were cultured In a serum free hormonally 
defined medium in 60X15 mm Falcon Primaria dishes.
cell growth/survival in culture
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over serum supplemented medium alone. The conditioned 
on the other hand, did not appear to have an 
advantage over serum free hormonally defined medium in 
combination at 10% and 50% (fig 3.9a and fig 3.9b). 
Serum free medium alone gave better results as compared 
to combinations of conditioned media with serum 
supplemented or serum free media.
3.3.2.5 Tumour and normal cells in vitro ; Peroxisome 
proliferator-induced liver tumour cells and normal 
liver cells were propagated in vitro, in serum free and 
in serum supplemented media (fig 3.10 and fig 3.11). 
Normal cells survived for up to 15 days in serum 
supplemented medium and for about 28 days in serum free 
medium. Tumour cells, on the other hand, died in 18 
days in serum supplemented medium and survived for up 
to a period of 57-60 days in vitro in serum free medium 
(Ü 9 3.12). A significant difference was not found in 
cell morphology of tumour cells as compared to normal 
cells, as observed by light microscopic examination. 
Tumour cells did not develop as a permanent cell line 
but showed a tendency to limited cell proliferation and 
longer survival, which was higher than their normal 
counterparts. Cells, both normal and tumour, exhibited 
better results with serum free medium compared with 
serum supplemented medium.
3'3'2.6 Effect of substrata: Substrata like collagen, 
fibronectin, laminin and poly—L—lysine were also used
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Fig 3.9a
Effect of conditioned medium
Viable Cells (X 10"3)
600
500
400
300
200
100
A * Medium * 16% Fetal Calf serum * Insulin 
50 ug/ml * Hydrocortisone 0.36/m l.
B « As A but withou Insulin and Hydrocortisone.
90% Medium A * 10% Conditioned Medium.
D » 50% Medium A * 50% Conditioned  
Medium.
E - S e r u m  ~free -Medium:
90% Medium E * 10% Cond. Medium. 
50% Medium E * 50% Cond. Medium
0 6 8 10 
Days in culture
12 14 16
B
-A-
-S- D
Basic medium was RPMI-1640 * Glutamine 2 mM * Pencillin  
6 mg% * Streptomycin 10 mg%. Serum free medium was a 
chemically and hormonally defined medium.
Hepatocytes culture
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Fig 3.9b
Effect of conditioned medium
600
500
400
300
200
100
Viable Cells (X lO'S)
A « Medium * 16% Fetal Caff Serum * Insulin 
50 ug/ml * Hydrocortisone 0 .36  ug/ml.
‘’ As A but without Insulin and Hydrocortisone  
C “ 90% Medium A * 10% Cond. Medium.
D » 60% Medium A * 60% Cond. Medium. 
E » Serum Free Medium.
F  ® 90% Medium E * 10% Cond. Medium 
“ 60% Medium E * 60% Cond. Medium
0 6 8 10 
Days in culture
12 14 16
-e-
B
G
- B -
Basic medium was RPMI-1640 * Glutamine 2 mM * Pencillin 
6 mg% * Streptomycin 10 mg%. Serum free medium was a 
chemically and hormonally-defined medium.
Hepatocytes culture
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Fig 3.10 Peroxisome proliferator-induced rat liver 
tumour cells ±n vitro after 25 days. A few dead cells 
are also visible in the field (20X phase contrast).
Fig 3.11 Peroxisome proliferator-induced rat liver 
tumour cells In vitro after 57 days. Dead and 
disintegrated cells are visible (20X phase contrast).
n s
Fig 3.12 
Hepatocytes & Hepatic tumour cells
Viable Cells (X 10'3)
1000
800
A - Normal rat liver cells (5 X  10"6) in a serum free  
chemically and hormonally defined medium.
B - Normal rat liver cells in a medium having 15% fetal 
calf serum, 60 ug/ml Insulin and 0.36 ug/ml Hydrocortisone.
Hat-liver-lijmour-ceils-ln-serumfree-medium-as-A^
' Rat liver tumour cells In a serum 
supplemented medium as in B.
600
400
200
20 30 40 50
Days in culture
B C
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to coat the dishes for In vitro culture of normal and 
tumour cells. Collagen, fibronectin and laminin 
appeared to give better results in terms of cell 
viability and survival for normal cells as compared to 
vitro culture without a special substratum, using 
either a serum free or a serum supplemented medium 
(fig 3.13a and fig 3.13b). Poly-L-lysine was not 
effective. Treated substrata also appeared to provide 
better results for tumour cells, when using serum 
supplemented medium. However they failed to show any 
significant advantage when used with serum free 
hormonally defined medium or over serum free medium 
used alone.
3 « 3.2.7 Effect of trypsin ; Trypsin was used in 
different concentrations to determine its proliferative 
effect on tumour cells. The growth index was calculated 
by dividing the number of viable cells in the test 
culture by the number of viable cells in the control. 
Exposure of the cells to a 1/10 dilution (see section 
2.3.11) of trypsin appeared to provide some growth 
stimulatory effect on the tumour cells for upto 6 days 
after which the effect decreased (table 3.1).
3.3.3 DISCUSSION;
3.3.3.1 Culture in LPSR, PCS and rat serum: The
behaviour of hepatocytes, with regard to survival and 
proliferation, is determined by many factors some known
200
roo o O)o 00o oo
i
Ios
e;
i; 
iî
Ç I
r
iî
i f
N
O
O
roo
00o
o
iii{Olo
0>o
<
(T
(D
OO
:
X
Ô
>00
m
—4$0
O
CO T l
CO CO 
0> CO
o3
oo
5=
ro 00o o eno O)o No
3I + Dfi)
O
en
Ô
toi
ÿi
roo
l| I
m
Oo
c 31 cr (Q
2- CO 
p 0>
o3
O
CD
w"
201
TABLE 3.1
TRYPSIN TREATMENT OF RAT LIVER TUMOUR CELLS
Growth Index = Cell count of test/Cell count of control
EXPOSURE TIME 
IN MINUTES
TRYPSIN CONC. 
X = 0.05% w/v
GROWTH INDEX
3 days 6 days 9 days 12 days
2 mins 0.00 1.00 1.00 1.00 1.00
X/10 1.02 1.38 1.06 1.07
X 0.71 0.89 0.69 0.84
5X 0.78 1.09 0.82 0.87
lOX 0.93 0.97 0.61 0.47
50X 0.38 0.31 0.29 0.00
10 mins 0.00 1.00 1.00 1.00 1.00
X/10 1.03 1.49 1.10 1.13
X 0.65 0.82 0.66 0.73
5X 0.68 1.04 0.62 0.64
lOX 0.74 0.88 0.30 0.30
50X 0.40 0.00 0.00 0.00
30 mins 0.00 1.00 1.00 1.00 1.00
X/10 0.75 1.18 0.74 0.61
X 0.81 1.37 0.70 0.56
5X 0.82 0.87 0.39 0.28
lOX 1.03 0.68 0.05 0.00
50X 0.47 0.00 0.00 0.00
2 0 2
and others yet to be determined. Fetal calf serum is 
found by some authors to be cytostatic and cytotoxic 
( Enat et al, 1984 ) while others believe it is 
supportive for the In vitro culture of hepatocytes 
(Draghi et al, 1980). Rat serum was also reported as 
supportive (Michalopoulos et al, 1982). Serum 
replacements and substitutes have also been tried. It 
appears that 15% FCS is better than lower or higher PCS 
concentrations, rat serum and serum replacements 
tested. Rat serum, in normal animals, may contain some 
growth inhibiting factors keeping control over cell 
proliferation beyond a desired limit. This limit may 
well be lifted temporarily by reduction in level of 
growth inhibitors or by production of some 
un-identified growth factors following partial 
hepetectomy, during embryogenesis or in the neonate 
(Draghi et al, 1980 : Leffert and Paul, 1972). The 
serum of partially hepatectimized animals is also said 
to support the cells in vitro (Michalopoulos et al, 
1982). Low FCS levels are probably insufficient and 
higher concentrations are not supportive, and have a 
retarding effect on cell growth and viability. LPSR 
gives comparable results to 15% FCS.
3.3.3.2 Growth factors and serum free medium: Many 
hormones and growth factors are believed to support 
hepatocytes In vitro (Enat et al, 1984 : Higgins and 
Borenfreund, 1986 : Paul et al, 1988 : Strain et al.
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1986). Many transformed, fetal and normal cells are 
also said to secrete growth factors as described in 
section 2.3.1 . The factors found to support in vitro 
culture of hepatocytes were epidermal growth factor, 
prolactin, glucagon, insulin and hepatocyte growth 
factor in that order, A few other factors also had 
some positive but less pronounced effect.
It appears that the factors act synergistically, as 
their overall combined effect is potentiated. A serum 
free culture medium was prepared in RPMI-1640 
containing the growth-supportive elements at 
appropriate concentrations. Chemically defined serum 
free medium has been shown to have a beneficial effect 
on cells due to the well defined culture conditions 
(Enat et al, 1984 : McGowan et al, 1981 : Paul et al, 
1988). Our results also appeared in conformity with 
these and some growth factors are found supportive to 
liver cells in culture and a serum free medium was 
apparently found superior to other media.
3'3'3'3 Cell seeding density: Cell seeding density is 
an important factor for in vitro cell culture and may 
be responsible for determining the behaviour of cells. 
Low cell seeding density as well as overcrowding of 
cells does not support cell growth. There is, usually, 
an optimal cell density at which the cells grow better 
and remain viable longer (Bissell et al, 1987 : Enat et 
al, 1984 : Fleig et al, 1984 : Schuetz et al, 1988).
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They remain viable, healthy and may replicate. Seeding 
density is variable according to culture conditions and 
depends on cell type as well.
3.3.3.4 Conditioned medium; Fetal and neonatal cells 
usually show a higher potential for survival and growth 
compared to adult cells (Draghi et al, 1980 : Leffert 
and Paul, 1972). They may well secrete some growth 
promoting factors or macromolecules to overcome growth 
inhibitory signals, normally found in adults. Other 
cells of liver architecture/tissues like fibroblasts, 
epithelial cells, endothelial cells or Kupffer cells 
may be the source of these macromolecules and may well 
account for the post partial hepatectomy surge of cell 
proliferation.
Cells in vitro can secrete macromolecules in the 
culture medium which is then called conditioned medium 
(Chang et al, 1985 : Ove et al, 1989). It seems as if 
cells of liver architecture/tissues, neonatal rat liver 
cells and rat embryonic cells secrete some form of 
growth supporting macromolecular factors. Their effect, 
which is not a strong one, is mediated either through 
^i^Gct cell stimulation or indirectly by removal of 
inhibition imposed on cells by other factors.
3.3.3.5 Tumour cells and normal cells in vitroi Tumour 
cells usually differ from their comparable normal 
counterparts in their potential for survival and 
proliferation. This feature is variable, with different
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tumours, in a wide spectrum ranging from just 
maintaining in culture for months (Kerler and Rabes, 
1988) to developing into permanent propagatable cell 
lines (Pettengill and Lewko, 1989). Some tumours show a 
slower cell growth in vivo than their normal 
counterparts (Franks, 1988). On the other hand, 
spontaneous transformation may occur in normal cells, 
or transformed cells lines may revert and de­
differentiate into normal cells (Jamasbi and 
Nettesheim, 1979 : Tateyama et al, 1988).
Ciprofibrate peroxisome proliterator-induced hepatic 
tumour cells apparently have a higher potential for 
survival in culture, compared to their normal
counterparts in both serum free and serum supplemented
cells
medium. The tumour^survive longer in serum free medium 
suggesting the possibility that serum lacks certain 
growth factors or contains factors inhibitory to the 
cell growth. The cells also show some potential of 
proliferation and cell division but do not develop into 
cell lines. The amount of cell division may be much 
higher than apparent because some cells in the culture 
are also dying.
There are reports of continuous propagatable cultures 
of rat hepatocytes in serum supplemented medium. Such 
cultures usually consists of non-parenchymatous 
hepatocyte-like cells exhibiting some of the hepatocyte 
functions (Grisham, 1980). The identity of these cells
206
in such long term hepatocyte cultures is uncertain.
3.3.3.6 Effect of substrata: The interaction between 
cells, medium and substratum is also responsible for 
determining the fate and behaviour of cells in vitro. 
It is reported that normal hepatocytes in serum 
supplemented medium probably depend on the substratum 
for improved culture results (Bissell et al, 1987 : 
Enat et al, 1984 : Schuetz et al, 1988), and thus 
tumour cells do not need a specific substratum. The 
results presented here indicate that the treated 
substrata (collagen, fibronectin and laminin) may have 
a positive supporting effect on normal hepatocytes in 
terms of viability and survival, in both serum free and 
serum supplemented medium. The tumour cells do not seem 
to have growth advantage on any of the substrata, 
confirming the previous reports for other cell types. 
The normal cells particularly needed a substratum for 
better survival and viability especially in serum 
supplemented medium, while the tumour cells did not 
show such a dependence. Poly-L-lysine was not found to 
be an effective substratum.
3.3.3.7 Effect of trypsin: Trypsin causes various
molecular changes at the cell surface (Grisham, 1980), 
which in turn may result in the triggering of cell 
proliferation or the evasion of inhibitory controls on 
cell proliferation. Trypsin treatment (0.005% w/v) gave 
some brief proliferative stimulus to the tumour cells.
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This effect was short lived and disappeared within 6 
days. High trypsin concentration digested the cells and 
lower one seemed to have no effect. This trypsin effect 
may be a contributory factor to the initial rapid cell 
proliferation seen after a confluent slow growing 
culture is trypsinized and subcultured.
3.4 AGGLUTINATION BY PLANT LECTINS:
3.4.1 INTRODUCTION:
Plant lectins, in addition to other functions, can 
preferentially agglutinate tumour or transformed cells 
to a greater extent than their normal counterparts 
(Moscana, 1971 : San et al, 1979) and is believed to be 
an important marker of neoplastic change. This property 
was studied in peroxisome proliterator-induced hepatic 
tumour cells as compared to their normal counterparts 
and a panel of other cell lines.
3.4.2 RESULTS:
It appeared that the tumour cells exhibited an 
increased tendency to agglutinate as compared to their 
normal counterparts (fig 3.14 and fig 3.15). Maximum 
agglutination was seen at 50 uG/ml of wheat germ 
agglutinin and 200 uG/ml of concanavalin-A. The cell 
lines (BHK, MAK hybridoma, HeLa and MRC-5) showed a 
higher tendency to agglutinate. Culturing of the tumour 
cells for 20-25 days in vitro had an almost
208
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insignificant effect on their agglutinibility.
3.4.3 DISCUSSION:
The increased agglutinibility of tumour cells by plant 
lectins is probably due to certain of the cell surface 
changes, induced by carcinogenesis and transformation. 
It appears that peroxisome proliferator-induced tumour 
cells exhibit higher agglutinibility with wheat germ 
agglutinin and concanavalin-A than their normal 
counterparts. This agglutinibility was, however, much 
lower than established cell lines like BHK, HeLa and 
hybridomas, which all exhibit high agglutinibility. 
MRC-5, the human lung fibroblast cell line of finite 
life span, seems to have an intermediate 
agglutinibility. Agglutinibility of cells may therefore 
be directly proportional to the degree of cell 
transformation. Peroxisome proliferator-induced tumour 
cells apparently are not transformed to the extent of 
established cell lines. Culture of the tumour cells 
fails to induce any significant change in terms of 
transformation (as indicated by agglutinability) 
ÎJ^tîicating that this aspect of their phenotype is not 
altered by growth in vitro.
3.5 GROWTH IN SEMISOLID MEDIUM:
3.5.1 INTRODUCTION:
Tumour or transformed cells can exhibit anchorage 
independent growth in semisolid medium, although tumour
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cells from biopsy specimens may vary greatly in their 
potential to grow and form colonies in such semisolid 
media. This property was studied in the peroxisome 
proliferator-induced liver tumour cells.
3.5.2 RESULTS:
HeLa, BHK and hybridoma cells, which are transformed 
cells with infinite life spans, were capable of growth 
and colony formation in the semisolid media at all 
cell seeding densities (table 3.2 and 3.3). MRC-5, 
which is a cell line with finite life span, exhibited 
growth only at the 10^ cells/dish seeding density. The 
peroxisome proliferator-induced liver tumour cells 
formed very small colonies of cells, 5-20 cells each, 
and then growth ceased. After in vitro culture the 
tumour cells did not form colonies. Normal liver cells 
showed no growth at all.
3.5.3 DISCUSSION:
It appears that normal liver cells are not capable of 
growth in semisolid media while transformed cell lines 
grow well and cell lines of finite life span such as 
MRC-5 exhibited growth in semisolid media only at 
higher cell seeding densities. It has been proposed 
that the potential for anchorage independent growth and 
colony formation is an indicator of metastatic 
potential (Ahman et al, 1986 : Ottestad et al, 1988 : 
Pretlow et al, 1986) and may be directly related to the
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TABLE 3.2
GROWTH OF CELLS IN SEMISOLID MEDIA
(No. of colonies X 10^ after two weeks)
CELL SEEDING SOFT AGAR METHOCEL METHOCEL
TYPE DENSITY SERUM-FREE WITH SERUM
HeLa 10^ 10.8+0.30 14.0+0.40 12.0+0.40
10^ 2.6+0.21 2.8+0.10 2.7+0.17
10^ 0.6+0.03 0.7+0.04 0.6+0.04
MRC-5 105 # # #
104 * * *
10^ * * *
BHK-M 10^ 1.6+0.05 1.8+0.06 1.5+0.03
104 0.6+0.02 0.7+0.03 0.6+0.04
10-3 0.1+0.01 0.1+0.01 0.1+0.01
BHK-S 105 # # #
10^ 6.1+0.07 - 6.3+0.08 6.0+0.07
10^ 0.7+0.02 0.7+0.02 0.7+0.03
MAK-H 10^ 2.8+0.06 3.0+0.05 2.9+0.09
icd 0.3+0.02 0.3+0.02 0.3+0.02
10^ 0.1+0.001 0.1+0.001 0.1+0.001
Rat 105 @ @ @
Normal 10^ @ @ @
Liver 10^
Cells
Rat 105 ~ ~ -
Liver 104 ~
Tumour 10^ * * *
Cells
Rat 10^ * * *
Liver 10^ * * *
Tumour 103 * * *
Cells in
culture
(25 days)
1. # Confluent cell layer. 2. * All cells died
3. (3 No colony growth at all.
4. ~ 10-50 colonies of 5-20 cells only.
5. HeLa Cervical cancer line of human.
6. MRC-5 Lung fibroblast cell line of finite life span.
7. BHK-M Baby hamster kidney monolayer cell line.
8. BHK-S Baby hamster kidney suspension cells.
9. MAK-H A mouse hybridoma cell line secreting a MoAb.
2 i 2
TABLE 3.3
GROWTH OF CELLS IN SEMISOLID MEDIA
(No. of Colonies X 10^ after three weeks)
CELL
TYPE
SEEDING
DENSITY
SOFT AGAR METHOCEL 
SERUM FREE
METHOCEL 
WITH SERUM
HeLa 10^ 15.4+0.7 17.4+0.6 17.9+0.5
10^ 3.4+0.2 3.7+0.06 3.2+0.2
10-^ 0.8+0.03 0.9+0.04 0.6+0.05
MRC-5 10® * * *
10^ * * *
10^ * * *
BHK-M 10^ 2.0+0.07 2.2+0.05 1.8+0.07
10^ 1.5+0.04 1.8+0.05 1.5+0.05
103 0.6+0.01 0.7+0.02 0.7+0.02
BHK-S 105 # # #
io! # # #
10^ 4.3+0.05 4.5+0.07 ■ 4.1+0.06
MAK-H 105 # # #
lOq 0.7+0.03 0.7+0.04 0.8+0.02
10-^ 0.4+0.01 0.4+0.02 0.4+0.01
Rat 105 0 0
Normal 10^ @ 0 0
Liver
Cells
10"^ 0 0
Rat 10^ * * *
Liver 10^ * * *
Tumour
Cells
10® * * *
Rat 10® 0 0 0
Liver 10^ 0 0 0
Tumour 
Cells i] 
Culture 
(25 day
10®
a
3)
0 0 0
1. # Confluent cell layer. 2. * All cells died.
3. @ No colony growth at all.
4. HeLa Human cervical cancer cell line.
5. MRC-5 Lung fibroblast cell line of finite life span.
6. BHK-M Baby hamster kidney monolayer cell line.
7. BHK-S Baby hamster kidney suspension cell line.
8. MAK-H A mouse hybridoma cell line secreting a MoAb.
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degree of cell transformation, thus explaining the wide 
range of anchorage independent growth exhibited by 
different tumours (Courtney et al, 1977 : Ottestad et 
al, 1988 : Pretlow et al, 1986 : San et al, 1979). 
However some tumours do not show any anchorage 
independent growth in semisolid media, probably because 
they need stimulatory signals from the company of cells 
nearby (Ahmann et al, 1986 : Pavelic et al, 1980).
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SECTION-4
PRODUCTION/ISOLATION OF TUMOUR-SPECIFIC 
MONOCLONAL ANTIBODIES
4.1 IMMUNIZATION;
4.1.1 INTRODUCTION;
The immunization of mice, in the production of MoAb to 
Ciprofibrate-induced rat liver tumour cell, serves the 
purpose of expanding specific desired clones of 
B-lymphocytes which then divide and differentiate. This 
increases the chances of obtaining a relevant hybrid 
(from an activated B-cell) secreting a specific 
antibody. The immune response of the mouse is further 
boosted by antigen 3-4 days prior to fusion with the 
tumour cells (Campbell, 1987). This appears to increase 
the chance of a successful fusion, indicating that 
recently-activated lymphocytes fuse preferentially.
4.1.2 RESULTS:
Two schedules of immunization were used for the two 
fusions. For the first fusion three injections of 
antigen were given, each two weeks apart. The second 
fusion was done after seven immunizing injections of 
antigen given in a similar way. The immunized mice were 
bled to determine the reactivity of serum to the 
antigens (tested by the ELISA as described in section 
2.6.2). A +3 reaction (on a standard scale of 0-4) was 
seen with the first immunization schedule and a +2 
reaction was seen with second schedule of immunization, 
where 0 = O.D in ELISA with normal liver cells, 
■*■1 - >2X, +2 = >3X, +3 = >4X and +4 = >5X of this 
value.
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4.1.3 DISCUSSION:
The whole cells used as the immunizing antigen are a 
source of many antigens. Some of these are relatively 
strong and dominant while others are weak and sub­
dominant. The immunological response is either strong 
or is mainly against stronger antigens with the first 
immunization schedule as compared to the second one. 
The response, with the second longer schedule of 
immunization either the response becomes weak with 
repeated doses of antigens or the response elicited is 
mainly against weak and immune-subdominant antigens. 
There is a possibility that with additional doses and 
repeated and prolonged immunizations, using a complex 
antigenic mixture, the immunelogical response 
gradually fades off in the order of strength of the 
antigens (Kumar, 1989). This may well increase the 
chances of obtaining a response against weak and sub­
dominant antigens using a longer immunization schedule.
4.2 FUSION:
4.2.1 INTRODUCTION:
SP2/0 mouse myeloma cells and B —lymphocytes from 
immunized mice were fused chemically, using 
polyethylene glycol (section 2.7.2). Chemical fusion is 
the most reliable, highly successful and the most 
commonly used method.
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4.2.2 RESULTS:
The immunized mice were sacrificed and their spleens 
recovered by aseptic techniques. The spleens were found 
to be enlarged (splenomegaly) and darker in colour than 
non-immunized control ones. Lymphocytes were isolated 
from these spleens and fused with myeloma cells as 
described in section 2.7.2. 10® B-cells (spleen cells) 
were used to fuse with 10^ myeloma cells. The cell 
pellet, formed after fusion, was resuspended and plated 
out in 4 tissue culture microplates (96 wells each). 
All the wells were examined and inspected daily under 
an inverted microscope. Medium was changed on day 3, 6, 
9 and 12. The myeloma cells were dead by day 4 and the 
B-lymphocytes died by day 7. Small colonies of 
hybridoma cells started appearing by day 11 (fig 4.1). 
Most of these colonies were fully grown by day 21 
(fig 4.2). However some hybridomas appeared late and 
were slow to grow. Plates were maintained for five 
weeks to allow such slow growing colonies to appear. 
136 wells out of 372 (37%) from the first fusion 
(double immunization) showed hybridoma growth while 351 
wells out of 372 (94%) from the second fusion (several 
immunization) showed growth.
4.2.3 DISCUSSION:
The chemical method of fusion, using polyethylene 
glycol (PEG), is a simple and efficient method. The 
cell hybridization frequencies are in the order of
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Fig 4.1 Appearance of a hybridoma clone 11 days 
after fusion (20X).
Fig 4.2 A full grown hybridoma colony 21 days after 
fusion (20X).
1-100 clones/io"^ B-lymphocytes (Campbell, 1987 ), 
depending upon the myeloma cell line used, immunization 
technique and chemicals used. The expected number of 
clones using 10® lymphocytes is thus around 10-1000. 
The results obtained here are clearly within this 
range.
4.3 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA):
4.3.1 INTRODUCTION:
The enzyme linked immunosorbent assay (ELISA) was 
optimized for use in the screening of hybridomas and 
detection of clones of interest secreting monoclonal 
antibodies.
4.3.2 RESULTS:
Hepatocytes, as whole intact cells, were used as 
iri liquid phase ELISA and plates were 
centrifuged for washing in between the steps. Results 
are shown in figs 4.3, 4.4, 4.5, 4.6 and 4.7.
1. The minimum and optimal number of cells used per 
well was found as 5 X 10^ to give a clear distinction 
between positive and negative.
2. Optimum dilution of conjugate was found to be 1/300.
3. Reaction was not detected between well plastic and 
antiserum, conjugate or substrate.
4. Non-specific reactivity between cells and substrate 
was not detected in the test system.
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Fig 4.3 ELISA (enzyme-linked immunosorbent assay) with 
1 X 10^ liver cells per well as antigen and different 
dilutions of antiserum (to rat hepatocytes) used as 
antibody.
(A = 1/1600 , B = 1/3200, C = 1/6400 and D = 1/12800 
dilutions of antiserum while E is the control without 
any antibody).
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5. Non-specific reaction was not found between antigen, 
conjugate and substrate.
6. There was a proportional increase in the optical 
density (indicator of antigen antibody reaction) with 
increase of cell number per well, antiserum 
concentration and conjugate concentration.
7. Clear distinctive positive results, as compared to 
negative control serum, were found up to 1/400 dilution 
of conjugate, 1 X 10^ cells per well and 1/12800 
dilution of antiserum.
8. A positive reaction was not detected with Balb/c 
mice negative control serum, eliminating the 
possibility of false positive or cross reaction.
9. Cross-reaction with HAT medium having 15% Fetal calf 
serum was not detected.
4.3.3 DISCUSSION:
If the concentration of antibody in polyclonal 
antiserum is say 1 mg/ml (Usually 8-12 mg/ml) then the 
test can detect 0.6 uG/ml (with 1/1600 dil of 
antiserum) and 0.16 uG/ml (with 1/6400 dil of 
antiserum) with accuracy. This is important as the 
amount of monoclonal antibody produced and found in 
culture supernatant of hybridomas is of the order of 
6-10 uG/ml.
ELISA is a convenient, sensitive, automated and 
reproducible method of detection of antibodies. It 
also avoids human observation variability and error
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which is possible in immunofluorescence methods. Intact 
whole cells based ELISA are used by many investigators 
for the detection of cellular antigens especially on 
the surface (Becker et al, 1986 : Campbell, 1987 : 
Douillard et al, 1980 : Trejdosiewicz et al, 1984). 
ELISA chemicals also have a longer shelf life and the 
required equipment is economical (Reif, 1982).
4.4 SCREENING OF WELLS :
4.4.1 INTRODUCTION:
The screening of the wells exhibiting hybridoma growth 
is an essential step in identifying the clones 
secreting the antibody of interest. Usually there are a 
number of hybridoma clones from every fusion which are 
non-secretors that grow rapidly. Screening, therefore, 
should be quick, accurate and efficient and should be 
done more than once. It should be effected as soon as 
Golo^iGS are visible to prevent them being overgrown by 
seeretors. It is widely believed that antibody 
secreting hybridomas are usually slow growing as most 
of the cell’s energy is consumed in antibody production 
rather than DNA synthesis and cell division. However 
alternate views do not associate antibody production 
with either rapid or slow growing cells (Modha, 1990). 
The reverse is true for non-secretors.
4.4.2 RESULTS:
The cell culture supernatants from the wells showing
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hybridoma growth were screened for the presence of 
antibodies against normal hepatocytes and for rat liver 
tumour cells as described in section 2.6.2.
The optical density (O.D) values obtained were 
determined from the ratio of the O.D of a test well to 
the O.D of the control well. The control well received 
complete hybridoma HAT medium in place of cell culture 
supernatant. A negative control (Balb/c mouse serum 
1/1600 dilution) and a positive control (1/1600 
dilution of antiserum raised in mouse against rat 
hepatocytes) were also examined on each plate.
The positive hybrids identified by ELISA were divided 
into three distinct groups according to their 
reactivity with normal rat hepatocytes or rat liver 
tumour cells. In the first group were placed hybridoma 
clones secreting antibodies reactive with both normal 
and tumour cells. Clones reacting with normal cells 
only were placed in the second group. The third group 
contained hybridoma clones secreting antibodies which 
reacted preferentially or only with tumour cells 
(table 4.1 and table 4.2).
A total of 36 positive hybridomas were obtained 
reactive to antigens of liver cells from the first 
fusion. 17 (47%) of these were reactive to both normal 
and tumour cells, 11 out of the 36 (31%) were reactive 
with normal cells only, and 8 clones (22%) were 
reactive with tumour cells only.
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TABLE 4.1
MoAb-SECRETING HYBRIDOMAS FROM THE FIRST FUSION
GROUP CLONES NORMAL CELLS TUMOUR CELLS
A M-1, M-9, M-10, 
M-12, M-14, M-15, 
M-16, M-20, M-22, 
M-25, M-27, M-29, 
M-31, M-32, M-33, 
M-34 and M-35.
(n = 17)
+ +
B M-2, M-3, M-4, 
M-6, M-7, M-8, 
M-11, M-13, M-21, 
M-26 and M-36.
(n = 11)
+
c M-5, M-17, M-18, 
M-19, M-23, M-24, 
M-28 and M-30.
(n = 8)
+
N.B. ELISA test done on tissue culture well supernatant 
showing colony growth.
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TABLE 4.2
MoAb-SECRETING HYBRIDOMAS FROM THE SECOND FUSION
GROUP CLONES NORMAL CELLS TUMOUR CELLS
None.
(n = 0)
B M-42, M-43, M-44, 
M-45, M-46, M-47, 
M-49, M-51, M-52, 
M-53, M-55, M-57, 
M-58, M-60, M-78, 
M-79, M-80, M-81, 
M-82, M-84, M-86, 
M-87, M-88, M-89, 
M-90, M-91 and 
M-92.
(n = 27)
M-41, 
M-54, 
M-61, 
M-64, 
M-67, 
M-70, 
M-73, 
M-76, 
and M-
M-48, 
M-56, 
M-62, 
M-65, 
M-68, 
M-71, 
M-74, 
M-77, 
•85.
M-50, 
M-59, 
M-63, 
M-66, 
M-69, 
M-72, 
M-75, 
M-83
(n = 25)
N.B. ELISA test done on tissue culture well supernatant 
showing colony growth.
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In the second fusion a total of 52 hybridomas were 
found positive reactive with antigens of rat liver 
cells. None was reactive to both normal and tumour 
cells simultaneously, 27 (52%) were reactive with
normal cells only while 25 (48%) were reactive with 
tumour cells only.
4.4.3 DISCUSSION:
In this study the object was to isolate hybridoma 
clones secreting antibodies which preferentially or 
selectively identified tumour cells. As selected above 
three distinct groups of clones secreting antibodies 
were identified according to their reactivity with 
normal and tumour cells. The remaining wells expressing 
hybridoma growth were negative in the ELISA test 
indicating non-secretor status.
It was surprising not to find any hybridoma clone, from 
the second fusion, reacting with both normal and tumour 
cells. The common antigens, on both normal and tumour 
cells, are probably strong antigens and the immune 
response to them is weakened or abolished by prolonged 
repeated immunization (as in the second fusion). The 
immune response found is thus only against the weak and 
sub-dominant antigens. This is also experienced by 
other workers (Kumar, 1989). The results also indicate 
that there are probably many qualitative and 
quantitative changes in antigenicity of tumour cells as 
compared to their normal counterparts.
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4.5 CLONING OF HYBRIDOMAS:
4.5.1 INTRODUCTION:
Hybridomas from wells of interest should be cloned as 
early as possible to reduce the chances of them being 
overgrown by non-secretor cells (Campbell, 1987). 
Cloning, at the earliest possible stage, is thought to 
be necessary for two reasons. Firstly hybridoma cells 
of tetraploid chromosome number have to put more energy 
into DNA replication and cell division compared to a 
non-secretor which may shed chromosomes and is thus 
growing more rapidly. Secondly much of the energy 
production in hybridoma cells is diverted to antibody 
synthesis leaving a relatively small amount of energy 
for cell division. Thus antibody secreting hybridomas 
can always be in danger of being overgrown by 
non-secretor cells in the well. However alternate views 
and work do not associate antibody production with 
either rapid or slow growing cells (Modha, 1990). So it 
is possible to clone them later if necessary.
4.5.2 RESULTS:
Out of 88 hybridoma clones of interest, from the two 
fusions, 56 were sub-cloned and stored successfully 
after propagation. 32 hybridomas (36%) were lost in the 
process of cloning or by contamination. The total 
number of hybridomas cloned and stored, reacting with 
tumour cells preferentially, was 23. A further 23
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clones reactive with normal cells only and not tumour 
cells, and 10 clones reactive with both normal and 
tumour cells were also cloned and stored successfully.
4.5.3 DISCUSSION:
A loss of about 30% clones in sub-cloning is not 
infrequent and up to 50% of initial positive clones can 
be lost during the process due to cessation of growth, 
contamination or failure of cloning (Campbell, 1987). 
The results obtained here were relatively successful by 
these criterion.
4.6 ADAPTATION OF HYBRIDOMAS TO HAT-FREE MEDIUM AND 10% 
FETAL CALF SERUM:
4.6.1 INTRODUCTION:
The established hybridoma cell lines were adapted to 
grow in HAT free culture medium and the concentration 
of fetal calf serum was reduced to 10%. Usually the 
aminopterin is omitted first and the HT maintained to 
allow the cells to use both the main and alternative 
pathways of deoxyribonucleic acid (DNA) synthesis. The 
HT is then omitted from the cell culture medium.
4.6.2 RESULTS:
At first aminopterin was omitted completely from the 
medium and the cells were allowed to grow in HT 
containing medium. The concentration of HT was reduced 
by 50% at every passage and the FCS was gradually 
reduced to 10% at the same time. HT was then totally
230
omitted and the cells were cryopreserved over liquid 
nitrogen at a concentration of 2.5-5.0 X 10^/ml.
4.6.3 DISCUSSION:
All hybridomas were successfully adapted to grow in HAT 
free medium at 10% FCS. Some cell death was observed 
during the process, but most cells did not show any 
adverse effects following HAT removal, and serum 
reduction.
4.7 MoAb CONCENTRATIONS IN ASCITIC FLUID AND IN CELL 
CULTURE SUPERNATANT:
4.7.1 INTRODUCTION:
Hybridoma culture supernatant, using standard small 
scale tissue culture techniques in flasks, contains 
ug/mL quantities of MoAb, while ascitic fluids usually 
contains mg/mL quantities. In order to obtain 
appropriate amount of MoAbs for further tests and 
experiments, ascitic fluids were produced by in vivo 
propagation of hybridomas.
4.7.2 RESULTS :
5-10 X 10^ cells from each hybridoma were injected 
intra-peritoneally into 3 Balb/c mice primed with 
pristane (section 2.7.2). Hybridomas were allowed to 
grow as ascites tumours and the animals were examined 
daily. Ascitic fluid was tapped whenever a sufficient 
amount of fluid was palpable, usually 1-3 weeks after
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injections. RBCs (if a n y ) were removed by 
centrifugation and ascitic fluid was stored at -20°C in 
small aliquots.
Ascitic fluid was diluted and tested for MoAb 
reactivity with normal and tumour cells. Most ascitic 
samples showed the same activity with target cells as 
was observed with the hybridoma culture supernatants 
during the screening. A few either lost activity or 
displayed reduced activity.
Hybridomas were also grown in culture medium to full 
confluency and cell death. The culture supernatant 
medium was then centrifuged to separate cell debris and 
the supernatant stored at -20°C.
Ascitic fluid (1/1500 dilution) and cell culture 
supernatant were tested. Values of T-N and T-N/N were 
calculated for each MoAb, where T is the ELISA O.D. 
with tumour cells and N is the ELISA O.D. with normal 
cells. On this basis, ten clones were selected showing 
strong and/or preferential reactivity with tumour cells 
only. The hybridoma clones were M-56, M-54, M-19, M-28, 
^”30, M-18, M-64, M-62, M-77 and M-48 in descending 
orders of potency.
4.7.3 DISCUSSION;
Ascitic fluid from most of the hybridomas showed un­
altered reactivity to their target cells compared to 
the initial screening of culture fluid from the 96 well 
plates. A few either showed a reduction in reactivity
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or a totally lost reactivity when propagated in vivo. 
The most likely reason for this change is a loss of 
chromosomes during extensive growth followed by 
overgrowth of these non-secretor cells. Such 
reversibility has been reported by many authors 
(Campbell, 1987).
4.8 REACTIVITY OF THE MoAbs WITH PERI-NEOPLASTIC TISSUE 
AND OTHER LIVER TUMOURS INDUCED BY CIPROFIBRATE 
PEROXISOME PROLIFERATOR:
4.8.1 INTRODUCTION;
Peri-neoplastic tissue and cells from the tumour 
bearing rat liver, well clear of the morphological 
margins of the tumours, were probed whether they had 
any reactivity with the tumour-specific antibodies. It 
is possible that Ciprofibrate (chemically)-treated 
livers without morphologically-evident tumours may show 
some reactivity to these antibodies thus indicating 
that antigenic changes may precede any observable 
neoplastic transformation. In addition MoAbs were 
tested for cross-reactivity with tumours and peri- 
neoplastic tissue taken from different animals.
4.8.2 RESULTS;
An ELISA assay technique using whole cells and 
immunestaining of the tissue sections were used to 
define the reactivity of the MoAbs. Tumour-specific 
MoAbs raised against tumour cells from animal C were
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tested for reactivity against tumour cells of animals A 
and B. Peri-neoplastic cells from animals A, B and C 
were also tested for reactivity. Normal liver cells and 
a control antibody (MoAb against yellow fever virus) 
were used as negative controls. Ascitic fluid 
(obtained by injecting hybridomas secreting MoAbs 
against tumour cells) at a dilution of 1/1500 was used 
as a source of MoAbs. O.D values similar to normal 
cells were taken as negative, 2X to 3X the O.D. of 
normal cell control as +, and over 3X normal values as 
++. The results are shown in table 4.3. Some antibodies 
e.g., M-18, M-74 and M-83 seem to react with all 
tumours and peri-neoplastic cells. Others react only 
with the tumour against which antibodies were raised, 
e.g., M-23, M-28, M-30, M-41 and M-50. A third group of 
MoAbs reacted only with tumours from animal C and A, 
e.g., M-19, M-24, M-48, M-54, M-56 and M-59. All others 
exhibit a mixed pattern of reactivity with both, 
tumours and peri-neoplastic tissues.
4.8.3 DISCUSSION:
Some peri-neoplastic cells (Prime et a l , 1987 :
Seilstad et al, 1985) and chemically-treated tissues, 
which do not show any apparent neoplastic change 
(Trejdosiewicz et a l , 1984), can demonstrate the 
appearance of new tumour antigens. It is thus possible 
that antigenic changes occur much earlier in exposed 
tissues than other detectable morphological or
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TABLE 4.3
REACTIVITY OF MoAbs WITH DIFFERENT TUMOURS
GROUP MoAbs ANIMAL C ANIMAL B ANIMAL A
T P.N.T. T P.N.T. T P.N.T.
I M-18 + + + + ++ +
M-74 + + + + + + + +
M-83 ++ ++ + + + +
II M-23 + — — — — ' —
M-28 ++ - - - - -
M-30 ++ - - - . - —
M-41 + - - - - -
M-50 ++ - - - - ■ -
III M-19 ++ _ — _ + _
M-24 ++ — — - + -
M-48 ++ - ... — -
M-54 ++ - - + —
M-56 + + - - — + -
M-59 + - - - + —
IV , M-61 + ++ +/- + /- + +
M-63 + ++ +/“ +/- + +
M-85 ++ ++ + /- + /- + +
V M-68 + ++ + _ + +
M-70 + + + - + +
VI M-62 + ++ + /- + + +
M-64 + + +/- - + +
M-65 + + - — + +
M-77 + ++ — + /“ + +
T = Tumour cells.
P.N.T. = Peri-neoplastic cells.
+/- = Not sure.
+ = 2X-3X O.D. value of negative cells. 
++ = >3X O.D. value of negative cells.
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cytological change and indeed may be concurrent with 
oncogene activation in peri-neoplastic cells. Such 
changes in antigenicity may therefore have significant 
diagnostic and therapeutic implications.
Some of the MoAbs (M-18, M-62, M-63, M-64, M-65, M-68, 
M-70, M-74, M-77, M-83 and M-85) cross-reacted with the 
peri-neoplastic cells of Ciprofibrate-treated animals. 
This indicate that some of the antigenic changes found 
in Ciprofibrate-induced tumours are also detectable, to 
a variable but usually lower degree, in the apparently 
normal looking non-tumourous peri-neoplastic cells.
The tumour antigens of chemically-induced tumours are 
believed to be diverse and polymorphic (Baldwin, 1973), 
and it has been suggested they may be unique to each 
tumour produced, e.g., even by the same chemical agent 
in the same strain of animal (Baldwin, 1973 : Baldwin, 
1978). On the other hand there are reports of antigens 
which are expressed on all tumours when a potential 
chemical is used in particular strain of species, and 
even occasionally in different species as well 
(Embleton et al, 1980 : Hellstrom et al, 1985 : Holmes 
et al, 1971).
In peroxisome proliferator-induced tumours, many of the 
antigens identified by MoAbs are apparently unique to 
an individual animal, but there are also antigenic 
determinants which are present on tumours from 
different animals. For example there is a significant 
cross-reactivity of certain MoAbs identifying antigens
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on the tumour in animal C (against which initially 
MoAbs were raised) with cells from tumour in animal A. 
It is also significant to note that MoAbs from the 
first fusion (with a short immunization protocol) 
mostly identify tumour-unique antigens, while MoAbs 
from the second fusion (with a repeated and longer 
immunization protocol) identify common antigens on 
different tumours of similar etiology. However it is 
also clear that MoAbs from the second fusion are mostly 
weaker in reactivity than those from the first fusion. 
This again indicate the diversity of tumour antigens 
produced. In most liver cells following Ciprofibrate 
treatment, some of these at least must relate to the 
observed hepatomegaly, while others to the subsequent 
neoplastic change.
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SECTION-5 
CHARACTERIZATION OF TUMOUR ANTIGENS
5.1 HISTOLOGICAL EXAMINATION OF FIBRATE PEROXISOME 
PROLIFERATOR-INDUCED RAT LIVER TUMOURS :
5.1.1 INTRODUCTION:
Ciprofibrate peroxisome proliferator-induced rat liver 
tumours were examined histologically to confirm the 
diagnosis (hepatocellular carcinomas) and to study the 
microscopic structure of tumours using standard 
haematoxylin and eosin staining. The histological 
examination of tumours was also carried out at Sterling 
Winthrop Research centre, Alnwick and the tumours were 
reported to be non-metastatic hepatocellular 
carcinomas.
5.1.2 RESULTS :
The microscopic examination of haematoxylin and eosin 
stained rat liver tumour sections (Figs. 5.1 to 5.4) 
revealed a loss of the normal lobular architecture. 
These tumour cells were enlarged, granular and were 
arranged in small islands of abnormal cells. Nuclei of 
such cells were enlarged and densely stained. Changes 
ranging from liver cell adenoma (hyperplasia, normal 
cell structure, excluding significant mitotic activity, 
excluding invasion of adjacent parenchyma) to 
hepatocellular carcinoma of low anaplastic grade (loss 
of trabecular cell arrangement, large vesicular deep 
and dark stained nuclei with prominent nucleoli, 
eosinophilic non-vacuolated cytoplasm, excluding acinar 
formation, excluding fibrosis, excluding necrosis,
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Fig 5.1 Normal rat liver H & E stain (lOX).
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Fig 5.2 Peroxisome proliferator induced rat liver
tumour H & E stain (lÔX).
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Fig 5.3 Peroxisome proliferator induced rat liver 
liver tumour H & E stain (20X).
m
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Fig 5.4 Peroxisome proliferator induced rat liver
tumour H & E stain (40X).
& 4 0
excluding glandular regeneration, irregular groups of 
abnormal tumour cells, some mitotic figures, very 
little glycogen, without haemorrhage or calcification) 
were found in different parts of the livers examined.
5.1.3 DISCUSSION:
It appears that peroxisome proliterators can induce 
liver tumours (of hepatocyte origin) in rats which 
range in histology from benign adenoma to malignant and 
anaplastic hepatocellular carcinoma (Conway et al, 
1989 : Dwivedi et al, 1989 : Lalwani et al, 1981a : Rao 
et al, 1988a : Reddy and Lalwani, 1983) depending upon 
various known (chemical, dose, duration) and unknown 
factors. The tumours are non—neerogenic and there is 
not a connective tissue involvement or reaction. 
Tumours can metastasize and are similar in histology to 
other hepatocellular carcinomas induced by other 
different etiological agents (Reddy and Lalwani, 1983).
5.2 IMMUNOCYTOCHEMICAL CHARACTERIZATION OF TUMOUR 
SPECIFIC MoAbs USING A PANEL OF NORMAL RAT TISSUES:
5.2.1 INTRODUCTION:
The analysis and characterization of antigens 
identified by antibodies is important in determining 
the specificities of the identified antigens (Baldwin, 
1978), since apparently specific antigenic determinants 
found on tumour cells can also be detected at low
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levels on normal and fetal tissues. A panel of normal 
and fetal tissues of Fischer F344 rats were used here 
to define reactivity of the tumour-specific MoAbs, and 
in turn the distribution/specificity of the antigens 
detected by these antibodies.
5.2.2 RESULTS :
The results are shown in tables 5.1, 5.2, 5.3 and 5.4. 
Negative and positive controls were run with all the 
tests. A total of 23 monoclonal antibodies which had 
showed preferential or exclusive reactivity with tumour 
cells only were tested. Ascitic fluid was used as 
source of MoAbs and the optimal dilution was between 
1/150-1/800 giving least background and high distinct 
positive results. Five antibodies (M-19, M-23, M-28, 
M-54 and M-56) did not react with any of the normal rat 
tissues tested. All the other antibodies reacted with 
at least one other normal tissue and organ. It is 
interesting to note that none of the MoAbs from the 
first fusion reacted with rat fetal liver. A summary 
of these reactivities is given in table 5.5 (Figs. 5.11 
to Figs. 5.35 show the pattern of reactivity of MoAbs 
with normal and fetal rat tissues). The difference seen 
in the background of some of the photographs is due to 
different makes of film, amount of light, photographic 
paper and processing conditions of the films by 
different developers, which could not be specifically 
controlled.
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TABLE 5.1
MoAb REACTIVITY WITH NORMAL RAT TISSUES
MoAb HEART BRAIN LUNG FOETAL LIVER
Negative
Control
- - -
Positive
Control
+ + ++ ++
M-18 — — — -
M-19 -, - - -
M-23 - - -
M-24 - - — -
M-28 - - - -
M-30 - - - ■ -
M-41 - - - -
M-48 - - - +/-
M-50 - + /- - + /-
M-54 - - - -
M-56 - - - -
M-59 + + /- + -
M-61 — - - -
M-62 - - - +
M-63 - - - +
M-64 - — - +
M-65 + /- - - + /-
M-68 + - + /“ +
M-70 - - - +
M-74 +/- - - +
M-77 - - - ++
M-83 - - - +
M-85 - - - +
1. - negative
2. + positive
3. ++ strong positive
4. +/- doubtful
5. Negative control is the mouse serum.
6. Positive control was the antiserum raised against 
Fischer F344 rat hepatocytes and serum proteins in 
mouse.
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TABLE 5.2
MoAb REACTIVITY WITH NORMAL RAT TISSUES
MoAb STOMACH PANCREAS SMALL
INTESTINE
LARGE
INTESTINE
Negative
Control
- - — -
Positive
Control
+ + ++ +
M-18 _
M-19 - — — —
M-23 - - — —
M-24 - - — —
M-28 - - - —
M-30 — + — —
M-41 - — — —
M-48 - ■ — - - —
M-50 - — — —
M-54 - — — —
M-56 - + /- — —
M-59 - — —  ■
M-61 - — — _
M-62 - — _  ’
M-63 + + + +
M-64 - - — _
M-65 - + — _
M-68 - - — _
M-70 - - — _
M-74 , — - — —
M-77 - - — _
M-83 + + — _
M-85 — - - -
1.
2 .
3.
4.
5.
6 .
negative 
+ positive 
++ strong positive 
+/- not sure
Negative control was normal mouse serum.
Positive control was antiserum raised against 
Fischer F344 rat hepatocytes and serum proteins in 
mouse.
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TABLE 5.3
MoAb REACTIVITY WITH NORMAL RAT TISSUES
MoAb KIDNEY SPLEEN SKELETAL
MUSCLE
URINARY
BLADDER
Negative
Control - - - -
Positive + + + + +
Control
M-18 + +
M-19 - + -  . -
M-23 - + - -
M-24 +/- + - -
M-28 - + - -
M-30 + + - -
M-41 - + - -
M-48 + + - —
M-50 — + - -
M-54 - + — —
M-56 - + - —
M-59 + ++ — —
M-61 — + - —
M-62 - + + /- -
M-63 + + —
M— 64 # + — —
M-65 # + — —
M-68 + + — —
M-70 - + + -  ■ —
M-74 + + — —
M-77 - + +/- $
M-83 - + /- —
M-85 - + + /- -
1 .
2.
3.
4.
5.
6.
7.
8.
negative 
positive 
strong positive 
very strong positive
negative but some glomeruli are positive 
only elements in submucosa are positive 
Negative control was normal mouse serum.
Positive control was antiserum against Fischer
+
++
+++
#
$
F344 rat hepatocytes and serum proteins in mouse
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TABLE 5.4
MoAb REACTIVITY WITH NORMAL RAT TISSUES
MoAb RBCs TESTIS OVARY FALLOPIAN
TUBE
CORPUS
LUTEUM
Negative
control — — $ : — —
Positive ++ +/” * '+ :■ ++
control
M-18 $
M-19 - $ . —
M-23 - $ -r
M-24 + - $ h
M-28 — - $
M-30 + ' ' —
M-41 . - - $ + /-
M-48 - — ■ #
M-50 — - $
M-54 - - +/-
M-56 - — $
M-59 + —
M-61 - - $
M-62 - +/- $
M-63 - $
M-64 — - $
M-65 + ■ ■ - $
M-68 + - #
M-70 - — $ _
M-74 - - / $
M-77 - + /- $ h
M-83 - $
M-85 + +/- # -
1
2
3
4
5
+
++
+++
$
staining
6 .
7.
8.
9.
10. 
1 1 .
h
+ / ■
negative 
positive 
strong positive 
very strong positive 
connective tissue stroma show minimal
connective tissue stroma moderately stained 
connective tissue stroma intensely stained 
only submucosa show staining 
not sure
Negative control was normal mouse serum.
Positive control was antiserum raised in mouse 
against Fischer F344 rat hepatocytes and serum 
proteins.
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TABLE 5.5
SUMMARY OF CROSS-REACTIVITY OF TUMOUR-SPECIFIC
MoAbs WITH NORMAL RAT TISSUES
MoAb CROSS-REACTIVITY WITH
M-18 Kidney.
M-19 None.
M-23 None.
M-24 Kidney, RBCs and Fallopian tube.
M-28 None.
M-30 Kidney, Pancreas and RBCs.
M-41 Fallopian tube.
M-48 Kidney and Ovary.
M-50 Brain.
M-54 None.
M-56 None.
M-59 Heart, Lung, Kidney, Spleen, Brain and RBCs.
M-61 Foetal liver.
M-62 Testis,Skeletal muscle. Spleen & Foetal liver.
M-63 Kidney, Stomach, Small intestine. Large 
intestine and Foetal liver.
M-64 Kidney and Foetal liver.
M-65 Pancreas, Kidney, Heart and RBCs.
M-68 Heart, Kidney, Ovary, RBCs and Foetal liver.
M-70 Spleen and Foetal liver.
M-74 Kidney, Heart and Foetal liver.
M-77 Testis, Fallopian Tube, Skeletal Muscle, 
Urinary bladder and Foetal liver.
M-83 Stomach, Pancreas and Foetal liver.
M-85 Testis, Skeletal muscle. Ovary, RBCs and 
Foetal liver.
......... . ..  . .. .................. ..
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Fig 5.5 Peroxisome proliferator induced rat liver 
tumour, reactivity of MoAb M-18 (20X).
Fig 5.6 Peroxisome proliferator induced rat liver
tumour, reactivity with MoAb M-23 (20X).
Fig 5.7 Peroxisome proliferator induced rat liver 
tumour, reactivity with MoAb M-28 (40X).
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Fig 5.8 Peroxisome proliferator induced rat liver
tumour, reactivity with MoAb M-30 (20X).
Fig 5.9 Peroxisome proliferator induced rat liver 
tumour, reactivity with MoAb M-54 (20X).
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Fig 5.10 Peroxisome proliferator induced rat liver
tumour, reactivity with MoAb M-56 (20X)
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Fig 5.11 Reactivity of MoAb M-48 with normal rat 
brain (20X).
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Fig 5.12 Normal rat heart H & E stain (lOX).
2S(
m#
I
Fig 5.13 Reactivity of MoAb M-68 with normal rat 
heart (lOX).
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Fig 5.14 Normal rat lung H & E stain (20X).
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Fig 5.15 Reactivity of MoAb M-59 with normal rat 
lung (20X).
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Fig 5.16 Reactivity of MoAb M-77 with rat foetal 
liver (lOX).
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Fig 5.17 Normal rat stomach H & E stain (lOX).
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Fig 5.18 Reactivity of MoAb M-83 with normal rat 
stomach (lOX).
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Fig 5.19 Normal rat pancreas H & E stain (lOX)
Fig 5.20 Normal rat small intestine H & E stain (lOX)
Fig 5.21 Reactivity of MoAb M-63 with normal rat 
small intestine (lOX).
Fig 5.22 Normal rat large intestine H & E stain (10x7
Fig 5.23 Reactivity of MoAb M-63 with normal rat 
large intestine (lOX), 
counter-stained with neutral red.
Fig 5.24 Normal rat renal cortex H & E stain (lOX)
Fig 5.25 Normal rat spleen H & E stain (lOX).
Fig 5.26 Reactivity of MoAb M-59 with normal rat
spleen (10%),counter-stained with neutral red
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Fig 5.27 Normal rat skeletal muscle H & E stain (lOX).
t
Fig 5.28 Normal rat urinary bladder H S E stain (lOX)
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Fig 5.29 Reactivity of MoAb M-77 with normal rat 
urinary bladder (lOX), 
counter-stained with neutral red.
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Fig 5.30 Normal rat testis H & E stain (lOX).
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nFig 5.31 Reactivity of MoAb M-85 with normal rat 
testis (lOX),
counter-stained with neutral red.
Fig 5.32 Normal rat ovary H & E stain (lOX)
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Fig 5.33 Reactivity of MoAb M-68 with normal rat
ovary (lOX), counter-stained with neutral red.
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Fig 5.34 Normal rat fallopian tube H & E stain (lOX).
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5.2.3 DISCUSSION:
The specificity and distribution of a tumour antigen is 
usually measured in terms of the non-reactivity of 
identifying MoAbs with other normal tissues. Some 
tumour antigens like carcinoembryonic antigen, alpha 
fetoprotein, human chorionic gonadotrophin and 
prostatic acid phosphatase are present in small amounts 
on normal tissues (Abelev, 1971 : Cole et al, 1983 : 
Daar et al, 1981 : Gold and Freedman, 1965 : Kenemans 
et al, 1988 : Schol et al, 1988), other tumour antigens 
are detected in variable amounts on fetal tissues in 
addition to tumours (Gooi et al, 1983 : Hole and Stern, 
1988). There are also tumour antigens described which 
are found only on tumour cells (Albino and Houghton, 
1985 : Baldwin, 1973 : Wortzel et al, 1985).
Five of the MoAbs raised here against peroxisome 
proliterator-induced rat tumour cells (M-19, M-23,
M-28, M-54 and M-56) showed minimal, or no cross­
reactivity with the normal or fetal rat tissues tested. 
On the basis of these results and of results described 
in section 4.4 and 4.8, these five MoAbs were selected 
for further study and characterization.
5.3 REACTIVITY OF TUMOUR SPECIFIC MoAbs WITH RAT 
TUMOURS :
5.3.1 INTRODUCTION:
Tumour antigens can be glycoproteins, glycolipids,
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gangliosides or any normal or altered cell proteins. 
They could be found at the cell surface, in the 
cytoplasm or in the nucleus. MoAbs selected in section
5.2 were used to ,characterize their reactivity with 
individual cells within the peroxisome proliferator- 
induced liver tumours, and to detect the location of 
antigenic molecules in the cells using the 
immunocytochemical staining methods described in 
section 2.8.1.
5.3.2 RESULTS:
The results are shown in figures 5.5 to 5.10 (page 
248-250) and demonstrate the intensity and pattern of 
reactivity of the antibodies with rat liver tumours 
induced by the peroxisome proliferator. These also 
confirmed the results described in section 4.8 using 
ELISA assay to test reactivity. Immunostaining of 
tumours with these MoAbs was not a uniform phenomenon. 
Clusters or groups of cells were irregularly (non- 
homogeneously) stained in the tumour tissue sections. 
There was inter-tumour and intra-tumour variation in 
the intensity of immunostaining. The antigenic moieties 
stained were mostly intra-cytoplasmic (within the 
cytoplasm). No significant cell surface or nuclear 
staining was observed. All five tumour-specific MoAbs 
tested exhibited reactivity with tumour sections but 
the pattern and area of stain were different with 
little overlap.
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5.3.3 DISCUSSION:
MoAbs are an important aid to histological diagnosis 
(Sloane and Ormerod, 1987). All five tumour-specific 
MoAbs identified and stained chemical antigenic 
moieties in the tumour cells. The patchy, irregularly 
(non-homogenous) nature and variability of staining 
probably indicate either that only some tumour cells 
are antigen positive or that the antigen is expressed 
transiently in a particular phase of carcinogenesis. It 
is also possible that not all the cells in the tumour 
are fully transformed. Heterogeneity of tumours in 
relation to their antigenic features is also described 
by others (Chedid et al, 1990 : Giwercman et al, 1990 : 
Schol et al, 1988 ) and different degrees of 
immunostaining are described (Asamoto et al, 1989 : 
Durrant et al, 1989). Sometimes immunostaining is seen 
in peri-neoplastic tissues (Haglund et al, 1989) and it 
may be related to and indicative of the stage of 
disease (Jones et al, 1990).
The MoAbs raised here against rat liver tumours 
apparently failed to demonstrate any antigenic 
iï^ol6cules on the cell surface or in the nucleus as 
described in other tumour systems (Babin and Anderson, 
1988 : Ghazizadeh, 1989 : Hole and Stern, 1988 : 
Maruyama et al, 1983). However most MoAbs raised 
against tumour cells are directed against cytoplasmic 
antigens (Edwards, 1985), and nuclear or cell-surface
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antigens are themselves synthesized in the cytoplasm. 
This is a continuous process and many antigens are 
finally shed or lost from the cell surface (Herlyn et 
r 1987 : Sears et al, 1982) their presence in body 
fluids or secretions/excretions constituting an 
important mode of diagnosis. It is also of note that 
tumour cells in culture have been shown not to express 
cell surface tumour antigens (Martin et al, 1989). Thus 
the apparent specificity of the MoAbs for the 
cytoplasmic antigens should not be taken as necessarily 
denoting the ultimate intra-cellular location of these 
antigens. These results of our work are in conformity 
with the work discovered so far in this area.
5.4 REACTIVITY OF RAT TUMOUR CELL SPECIFIC MoAbs WITH 
HUMAN NORMAL AND TUMOUR TISSUES;
5.4.1 INTRODUCTION;
Tumour specific MoAbs from one tumour system are known 
to have cross-reactivity with various normal and tumour 
tissues in different tumour system or species (Kenemans 
et al, 1988 ; Reif, 1982). A panel of normal human 
tissues and human tumours were used to determine 
cross-reactivity of these tumour specific MoAbs.
5.4.2 RESULTS;
The reactivity of these five rat liver tumour-specific 
MoAbs with human normal and tumour tissues are shown in
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tables 5.6 and 5.7. Negative controls were effected 
using a control ascitic fluid.
The results indicate that these rat liver tumour- 
specific MoAbs are mostly non-reactive with normal 
human tissues with an occasional exception. Most of 
antibodies did not show a reactivity with carcinoma of 
the colon (adenocarcinoma), carcinoma of the ovary 
(granulosa cell tumour), tumours of the kidney 
(nephroblastoma and carcinoma of the renal parenchyma) 
and carcinoma of the lung (oat cell carcinoma and large 
cell anaplastic carcinoma). The only exception was M-56 
which exhibited some positive reactivity with lung and 
kidney tumours.
All five rat liver tumour-specific MoAbs tested did not 
express reactivity with normal human liver. M-23 and 
M-28 showed a strong reactivity with human 
hepatocellular carcinoma (areas of strong positive 
immunostaining). M-19 and M-54 were also reactive with 
human hepatocellular carcinomas, but to a lesser 
degree. M-56 showed weak reactivity with normal human 
liver and hepatocellular carcinoma as well, (figures 
5.36 to 5.57 show the histology of human normal tissues 
and tumours and reactivity of MoAbs with these tissues, 
indicating intensity and pattern of reactivity)
5.4.3 DISCUSSION:
MoAbs against tumour cell antigens are reported to have 
a wide range of cross-reactivity within the same tumour
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Table 5.6
REACTIVITY OF MoAbS WITH NORMAL HUMAN TISSUES
TISSUE CONTROL M-19 M-23 M-28 M-54 M-56
Lung - — —
Bronchus - - - + /- - -
Brain - +/- - - - -
Skeletal-
muscle - - — — — _
Heart _ +/-
Artery - - * * * -
Spleen + + + * ++ +
Lymph-
Node - - - - - -
Kidney — — — + /-
Urinary- 
Bladder - - +/- - - -
Esophagus $ $ $ $ $ $
Stomach - - —
Colon h h h h h h
Appendix - — - - + /- —
Rectum - - - - -
Ovary — — ! _
Testis - - — — _
Prostate - - — — _
Fallopian
Tube + + + + + + +
Placenta - +/- + * _
Corpus
Luteum + + ++ + + +
Cervix - - — _
Uterus - - —  ■ —
Breast * @ @
1. * not tested
2. $ only submucosa is positive
3. connective tissue in lamina propria and
submucosa is positive
4. h only connective tissue is positive at few places
5. ! only connective tissue is weakly positive
6. (3 connective tissue is positive non-homogeneously
in places while glandular tissue is negative
7. +/- not sure.
8. Negative control was normal mouse serum.
9. Positive control was antiserum against Fischer F344 
rat hepatocytes and serum proteins raised in mouse.
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Table 5.7
REACTIVITY OF MoAbs WITH HUMAN TUMOURS
TUMOUR CONTROL M-19 M-23 M-28 M-54 M-56
Carcinoma
Lung - - - _ + +
Carcinoma
Ovary - - — +/- _
Carcinoma
Colon — - - — _
Carcinoma
Kidney - - - . * $
HCC @ - L h h h +/-
1. some secretions in lumini of glands are positive
2. * not tested
3. $ Very few cells in cortex are positive
4. @ Hepatocellular carcinoma
5. t Immunostaining is non—homogeneous. A few groups
of cells are positive in sections
6. Control was normal mouse serum.
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Fig 5.35 Reactivity of MoAb M-24 with normal rat 
fallopian tube (lOX),
counter-stained with neutral red.
Fig 5.36 Normal Human kidney H & E stain (lOX)
I'lo
Fig 5.37 Reactivity of MoAb M-28 with normal human
kidney (lOX), counter-stained with neutral red
Fig 5.38 Normal human spleen H & E stain (lOX)
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Fig 5.39 Reactivity of MoAb M-54 with normal human
spleen (lOX), counter-stained with neutral red.
Fig 5.40 Reactivity of MoAb M-54 with human heart 
(lOX), counter-stained with neutral red.
Fig 5.41 Normal human uterus and cervix H & E 
stain (lOX).
Fig 5.42 Normal human lymph node H & E stain (lOX).
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mFig 5.43 Normal human placenta H & E stain (lOX)
Fig 5.44 Normal human testis H & E stain (lOX)
%#
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Fig 5.45 Reactivity of MoAb M-23 with normal human
stomach ( lOX ), counter-stained with neutral red
w
.4»*
Fig 5.46 No reactivity of MoAb M-23 with normal 
human large intestine (lOX), 
counter-stained with neutral red.
E7S
Fig 5.47 Reactivity of MoAb M-54 with normal human
spleen (lOX), counter-stained with neutral red
Fig 5.48 Human carcinoma kidney H & E stain (lOX)
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Fig 5.49 Human adenocarcinoma colon H & E stain 
(lOX).
w & f i
Fig 5.50 Human hepatocellular carcinoma (HCC) H & E 
stain (lOX).
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Fig 5.51 Human Hepatocellular carcinoma (HCC) H & E 
stain (lOX).
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Fig 5.52 Reactivity of murine MoAb M-28 with human 
carcinoma kidney (lOX),
counter-stained with neutral red.
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Fig 5.53 Reactivity of murine MoAb M-19 with human 
adenocarcinoma colon (lOX), 
counter-stained with neutral red.
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Fig 5.54 Reactivity of murine MoAb M-23 with human 
hepatocellular carcinoma (HCC) lOX, 
counter-stained with neutral red.
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Fig 5.55 Reactivity of murine MoAb M-28 with human 
hepatocellular carcinoma (HCC) lOX, 
counter-stained with neutral red.
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Fig 5.56 Reactivity of murine MoAb M-54 with human 
hepatocellular carcinoma (HCC) lOX, 
counter-stained with neutral red.
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Fig 5.57 Reactivity of murine MoAb M-54 with human 
hepatocellular carcinoma (HCC) lOX, 
counter-stained with neutral red.
Fig 5.58 Gel showing electrophoretic separation of 
proteins from normal & peroxisome proliferator-induced 
rat liver tumour cells. Molecular weight markers "A"
(a = 26,600 : b = 36,500 : c 
e = 84,000 : f = 116,000 and 
(B = 0.2 Gm% : C = 0.1 Gm% 
tumour (E = 0.2 Gm% : F =
samples were used.
= 48,500 : d = 58,000 : 
f = 180,000), normal liver 
: D = 0.05 Gm%) and liver
0.1 Gm% : G = 0.05 Gm% )
9
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Fig 5.59 Normal rat liver and. peroxisome prolif erator- 
induced rat liver tumour proteins separated by Phast 
system on minigels showing the same pattern of protein 
bands as described in fig 5.58. Molecular weight 
markers are at both sides.
Fig 5.60 Two of the raised MoAbs (ascitic fluid 1/1600 
dilution) on a Phast system minigel showing one 
prominent band indicating MoAb, as shown by arrow.
system, with tumours of different histology or etiology 
and even with tumours in different species (Albino and 
Houghton, 1985 : Armitage et al, 1988 : Bidart et al, 
1989 : Couchman and Ljubimov, 1989 : Daynes et al, 1985 
: Groyer-Picard et al, 1990 : Imam and Taylor, 1989 : 
Mettler et al, 1990 ; Payne and Coggin, 1985 : Reisfeld 
and Cheresh, 1987 : Schol et al, 1988 : Smorodinsky et 
al, 1988 : Southall et al, 1990 : Trejdosiewicz et al, 
1984).
It appears that the murine MoAbs raised here against 
the rat liver tumours were non-reactive with most 
normal human tissues or non-hepatic human tumours. 
However MoAbsexhibited the similar patchy (but 
intense in places) immunostaining with human 
hepatocellular carcinomas as seen with the rat liver 
tumours.
It is possible that the human hepatocellular carcinomas 
exhibit antigenic determinants similar to those found 
in rat liver tumours. This may however be a transient 
and/or phase-specific phenomenon as only a small number 
of cells are antigenically positive, and leads to the 
question of whether all liver cells in the process of 
carcinogenesis pass through similar changes as 
determined by the expression of tumour-specific 
antigens and cross-reactivity of MoAbs. The presence of 
similar antigenic determinants on human hepatocellular 
carcinomas indicates that they may probably pass
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through some of the stages of biochemical and antigenic 
changes observed in the rat liver tumours. This leads 
to the further speculation that there may well be some 
similarity in biochemical processes in liver cancers 
and carcinogenesis regardless of etiology or species 
involved. Some of these antigenic changes will of 
course be common to all cancers, but they may not 
reflect the major antigenic changes in the cells.
5.5 CLONOTYPING OR CLASS DETERMINATION OF MoAbs:
5.5.1 INTRODUCTION:
Antibody class can readily be determined by the use of 
class specific antibodies in the ELISA assay, 
Ouchterlony assay or gel electrophoresis. It is helpful 
to determine the relative proportions of the two 
antibody chains (kappa and lambda) and can be a final 
proof that an antibody is effectively monoclonal. Some 
cross-reaction frequently occurs due either to 
contamination with irrelevant IgG molecules in ascitic 
fluid or some possible cross-reactivity with commercial 
materials.
5.5.2 RESULTS:
Clonotyping and class determination of the five rat 
tumour specific MoAbs was done using both hybridoma 
culture supernatant and a 1/1500 dilution of ascitic 
fluid. The results indicate that M-19 and M-28 are 
IgG^. M-54 and M-56 are IgGga while M-23 is found to be
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The results were more clear and pronounced with 
hybridoma culture supernatants. Ascitic fluid 
containing MoAb, in an appropriate dilution of 1/1500, 
was also run on a minigel Phast system (Pharmacia). The 
separated proteins bands also exhibited one major, 
single and distinct band of corresponding antibody with 
little contaminating proteins (fig 5.60 page 282).
5.5.3 DISCUSSION:
Whenever an immune competent living animal is exposed 
to foreign antigenic molecule, there is an 
immunological response comprising of both B and T cell 
components. The initial humoral response comprises of 
antibody production of the mainly IgM type which later 
is changed to an IgG type antibody production.
Most of the MoAbs raised against tumour antigens are 
described to be the IgG type (Dunk et al, 1987 : Holmes 
et al, 1982 : Payne and Coggin, 1985 : Schol et al,
1988). The single class of antibody found from one 
hybridoma clone is also an indication that the antibody 
in question is monoclonal.
5.6 CHARACTERIZATION OF THE RAT TUMOUR ANTIGENS 
IDENTIFIED BY MoAbs USING WESTERN BLOTTING:
5.6.1 INTRODUCTION:
Tumour and normal cell proteins were separated by gel 
electrophoresis, blotted onto nitrocellulose membrane
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and allowed to react with the tumour-specific 
antibodies as described in section 2.8.2. This was done 
to confirm the reactivity of antibodies with antigens 
in the tumours and the determination of the molecular 
weight of the antigens defined by these antibodies.
5.6.2 RESULTS:
The results are shown in figures 5.58 (page 281) and 
5.61 to 5.66 as the major reactive bands as the western 
blots. The antigens identified with their approximate 
molecular weights as shown in table 5.8.
The results with the Phast minigel system were not very 
impressive (Fig 5.59 page 282). The proteins tended to 
separate and transfer nicely to nitrocellulose but the 
reactivity with MoAbs tended to give a high background, 
even at high dilutions. This may well have been due to 
the small amount of sample applied and separated in the 
Phast minigel system. Higher concentration of primary 
antibody and conjugate were then required detection 
thus leading to a high background.
5.6.3 DISCUSSION:
The relative immunoreactivity and the molecular weight 
of the identified antigens provides a very useful 
method for defining MoAbs. Firstly, it confirms that 
the reactivity of the raised antibody is associated 
with the specific antigens in the tumour cells. 
Secondly, it determines whether a MoAb is reactive with 
more than one polypeptide. Thirdly, it defines the
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TABLE 5.8
TUMOUR-ANTIGENS DETECTED WITH WESTERN BLOT
MoAb •MOLECULAR WEIGHT OF IDENTIFIED ANTIGENS
M-18 49,500. app rox.
M-19 46,000.
- ----- i
// . ;
51,600. !» .
M-23 45,500. //
51,000. //
M-28 137,000. //
M-54 122,000. //
M-56 71,000.
122,000.
159,000. 'f •
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molecular weight of the antigen(s) identified by MoAb. 
Fourthly, by determination of molecular weight it helps 
to determine whether MoAb is reactive with an antigen 
already described by others. Also MoAb reacting with 
the same polypeptide, but perhaps with different 
antigenic epitope can also be detected with this system 
(Becker et al, 1986). Finally, in our experiments by 
running normal and tumour samples alongside in the same 
gel, it confirms non-reactivity of MoAbs with the 
normal controls.
The loss of a number of normal antigens and appearance 
of new antigens of different molecular weights has been 
described in different tumour systems. These antigens 
range between 15,000 to 250,000 molecular weight 
usually (Becker et al, 1986 : Brown et al, 1980 :
Davies et al, 1989 : Hixson et al, 1983 : Hole and 
Stern, 1988 : Imam and Taylor, 1989 : Janson et al, 
1987 : Martin et al, 1989 : Ogasawara et al, 1988 : 
Paterson et al, 1988 : Payne and Coggin, 1985 : Schol
et al, 1988) but there are reports of very high 
molecular weight tumour antigens e.g., pancreatic 
cancer associated antigen (Maruyama et al, 1983). As 
can be seen from my data antigens between 49,500 and
159,000 were detected by the MoAbs raised here. It is 
also clear that some of the MoAbs recognize more than 
one polypeptide, and that, since exact sizing is 
difficult, some of these may be shared by different
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MoAbs. None of these antigens have been described by 
other authors in the liver system or in tumours from 
other tissues. However it is quite possible that 49,000 
- 52,000 polypeptide are the Ciprofibrate-induced 
cytochrome P-450s of family IV. Similarly the 71,000 
polypeptide is very close to alpha fetoprotein. Further 
experiments with authentic enzymes are needed to 
examine this point.
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SECTION-6
DISCUSSION
6.1 PEROXISOME PROLIFERATOR-INDUCED TUMOURS :
An increasing number of chemicals have been identified 
in recent years as peroxisome proliferators and many 
are yet to be investigated and discovered. Chemicals of 
this group have the potential to induce tumours of 
different histogenic types in rodents. Their 
carcinogenic potential for humans has not yet been 
proved but the possibility is of concern. It appears 
that peroxisome proliferation in rodents is a change 
which precedes neoplastic change. Proliferation of 
peroxisomes and associated biochemical changes may, 
therefore, be regarded as early pre-neoplastic changes 
and may well be an important early indicator of 
impending neoplastic changes.
As shown in this study using ciprofibrate, peroxisome 
proliferators mainly cause hepatocellular carcinomas in 
rodents. The histology of these tumours varies (as 
described in section 5.1) from benign hyperplasia, 
adenoma, pre-neoplastic nodules and highly anaplastic 
metastatic carcinomas of hepatocyte origin. The 
histology seems to be comparable to liver tumours 
induced by any other etiological agents (section 5.1). 
There also seem to be other factors contributing to the 
tumour induction e.g., species, age, chemical, dose and 
duration.
6.2 CIPROFIBRATE-INDUCED TUMOUR CELLS IM VITRO:
The tumour cells from ciprofibrate-induced rodent liver
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tumours were studied for their in vitro characteristics 
in comparison with their normal counterparts and other 
transformed cells.
The tumour cells tend to disperse from tissues more 
easily than normal cells using a much lower collagenase 
concentration and in much less time (section 2.1 and 
section 3.1). This indicatesthat there is probably less 
efficient cell-cell binding by tumour cells which can 
be an important factor in determining metastatic 
potential.
The cells isolated from normal and tumour tissue by 
collagenase digestion (section 2.1) are physically and 
biochemically intact as shown by dye exclusion and MTT 
assays (section 2.1 and 3.1). The slicing method seems 
to be an efficient method for obtaining pure viable 
cells from liver tumours (section 3.1.3). The number of 
intact cells obtained is also not very different 
compared to in situ perfusion in terms of cells 
obtained per gram of tissue.
The tumour tissue was cryopreserved successfully using 
liquid nitrogen, and on thawing gave viable cells by 
enzymatic digestion as evidenced by dye exclusion and 
MTT assay. The results were comparable to fresh tissue 
digestion followed by cell separation (section 3.2).
The ciprofibrate-induced rat liver tumour cells and 
normal liver cells were grown in vitro to study growth 
differences. In the optimum conditions identified for 
normal liver cells (section 3.3), the tumour cells
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exhibit a higher potential for growth as indicated by 
longer in vitro survival and greater cell replication 
(section 3.3.2.5). Chemically and hormonally defined 
serum free medium (section 2.5) seems to be 
significantly better for normal liver cells and 
ciprofibrate-induced rat liver tumour cells as compared 
to that supplemented with PCS, rat serum, or conditioned 
media (section 3.3). The use of different substrata for 
in vitro culture appears to have a significant 
supportive effect on normal cells but not on the tumour 
cells in vitro (section 3.3.2.6). There is usually an 
optimal cell seeding density, depending upon cell type 
and culture conditions, which gives more efficient 
results. This was also observed with liver cells 
(section 3.3.2.3). Trypsin appears to have a short­
lived but significant stimulatory effect on the tumour 
cells in vitro at a concentration of 0.005% w/v 
(section 3.3.3). The mechanism of action of trypsin in 
this case is not fully understood.
6.3 CRITERIA OF CELL TRANSFORMATION IN CIPROFIBRATE- 
INDUCED RAT LIVER TUMOUR CELLS :
In addition to differences in cell growth in vitro, 
ciprofibrate-induced tumour cells also exhibit some 
other features of cell transformation. Tumour cells 
appear to have a significantly higher potential for 
agglutination with plant lectins compared to normal 
cells (section 3.4.2). This is however much lower than
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established transformed cell lines (section 3.4.2). 
This is an indication that the ciprofibrate-induced 
liver tumour cells are moderately transformed. This 
transformation appears to be comparatively lower than 
in established cell lines like BHK, HeLa or MRC-5. Thus 
lectin agglutinability can give information about 
transformation and also the comparative degree of cell 
transformation.
The tumour cells, when grown in a semisolid media of 
agar or methylcellulose, exhibit a potential for growth 
and colony formation (section 3.5). This colony forming 
potential is significantly higher than normal cells but 
is comparatively lower than established transformed 
tumour cell lines tested (section 3.5).
The above-described criteria indicate that 
ciprofibrate-induced rat liver tumour cells are 
transformed cells but the degree of transformation iâ 
comparatively lower than that of established 
transformed or tumour cell lines.
6.4 MONOCLONAL ANTIBODIES AGAINST CIPROFIBRATE-INDUCED 
RAT LIVER TUMOURS :
Monoclonal antibodies (MoAbs) were raised against 
ciprofibrate-induced rat liver tumour cells using two 
different schedules of immunization (section 4.1). 
MoAbs of interest were selected using an ELISA assay 
(section 4.3).
The MoAbs identified and selected could be divided into
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three distinct groups according to their reactivity 
with normal liver cells and the tumour cells, as 
detected by ELISA (section 3.1), This clearly indicates 
that induction of tumours by ciprofibrate and cell 
transformation leads to many qualitative and 
quantitative antigenic changes in the tumour cells. 
This may well be true with all peroxisome proliferator 
carcinogens.
The number of positive clones obtained was higher with 
the second fusion protocol (prolonged immunization) as 
compared to the first fusion (shorter immunization 
schedule). The second fusion, however, failed to 
produce any clones secreting MoAb reactive with both 
normal and tumour cells (and thus identifying a common 
antigen ; section 4.3.2). MoAbs preferentially or 
selectively reactive with the tumour cells were taken 
for further studies (section 4.3). Most MoAbs from the 
first fusion identified antigens which were unique to 
the immunizing tumour cells while those from the second 
fusion mainly identified antigens which were also 
present on ciprofibrate-induced liver tumours from 
different rats (section 4.7). MoAbs from the second 
fusion were weaker in reactivity as compared to MoAbs 
from first fusion as determined by their reactivity at 
different dilutions. It seems as if a longer 
immunization schedule, with multiple inoculations, may 
have a significantly important role in obtaining MoAbs
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against relatively weaker antigens from a complex 
antigenic mixture like the tumour cells in our case.
6.5 REACTIVITY OF THE TUMOUR-SPECIFIC MoAbs WITH 
CIPROFIBRATE-INDUCED RAT LIVER TUMOURS :
The antigens identified by these MoAbs, in 
ciprofibrate-induced rat liver tumours, are mostly 
unique and distinct (section 4.7) as also shown by 
others in different chemically-induced tumour systems 
(Baldwin, 1973 : Baldwin, 1978). Some of these tumour- 
specific MoAbs , however, identify antigens and cross- 
react with ciprofibrate-induced liver tumours in 
different rats (section 4.7) as also shown by other 
workers (Embleton et al, 1980 ; Hellstrom et al, 1985). 
Some of these MoAbs also react with peri-neoplastic 
tissue from livers of chemically-treated (ciprofibrate) 
animals without any apparent neoplastic change 
(section 4.7). This may be indicative of the 
possibility that antigenic changes precede any gross 
neoplastic change and thus may well be one of the 
earliest indicators of an impending neoplastic change. 
This may have diagnostic and therapeutic importance. 
Reactivity of apparently tumour-specific MoAbs with 
ps^ri-neoplastic tissues is also described by other 
workers (Haglund et al, 1989 : Prime et al, 1987 : 
Seilstad et al, 1985 : Trejdosiewicz et al, 1984). 
Immunocytochemistry and staining methods were used to 
detect the reactivity of MoAbs with the tumours
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(section 5.2). Immunostaining was non-homogenous and 
patchy showing inter- and intra-tumour variation. 
Heterogeneity of immunostaining with MoAbs is also 
described by others in tumour systems (Chedid et al, 
1990 ; Durrant et al, 1989 : Giwercman et al, 1990 : 
Schol et al, 1988). Heterogeneity of TAs and aberrant 
or heterogenous cell foci with varying degrees of 
positives and negatives are shown in chemically-induced 
(acetylaminofluorene) liver tumours (Embleton et al,
1989). This may be because TAs are phase specific or 
transient, or expressed by only a few tumour cells, or 
tumour cells vary in degree of transformation within 
the tumour.
The MoAbs failed to dentify any cell surface or 
nuclear antigens. Cell surface antigens may be lost in 
tissue section preparation and processing. It is also 
reported that most of MoAbs raised against tumour cells 
are usually directed against cytoplasmic antigens 
(Edwards, 1985).
6.6 CROSS-REACTIVITY OF TUMOUR-SPECIFIC MoAbs:
The specificity of an apparently tumour-specific MoAb 
is measured by its non-reactivity with other normal 
tissues. Many of the MoAbs raised against the 
ciprofibrate-induced rat liver tumours showed cross­
reactivity with normal and fetal tissues of the rats 
(table 5.5). These types of cross-reactivities of 
tumour-specific MoAbs are also reported by other
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workers (Abelev, 1971 ; Cole et al, 1983 ; Daar et al,
1981 ; Gold and Freedman, 1965 : Gooi et al, 1983 :
Hole and Stern, 1988 : Kenemans et al, 1988 : Schol et 
al, 1988). Only five of our raised MoAbs showed minimal 
or apparently no reactivity with normal and fetal rat 
tissues (section 5.2.3/table 5.5).
There are not many tumour-specific MoAbs, cited in the
iü®^3’ture, which exhibit cross—species reactivity in a
tumour system. Reactivity of tumour-specific MoAbs
across the species barrier is a rare phenomenon. The
cross-species reactivity of MoAbs can be of great
siG^iiicance, as tumours can be induced in experimental
animals with known etiological agents and MoAbs raised,
4 - 1 .  ^ the
to be used later in^human system. Five of the 
tumour-specific MoAbs were found to be non-reactive 
with a panel of normal human tissues and non-hepatic 
tumours (section 5.4). Two of the MoAbs, however, 
exhibited a similar pattern of immunostaining with 
human hepatocellular carcinomas. This staining with the 
MoAbs was, in places, more intense than seen with the 
ciprofibrate-induced rat liver tumours. One MoAb 
exhibited a minimal and insignificant reaction with 
human lung, colon and renal carcinoma. This indicates 
that human HCC also exhibit antigenic determinants 
similar to those seen in the ciprofibrate-induced rat 
liver tumours. There is a possibility that human HCC 
probably also passes through some similar stages of 
carcinogenesis as seen in ciprofibrate-induced rat
300
hepatic carcinogenesis, irrespective of the etiological 
agent involved. There may well be similarities in the 
underlying biochemical changes associated with 
carcinogenesis, or at least hepatocarcinogenesis, 
irrespective of etiology e.g., oncogene expression.
6.7 TARGET ANTIGENS IDENTIFIED BY THE MoAbs:
The five tumour-specific MoAbs identify different 
molecular weight antigens in tumour cells as shown by 
western blotting and their immuno-reactivity (section 
5.6). The MoAbs are reactive with antigens of molecular 
weight from 45,000 to 159,000. They did not show any 
significant detectable reactivity with normal liver 
extracts (section 5.6 and figs 5.61 to 5.66).
The MoAbs were found to be from classes IgG^, IgG^y and 
^9®2a (section 5.5.2). Most of the tumour-specific 
MoAbs described are of the IgG class (Dunk et al, 1987 
; Holmes et al, 1982 : Payne and Coggin, 1985 : Schol 
et al, 1988). It is an indication of monoclonality of 
an antibody if it belongs to one sub-class, being 
secreted by one hybridoma.
The molecular weights of peroxisomal enzymes are 
usually in the range 10,000 - 55,000. AFP has a 
molecular weight of 70,000. The molecular weight of CE A
180,000 and that of peroxisome proliferator associated 
antigen is 80,000, which is the most abund&nt 
associated protein. There are many believed protein, 
mRNAs, enzyme and transcriptional gene activation
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changes associated with peroxisome proliferation and 
subsequent carcinogenesis (Lock et al, 1989 : Reddy and 
Lalwani, 1983). There may well be many other associated 
changes which are yet to be found and more work is 
needed to examine it in detail.
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SECTION-7 
OUTLINE FOR FUTURE WORK
7. OUTLINE FOR FUTURE WORK;
Ciprofibrate—induced tumour cells separate easily 
with enzyme digestion compared to normal cells. This 
indicates a reduction in the force and strength of 
^^^1-cjell binding, which may be an important 
determinant factor of metastasis.
II- There are a number of characteristics indicative 
of 0611 transformation but they usually are variable 
and non-specific. In vitro studies with different 
tumour systems can be carried out to detect any 
specific, reliable and common feature indicative of 
cell transformation.
III- Serum of rat was found inhibitory to rat 
hepatocytes. There can be species specific growth 
inhibitory factors controlling and regulating the 
growth by a feed back mechanism. This aspect can be 
further studied in detail.
IV- A number of immunization schedules and protocols 
can be tested varying the timings and dose of antigens 
for producing MoAbs. It may prove interesting 
especially when a complex antigenic mixture is used or 
when it is desired to have MoAbs against the weaker and 
immuno-subdominant antigens.
V- A sequential analysis of peroxisome proliferator- 
induced tumours can be done, using the raised MoAbs, 
during the process of tumour induction. It may tell us 
more about the timings and pattern of appearance of
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these apparently tumour-specific antigens.
VI- These raised MoAbs can be used to detect the target 
antigens in serum of the animals bearing tumours, 
forming a basis for a serum assay/diagnostic test in 
this tumour system.
VII- Peroxisome proliferators are carcinogenic because 
of their ability to induce peroxisome proliferation 
(Lock et al, 1989). On the basis of our study, further 
work can be carried out to study the importance of 
peroxisome and their proliferation in other tumour 
systems.
VIII- Further studies can be carried out to detect the 
presence of same, similar or different antigens in 
peroxisome proliferator induced tumours. A set of 
different chemicals, animals, species, or tissues can 
be used for this purpose.
IX- A broad panel of normal and tumour tissues from 
different species, including that of human origin and 
with known etiology if possible, can be used to detect 
the cross-reactivity of these MoAbs. It may help to 
establish the importance of peroxisome proliferation as 
an integral change associated with malignancy. There 
can be a specific biochemical or antigenic change 
common to many, if not all, tumours.
X- Cross-species reactivity, as found in our study, can 
be very important. Animals can be used to induce 
tumours with the known etiological agents and species 
cross-reactive MoAbs can be raised to be used later in
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any desired species including humans.
XI- Further studies can be carried out to more fully 
characterize the antigens found in ciprofibrate-induced 
rat liver tumours. Some MoAbs were also found 
indicating some loss of antigens as a result of 
transformation, which can be used for further studies.
XII- These further studies can help in understanding 
the mechanism of carcinogenesis, especially by the 
chemical carcinogens which are non-genotoxic and non- 
mutagenic.
It can throw more light on and increase our 
understanding of the whole process of carcinogenesis 
and many genetic, molecular, enzymatic, hormonal, 
immunological, cytological and biochemical changes 
associated with it.
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SECTION-8
APPENDIX
I. PRESERVATION MEDIUM;
1. 70% RPMI-1640 with glutamine 2 m M ,
streptomycin 10 mg% and penicillin 6 mg%.
2. 20% Fetal calf serum.
3. 10% Dimethyl sulphoxide (DMSG).
II. METHOCEL (METHYLCELLULOSE) SEMISOLID MEDIUM;
To each 200 ml methocel was added the following;
1. RPMI-1640 medium (Flow) 10 X 22 ml.
2. MEM Amino Acids (Sigma) 50 X 4 ml.
3. Sodium pyruvate solution (Sigma) 100 X 4 ml.
(11.0 mg/L or 100 nM)
4. Penicillin-streptomycin solution IX 3 ml.
5. Glutamine solution 200 mM (Sigma) 3 ml.
6. Sodium bicarbonate (BDH) 8.8% solution 5 ml.
7. Sodium hydroxide (BDH) 2 M solution 0.5 - 2.0 ml.
III. ELISA CONJUGATE BUFFER;
It was prepared in PBS with following composition;
1. Magnesium chloride MgCl2 (BDH) 10 mM
2. 2-Mercaptoethanol (Sigma) 1 mM
3. Bovine serum albumin (Sigma) 1% w/v
IV. ELISA SUBSTRATE BUFFER;
It was prepared in PBS with following composition:
1. Calcium chloride CaCl2 (BDH) 10 mM
2. 2-Mercaptoethanol (Sigma) 0.1 M
306
FIXATIVE SOLUTION (10% Neutral buffered Formalin):
1. Formalin (40% formaldehyde)..................  100 ml
2. Sodium dihydrogen orthophosphate.............  4.5 Gm
(NaH2P04.2H2Û)
3. Anhydrous disodium hydrogen orthophosphate 6.5 Gm
(Na2HP0 4 )
4. Distilled water..................  to make One litre.
5. 5% glacial acetic acid can be added to it.
VI . PREPARATION OF SUBSTRATE SOLUTION FOR 
IMMUNOSTAINING AND IMMUNOBLOTTING:
a) Substrate stock solutions:
BCIP (Sigma) = 1 X 25 mg tablet in 1 ml Dimethyl 
formamide or DMF (Sigma).
NET (Sigma) = 1 X 10 mg tablet in 1 ml distilled water. 
Substrates are light sensitive.
b) Alkaline phosphatase buffer:
- 10.51 Gm 2-amino-2-methyl-l,3-propanediol or AMPD 
(Sigma) as 0.1 M final solution.
- 246.5 mg Magnesium sulphate MgS04 (Sigma) final 
strength 1 mM.
- 240.8 mg Levamisole (Sigma) final concentration 1 mM.
- Make to 1 litre and adjust the pH to 9.6 .
c) Working substrate solution:
- 500 uL NBT stock solution.
- 250 uL BCIP stock solution.
50 ml alkaline phosphatase buffer.
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VII. 4X Tris-Cl/SDS (SEPARATION OR LOWER GEL) BUFFER:
- 300 ml distilled water
- 91.0 Gm Tris base (Sigma)
- 2.0 Gm SDS (Sigma)
- Adjust pH 8.8 with IN HCl (hydrochloric acid).
- Add distilled water to make 500 ml, filter through 
0.45 uM filter and store at 4^0.
VIII. 4X Tris-Cl/SDS (STACKING OR UPPER GEL) BUFFER;
- 40 ml distilled water
- 5.05 Gm Tris base (Sigma)
- 0.4 Gm Sodium dodecyl sulphate SDS (sigma)
- Adjust pH to 6.8 with IN HCl (hydrochloric acid)
- Add distilled water to make 100 ml, filter through
0.45 uM filter and store at 4°C.
IX. 2X SDS-SAMPLE BUFFER:
- 40 ml distilled water
- 1.52 Gm Tris base (Sigma)
- 20 ml Glycerol (BDH)
- 2.0 Gm SDS (Sigma)
- 2.0 ml 2-mercatoethanol (Sigma)
- 1.0 mg bromophenol blue (Sigma)
- Adjust pH to 6.8 with 1 N HCl.
- Add distilled water to make 100 ml.
X. ELECTROPHORESIS BUFFER:
- 3.03 Gm Tris base (Sigma)
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- 14.4 Gm glycine (BDH)
- 1.0 Gm SDS (Sigma)
- Add distilled water to make 1000 ml.
XI. SEPARATING OR LOWER GEL (10%); 
CHEMICAL 1 GEL 2 GELS
Acrylamide gel sol 8.11 ml 16.22 ml
Bisacrylamide gel sol 3.38 ml 6.76 ml
Tris-Cl/SDS buffer 6.25 ml 12.50 ml
Distilled water 7.14 ml 14.28 ml
Amm. persulphate sol 125 uL 250 uL
TEMED 20 uL 40 uL
All the solutions were mixed gently and used 
immediately to prevent polymerisation.
XII. UPPER OR STACKING GEL:
CHEMICALS 1 GEL 2 GELS
Acrylamide gel sol 1000 uL 2000 uL
Bisacrylamide gel sol 400 uL 800 uL
Tris-Cl/SDS buffer 2500 uL 5000 uL
Distilled water 6000 uL 12000 uL
Amm. persulphate sol 100 uL 200 uL
TEMED 20 uL 40 uL
XIII. GEL FIXATIVE SOLUTION:
- 50% methanol v/v
- 10% glacial acetic acid v/v
40 distilled water v/v
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XIV. COOMASSIE BLUE GEL STAINING SOLUTION;
- 50% methanol v/v
- 0.05% coomassie brilliant blue R w/v (BDH)
- 10% glacial acetic acid v/v
- 40% distilled water v/v
XV. GEL DESTAINING SOLUTION:
- 50% methanol v/v
- 10% glacial acetic acid v/v
- 40% distilled water v/v
XVI. ELECTROBLOTTING BUFFER:
- 4.0 litres of distilled water
- 14.5 Gm Tris base (Sigma)
- 67.0 Gm glycine (BDH)
- adjust pH to 8.0
- Add 1200 ml methanol and make upto 6 litres with 
water.
XVII. PONCEAU S SOLUTION:
- 0.5 Gm Ponceau S (BDH)
- 1.0 ml glacial acetic acid
- Make upto 98.5 ml with distilled water.
XVIII. SUBSTRATE BUFFER FOR CLONOTYPING OF MoAbs:
- 400 ml distilled water
- 24.5 mg MgC1.6H20
- 48 ml diethanolamine
- pH adjusted to 9.8 with the help of 5N HCl
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- Make upto 500 ml with distilled water.
XIX. PHOSPHATE BUFFERED SALINE (DULBECCO'S):
1. CaCl2 .2H20 (Calcium chloride) 132.5 mg/L
2. KCl (Potassium chloride) 200.0 mg/L
3. KH2PO4 200.0 mg/L.
(Potassium dihydrogen orthophosphate)
4. MgCl2 .6H20 100.0 mg/L.
(Magnesium chloride hexahydrous)
5. NaCl (Sodium chloride) 8000.0 mg/L,
6 . Na2HP04 1150.0 mg/L.
(Disodium hydrogen orthophosphate)
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